Blueprint

0001654954-19-004354.txt : 20190412 0001654954-19-004354.hdr.sgml : 20190412 20190412170854 ACCESSION NUMBER: 0001654954-19-004354 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190412 DATE AS OF CHANGE: 20190412 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sunshine Biopharma, Inc CENTRAL INDEX KEY: 0001402328 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 205566275 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52898 FILM NUMBER: 19746985 BUSINESS ADDRESS: STREET 1: 6500 TRANS-CANADA HIGHWAY STREET 2: 4TH FLOOR CITY: POINTE-CLAIRE STATE: A8 ZIP: H9R 0A5 BUSINESS PHONE: 514-426-6161 MAIL ADDRESS: STREET 1: 6500 TRANS-CANADA HIGHWAY STREET 2: 4TH FLOOR CITY: POINTE-CLAIRE STATE: A8 ZIP: H9R 0A5 FORMER COMPANY: FORMER CONFORMED NAME: Mountain West Business Solutions, Inc DATE OF NAME CHANGE: 20071030 FORMER COMPANY: FORMER CONFORMED NAME: mountain west business solutions,inc DATE OF NAME CHANGE: 20070607 10-K 1 sbfm_10k.htm ANNUAL REPORT Blueprint

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________

FORM 10-K

__________________

(Mark one)

☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF1934 for the transition period from ________________ to________________________.

Commission File Number 000-52898

SUNSHINE BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Colorado		20-5566275
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

6500 Trans-Canada Highway

4th Floor

Pointe-Claire, Quebec, Canada H9R 0A5

(Address of principal executive offices)

(514) 426-6161

(Registrant’s Telephone Number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:

Title of each class		Name of each exchange on which registered
Common Stock, par value $0.001 per share		OTC MARKETS

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☑

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☑

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☑ No ☐ Yes

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐ (Do not check if a smaller reporting company)	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☑

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter on June 30, 2018 was $3,970,144 .

As of April 11, 2019, the Registrant had 89,348,981 shares of Common Stock issued and outstanding.

DOCUMENTS INCORPORATED BY REFERENCE - None

TABLE OF CONTENTS

		Page No.
Index

PART I		3

Item 1.	Business	3

Item 1A.	Risk Factors	11

Item 1B.	Unresolved Staff Comments	11

Item 2	Properties	11

Item 3.	Legal Proceedings	11

Item 4.	Mine Safety Disclosures	11

PART II		12

Item 5.	Market for the Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities	12

Item 6.	Selected Financial Data	14

Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14

Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	20

Item 8.	Financial Statements and Supplementary Data	20

Item 9.	Changes in and Disagreements on Accounting and Financial Disclosure	21

Item 9A.	Controls and Procedures	21

Item 9B.	Other Information	22

PART III		23

Item 10.	Directors, Executive Officers and Corporate Governance	23

Item 11.	Executive Compensation	25

Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	26

Item 13.	Certain Relationships and Related Transactions, and Director Independence	27

Item 14.	Principal Accounting Fees and Services	28

PART IV		29

Item 15.	Exhibits, Financial Statement Schedules	29

	Signatures	31

FORWARD LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. The statements regarding Sunshine Biopharma Inc. contained in this Report that are not historical in nature, particularly those that utilize terminology such as “may,” “will,” “should,” “likely,” “expects,” “anticipates,” “estimates,” “believes” or “plans,” or comparable terminology, are forward-looking statements based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements.

Important factors known to us that could cause such material differences are identified in this Report. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any future disclosures we make on related subjects in future reports to the SEC.

PART I

ITEM 1. BUSINESS

History

We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.” Until October 2009, our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies.

In October 2009, we acquired Sunshine Biopharma, Inc., a Colorado corporation holding an exclusive license to a new anticancer drug bearing the laboratory name, Adva-27a. As a result of this transaction we changed our name to “Sunshine Biopharma, Inc. and our officers and directors resigned their positions with us and were replaced by Sunshine’s management at the time, including our current CEO, Dr. Steve N. Slilaty, and our current CFO, Camille Sebaaly each of whom remain part of our current management. Our principal business became that of a pharmaceutical company focusing on the development of our licensed Adva-27a anticancer compound. In December 2015 we acquired all issued and pending patents pertaining to our Adva-27a technology and terminated the license. See “Part I, Item 1 – Business - Intellectual Property,” below for a more detailed explanation of this acquisition.

In July 2014, we formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”), for the purposes of offering generic pharmaceutical products in Canada and elsewhere around the world. In April and June 2016 Sunshine Canada signed licensing agreements for four (4) generic prescription drugs for the treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia).

In January 2018, we acquired all of the issued and outstanding shares of Atlas Pharma Inc., a Health Canada certified company dedicated to chemical analysis of pharmaceutical and other industrial samples.

In March 2018, we formed NOX Pharmaceuticals, Inc., a wholly owned Colorado corporation and assigned all of our interest in our Adva-27a anticancer compound to that company.

In December 2018, we launched our first over-the-counter Essential Brandtm product, Essential 9tm, a dietary supplement comprised of the nine amino acids which the human body cannot synthesize. Essential 9tm has been authorized for marketing by Health Canada under NPN 80089663.

Effective February 1, 2019, we completed a 20 to 1 reverse split of our $0.001 par value Common Stock reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400 (the “Reverse Stock Split”). All references in this report to our issued and outstanding Common Stock as well as the price per share of Common Stock are presented on a post Reverse Stock Split basis.

Our principal place of business is located at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada H9R 0A5. Our phone number is (514) 426-6161 and our website address is www.sunshinebiopharma.com.

Business Operations

As of the date of this report our operations include the following:

Proprietary Drug Development Operations

Since inception, our proprietary drug development activities have been focused on the development of a small molecule called Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patent Number 8,236,935. See “Part I, Item 1 – Business - Intellectual Property.”

Figure 1

Adva-27a is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin (see Figure 1). Another derivative of Podophyllotoxin called Etoposide is currently on the market and is used to treat various types of cancer including leukemia, lymphoma, testicular cancer, lung cancer, brain cancer, prostate cancer, bladder cancer, colon cancer, ovarian cancer, liver cancer and several other forms of cancer. Etoposide is one of the most widely used anticancer drugs. Adva-27a and Etoposide are similar in that they both attack the same target in cancer cells, namely the DNA unwinding enzyme, Topoisomerase II. Unlike Etoposide, and other anti-tumor drugs currently in use, Adva-27a is able to destroy Multidrug Resistant Cancer cells. Adva-27a is the only compound known today that is capable of destroying Multidrug Resistant Cancer. In addition, Adva-27a has been shown to have distinct and more desirable biological and pharmacological properties compared to Etoposide. In side-by-side studies using Multidrug Resistant Breast Cancer cells and Etoposide as a reference, Adva-27a showed markedly greater cell killing activity (see Figure 2).

Figure 2

Our preclinical studies to date have shown that:

●

Adva-27a is effective at killing different types of Multidrug Resistant cancer cells, including Pancreatic Cancer Cells (Panc-1), Breast Cancer Cells (MCF-7/MDR), Small-Cell Lung Cancer Cells (H69AR), and Uterine Sarcoma Cells (MES-SA/Dx5).

●

Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.

●

Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats.

●

Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.

●

Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar (this number has recently been reduce to 1.44 micromolar as a result of resolving the two isomeric forms of Adva-27a).

●

Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats.

●

Adva-27a does not inhibit tubulin assembly.

These and other preclinical data have been published in ANTICANCER RESEARCH, a peer-reviewed International Journal of Cancer Research and Treatment. The publication which is entitled “Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells” [ANTICANCER RESEARCH 32: 4423-4432 (2012)] is available on our website at www.sunshinebiopharma.com.

We have been delayed in our clinical development program due to lack of funding. Our fund raising efforts are continuing and as soon as adequate financing is in place we will continue our clinical development program of Adva-27a by conducting the following next sequence of steps:

●

GMP Manufacturing of 2 kilogram for use in IND-Enabling Studies and Phase I Clinical Trials

●

IND-Enabling Studies

●

Regulatory Filing (Fast-Track Status Anticipated)

●

Phase I Clinical Trials (Pancreatic Cancer Indication)

Adva-27a’s initial indication will be Pancreatic Cancer for which there are currently little or no treatment options available. We are planning to conduct our clinical trials at McGill University’s Jewish General Hospital in Montreal, Canada. All aspects of the clinical trials in Canada will employ FDA standards at all levels.

According to the American Cancer Society, nearly 1.5 million new cases of cancer are diagnosed in the U.S. each year. While particularly effective against Multidrug Resistant Cancer, we believe Adva-27a can potentially treat all cancer types as it is general chemotherapy drug. We believe that upon successful completion of Phase I Clinical Trials we may receive one or more offers from large pharmaceutical companies to buyout or license our drug. However, there are no assurances that our Phase I Trials will be successful, or if successful, that any pharmaceutical companies will make an acceptable offer to us. In the event we do not consummate such a transaction, we will require significant capital in order to manufacture and market our new drug. The following, Figure 3, is a space-filling molecular model of our Adva-27a.

Figure 3

Generic Pharmaceuticals Operations

In 2016, our Canadian wholly owned subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”), signed Licensing Agreements with a major pharmaceutical company for four prescription generic drugs for the treatment of Breast Cancer, Prostate Cancer and Enlarged Prostate. We have since been working towards commencement of marketing of these pharmaceutical products under our own, Sunshine Biopharma, label. These four generic products are as follows:

●

Anastrozole (brand name Arimidex® by AstraZeneca) for treatment of Breast Cancer;

●

Letrozole (brand name Femara® by Novartis) for treatment of Breast Cancer;

●

Bicalutamide (brand name Casodex® by AstraZeneca) for treatment of Prostate Cancer;

●

Finasteride (brand name Propecia® by Merck) for treatment of BPH (Benign Prostatic Hyperplasia)

Sunshine Canada is currently in the process of securing a Drug Identification Number (“DIN”) for each of these products from Health Canada. We are planning to use part of the already approved Atlas Pharma Inc. space as a drug warehouse to facilitate the process of obtaining a Drug Establishment License (“DEL”) from Health Canada. Upon receipt of the DEL and DIN’s, we will be able to accept orders for our own label SBI-Anastrozole, SBI-Letrozole, SBI-Bicalutamide and SBI-Finasteride. We cannot estimate the timing in our obtaining either the DIN’s or the DEL due to variables involved that are out of our control. Figure 4 below shows our 30-Pill blister pack of Anastrozole.

Figure 4

We currently have a number of additional Generic Pharmaceuticals under review for in-licensing. While no assurances can be provided that we will acquire the rights to all or any of these drugs, we are confident we will acquire most, if not all of these rights. We believe that a larger product portfolio will provide us with more opportunities and a greater reach into the marketplace. We hope to further build our generics portfolio of “SBI” label Generic Pharmaceuticals over time. There are no assurances this will occur.

Various publicly available sources indicate that the worldwide sales of generic pharmaceuticals are approximately $200 billion per year. In the United States and Canada, the sales of generic pharmaceuticals are approximately $50 billion and $5 billion, respectively. The generic pharmaceuticals business is fairly competitive and there are several multinational players in the field including Teva (Israel), Novartis - Sandoz (Switzerland), Hospira (USA), Mylan (Netherlands), Sanofi (France), Fresenius Kabi (Germany) and Apotex (Canada). While no assurances can be provided, with our offering of Canadian approved products we believe that we will be able to access at least a small percentage of the generic pharmaceutical marketplace.

While no assurances can be provided and subject to the availability of adequate financing, of which there is no assurance, we anticipate that profits from the sales of Generic Products will be used to finance our proprietary drug development program, including Adva-27a, our flagship anticancer compound. In addition to near-term revenue generation, building the generics business infrastructure and securing the proper permits will render us appropriately positioned for the marketing and distribution of our proprietary Adva-27a drug candidate, provided that Adva-27a is approved for such marketing and distribution, of which there can be no assurance.

Analytical Chemistry Services Operations

On January 1, 2018, we acquired all of the issued and outstanding shares of Atlas Pharma Inc. (“Atlas”). The purchase price was $848,000 Canadian (approximately $676,748 US). Payment of the purchase price was comprised of (i) a cash payment of $100,500 Canadian (approximately $80,300 US); (ii) the issuance of 1,000,000 shares of our Common Stock, and (iii) a promissory note in the principal amount of $450,000 Canadian (approximately $360,000 US), with interest payable at the rate of 3% per annum. We are required to make payments of $10,000 Canadian (approximately $8,000 US) per calendar quarter, due and payable on or before the end of each such calendar quarter through December 31, 2023.

Atlas is a Health Canada certified company dedicated to chemical analysis of pharmaceutical and other industrial samples. Atlas has 9 full-time employees and generated revenues of $580,558 and $598,109 Canadian (approximately $464,000 and $478,000 US) in 2018 and 2017, respectively. Housed in a 5,250 square foot facility, Atlas’s operations are authorized by a Drug Establishment License (DEL) issued by Health Canada and are fully compliant with the requirements of Good Laboratory Practices (GLP). Atlas is also registered with the FDA. Atlas Pharma Inc.’s website address is www.atlaspharmainc.ca.

In June 2018, we acquired testing and other laboratory equipment as part of our plan to expand Atlas’ business operations. Part of the expansion will include hiring additional technical and sales personnel and offering microbiology and other sample testing capabilities.

Dietary Supplements Operations

In 2018, we completed the development of Essential 9tm, the first in a line of essential micronutrients products that we are planning to launch. On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma Inc. to manufacture and sell the Essential 9tm product. Our Essential 9tm dietary supplement tablets contain a balanced formula of the 9 essential amino acids that the human body cannot make. Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma’s Essential 9tm provides all 9 Essential Amino Acids in freeform and in the proportions recommended by Health Canada. In addition to our own website, Essential 9tm is available on Amazon and other outlets. Figure 5 below shows our 60-Tablet Essential 9tm product.

Figure 5

Intellectual Property

Effective October 8, 2015, we executed a patent purchase agreement, with Advanomics Corporation (“Advanomics”), a related party, pursuant to which we acquired all of the right, title and interest in and to U.S. Patent Number 8,236,935 for our anticancer compound, Adva-27a. On December 28, 2015, we executed a second patent purchase agreement, with Advanomics, pursuant to which we acquired all of the right, title and interest in and to all of the remaining worldwide rights covered by issued and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for our anticancer compound, Adva-27a (“Patent Purchase Agreements”).

Effective December 28, 2015, we entered into amendments (the “Amendments”) of these Patent Purchase Agreements pursuant to which the total purchase price was reduced from $17,142,499 to $618,810, the book value of this intellectual property on the financial statements of Advanomics. Further, the Amendments provided for automatic conversion of the promissory notes representing the new purchase price into an aggregate of 16,065,271 shares of our Common Stock once we increased our authorized capital such that these shares can be issued. In July 2016 we increased our authorized capital and issued the 16,065,271 Common Shares to Advanomics thereby completing all aspects of the patent purchase arrangements and securing direct ownership of all worldwide patents and rights pertaining to Adva-27a.

In 2016 we signed Licensing Agreements with a major pharmaceutical company for four (4) prescription generic drugs for the treatment of Breast Cancer, Prostate Cancer and Enlarged Prostate. These agreements give us the right to register the four (4) generic products, Anastrozole, Letrozole, Bicalutamide and Finasteride in Canada under our own label and obtain a DIN for each in order to be able to place them on the market.

Our new wholly owned subsidiary, Atlas Pharma Inc., which we acquired on January 1, 2018 holds a Drug Establishment License from Health Canada and is registered with the FDA. Atlas Pharma Inc. is the owner of a relatively large portfolio of analytical chemistry methodology and Standard Operating Procedure. This intellectual property is protected as company secrets and controlled through employee and management confidentiality agreements.

In 2018 we completed the development of Essential 9tm, our first dietary supplement. On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma Inc. to manufacture and sell the Essential 9tm product. We are currently preparing the necessary documents for registration of our Essential 9tm trademark in the United States.

Government Regulations

All of our business operations, including the Proprietary Drug Development Operations, the Generic Pharmaceutical Operations, the Analytical Chemistry Services Operations, and Dietary Supplements Operations are subject to extensive and frequently changing federal, state, provincial and local laws and regulations.

In the U.S, the Federal Government agency responsible for regulating drugs and dietary supplements is the U.S. Food and Drug Administration (“FDA”). The Canadian counterpart to the FDA is Health Canada. Both the FDA and Health Canada have similar requirements for drugs and supplements to be approved for marketing. In Canada, drugs and dietary supplements are authorized through the issuance by Health Canada of a Drug Identification Number (DIN) and a Natural Product Number (NPN) on a per product basis, respectively. In both the U.S. and Canada, the quality standards for brand name drugs and generic drugs are the same. In addition, the ingredients, manufacturing processes and facilities for all drugs and supplements must meet the guidelines for Good Manufacturing Practices (“GMP”). Moreover, all drug manufacturers must perform a series of tests, both during and after production, to show that every drug batch made meets the regulatory requirements for that product.

In connection with our development of the new chemical entity, Adva-27a, we will be subject to significant regulations in the U.S. in order to obtain approval of the FDA to offer our product on the market. The approximate procedure for obtaining FDA approval involves an initial filing of an IND application following which the FDA would give the go ahead for the drug sponsor to proceed with Phase I clinical (human) trials. Following completion of Phase I, the results are filed with the FDA and a request is made to proceed to Phase II. Similarly, following completion of Phase II the data are filed with the FDA and a request is made to proceed to Phase III. Following completion of Phase III, a request is made for marketing approval. Depending on various issues and considerations, the FDA could provide limited marketing approval for “compassionate-use” if the drug treats terminally ill patients with limited other treatment options available. As of the date of this Report we have not made any filings with the FDA or other regulatory bodies in other jurisdictions. We have however had discussions with clinicians at the McGill University’s Jewish General Hospital in Montreal where we plan to undertake our Phase I study for pancreatic cancer and they believe that Health Canada is likely to grant us a so-called “fast-track” process on the basis of the terminal nature of the cancer type we will be treating. There are no assurances this will occur.

Employees

As of the date of this Report we have a total of twelve (12) employees. In addition to our management which comprises three (3) employees, our new wholly owned subsidiary acquired on January 1, 2018, Atlas Pharma Inc., has 9 employees. We anticipate that if we receive financing we will need additional employees in both our generic pharmaceuticals and proprietary drug development operations including accounting, regulatory affairs, marketing, sales and laboratory personnel.

Competition

In the area of proprietary anticancer drug development, we are competing with large publicly and privately held companies engaged in developing new cancer therapies. There are numerous other entities engaged in this business that have greater resources, both financial and otherwise, than the resources presently available to us. Nearly all major pharmaceutical companies including Amgen, Roche, Pfizer, Bristol-Myers Squibb and Novartis, to name a few, have on-going anticancer drug development programs and some of the drugs they may develop could be in direct competition with our own. Also, a number of small companies are also working in the area of cancer and could develop drugs that may be in competition with ours. However, none of these competitor companies can use molecules similar to ours as they would be infringing our patents.

The generic pharmaceuticals business is fairly competitive and there are many players in the field including several multinationals such as Teva (Israel), Novartis - Sandoz (Switzerland), Hospira (USA), Mylan (Netherlands), Sanofi (France), Fresenius Kabi (Germany) and Apotex (Canada)with annual sales in the range of approximately $2 billion to over $10. With our offering of Canadian approved generic products, we believe that we will be able to access at least a small percentage of the generic pharmaceuticals market.

Our analytical chemistry services business is also subject to significant competition. This competition however is entirely regional as only entities operating in Canada require Health Canada certified testing of their industrial samples. There are several local service providers operating in the same sector as ours which prevents us from obtaining greater value added for our services. We believe we have managed to secure an advantage over the completion by offering our clients faster turnaround.

Similarly, our Essential 9tm, together with our planned line of dietary supplement fall directly within a very crowded and highly competitive product sector. As of the date of this Report, Essential 9tm is the only Essential Amino Acid product that comprises all 9 essential amino acids in tablet form. We believe this will provide us with a competitive advantage, at least for the near future.

Trademarks-Tradenames

We are the exclusive owner of all worldwide rights pertaining to Adva-27a covered by PCT/FR2007/000697 and PCT/CA2014/000029. The patent applications filed under PCT/FR2007/000697 have been issued in Europe, Canada, the United States (8,236,935) and India. The patent application filed in the U.S. under PCT/CA2014/000029 has recently been allowed. The remaining international patent applications filed under the same PCT are still pending.

We are also the owner of Licensing Agreements for four (4) generic drugs which we are planning to market and sell under the tradenames SBI-Anastrozole, SBI-Letrozole, SBI-Bicalutamide and SBI-Finasteride.

Our newly acquired wholly owned subsidiary, Atlas Pharma Inc. holds Drug Establishment License Number 102041 issued by Health Canada.

In 2018 we completed the development of Essential 9tm, our first dietary supplement product. On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized us to manufacture and sell the Essential 9tm product. We are currently preparing the necessary documents for registration of our Essential 9tm product and trademark in the United States in 2019.

ITEM 1A. RISK FACTORS

We are a smaller reporting company and not required to include this disclosure in this report.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

During the first half of 2017, our principal place of business was located at 469 Jean-Talon West, 3rd Floor, Montreal, Quebec, Canada, H3N 1R4. On June 1, 2017 we moved our principal place of business to our current location at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada H9R 0A5. We pay a minimum monthly rate of $227 (Canadian), including tax, for this location. Pursuant to our lease agreement our landlord is able to provide us with increased office space for additional fees as may be requested by us from time to time.

Our newly acquired wholly owned subsidiary, Atlas Pharma Inc. leases an office and laboratory space at 7582 Chemin Cote-de-Liesse, Montréal, Quebec, Canada H4T 1E7. The lease expires on May 21, 2021. Minimum lease payments for the next remaining three (3) years are Canadian $62,213 (approximataely $47,904 US) in 2019, $62,213 (approximately $47,904 US) in 2020, and $25,921 (approximately $19,959 US) in 2021.

We believe that our existing facilities and equipment are adequate. We continuously review our anticipated requirements for facilities and equipment, and on the basis of that review, may from time to time acquire or lease additional facilities or equipment, or dispose of some of the existing space or equipment.

ITEM 3. LEGAL PROCEEDINGS

In November 2014, we entered into a Manufacturing Services Agreement with Lonza Ltd. and Lonza Sales Ltd. (hereinafter jointly referred to as “Lonza”), whereby we engaged Lonza to be the manufacturer of our Adva-27a anticancer drug. In June 2016 we received a sample of the pilot manufacturing run for evaluation. Our laboratory analyses showed that, while the sample meets all of the required chemical, physical and biological specifications, the amount of material generated (the “Yield”) by the pilot run was found to be significantly lower than anticipated. We are currently working towards finding possible solutions to increase the Yield and define a path forward. During the course of our discussions concerning the problem of the low Yield, Lonza informed us that they required us to pay them $687,818 prior to moving forward with any activity pertaining to the manufacturing agreement we have with them. We have repeatedly indicated to Lonza that a clear path defining exactly how the extremely low Yield issue would be addressed is imperative prior to us making any payments. We issued a letter to them in June 2017 advising of our position. As of the date of this Report we have not received a response to our letter and no further action has been taken by either party.

In June 2018 we filed an action in the Superior Court of the Province of Quebec in the District of Montreal (Canada) against one of our existing shareholders residing in Quebec City (Canada) arising out of a possible equity investment intended to be completed by August 2018. The complaint alleges among other things, claims of misrepresentations and misleading conduct resulting in damages to us in an amount of approximately $200,000 Canadian (approximately $154,000 US). As of the date of this report we are awaiting a court date for the hearings to commence.

To the best of our management’s knowledge and belief, there are no other material claims that have been brought against us nor any claims threatened.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Trading of our Common Stock commenced on the OTCBB in September 2007 under the symbol “MWBN.” Effective November 30, 2009, the trading symbol for our Common Stock was changed to “SBFM” as a result of our name change discussed above.

In the third quarter of 2016 our Common Stock began trading on OTC Pink (otcmarkets.com) because the price of our stock had dropped below $0.01 per share.

Effective February 1, 2019 we completed a 20 to 1 reverse split of our Common Stock, reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400 (the “Reverse Stock Split”).

The table below sets forth the reported high and low transaction prices for the periods indicated taking into account and giving retroactive effect to the Reverse Stock Split.

Quarter Ended	High	Low

March 31, 2017	$0.0502	$0.0502
June 30, 2017	$0.2680	$0.2200
September 29, 2017	$0.3100	$0.2810
December 29, 2017	$0.2600	$0.2000

March 29, 2018	$0.1620	$0.1580
June 29, 2018	$0.1340	$0.1060
September 28, 2018	$0.0340	$0.0300
December 31, 2018	$0.0200	$0.0160

As of April 11, 2019, the closing bid price of our Common Stock was $0.012 per share.

Trading volume in our Common Stock varies between a few thousand shares to several hundred thousand shares per day. As a result, the trading price of our Common Stock is subject to significant fluctuations.

The Securities Enforcement and Penny Stock Reform Act of 1990

The Securities and Exchange Commission (“Commission” or “SEC”) has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the Nasdaq system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system).

As of the date of this Report, our Common Stock is defined as a “penny stock” under the Securities and Exchange Act. It is anticipated that our Common Stock will remain a penny stock for the foreseeable future. The classification of penny stock makes it more difficult for a broker-dealer to sell the stock into a secondary market, which makes it more difficult for a purchaser to liquidate his/her investment. Any broker-dealer engaged by the purchaser for the purpose of selling his or her shares in us will be subject to Rules 15g-1 through 15g-10 of the Securities and Exchange Act. Rather than creating a need to comply with those rules, some broker-dealers will refuse to attempt to sell penny stock.

The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document prepared by the Commission, which:

●

contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading;

●

contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of the Securities Act of 1934, as amended;

●

contains a brief, clear, narrative description of a dealer market, including "bid" and "ask" prices for penny stocks and the significance of the spread between the bid and ask price;

●

contains a toll-free telephone number for inquiries on disciplinary actions;

●

defines significant terms in the disclosure document or in the conduct of trading penny stocks; and

●

contains such other information and is in such form (including language, type, size and format) as the Securities and Exchange Commission shall require by rule or regulation;

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, to the customer:

●

the bid and offer quotations for the penny stock;

●

the compensation of the broker-dealer and its salesperson in the transaction;

●

the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and

●

monthly account statements showing the market value of each penny stock held in the customer's account.

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules; the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements will have the effect of reducing the trading activity in the secondary market for our stock because it will be subject to these penny stock rules. Therefore, stockholders may have difficulty selling their securities.

Holders

We had 147 holders of record of our Common Stock as of the date of this Report, not including those persons who hold their shares in “street name.”

Our CEO, Dr. Steve N. Slilaty, holds all 500,000 shares of our Series “B” Preferred Stock issued in 2015.

Stock Transfer Agent

The stock transfer agent for our securities is Corporate Stock Transfer, Inc. Their address is 3200 Cherry Creek South Drive, Suite 430, Denver, Colorado, 80209. Their phone number is (303) 282-4800.

Dividends

We have not paid any dividends since our incorporation and do not anticipate the payment of dividends in the foreseeable future. At present, our policy is to retain earnings, if any, to develop and market our products. The payment of dividends in the future will depend upon, among other factors, our earnings, capital requirements, and operating financial conditions.

Reports

We are subject to certain reporting requirements and furnish annual financial reports to our stockholders, certified by our independent accountants, and furnish unaudited quarterly financial reports in our quarterly reports filed electronically with the SEC. All reports and information filed by us can be found at the SEC website, www.sec.gov.

ITEM 6. SELECTED FINANCIAL DATA.

Not applicable.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our audited financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward looking statements in the following discussion and elsewhere in this Report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward looking statements made by, or on our behalf. We disclaim any obligation to update forward looking statements.

Overview and History

In March 2018, we formed NOX Pharmaceuticals, Inc., a wholly owned Colorado corporation and assigned all of our interest in our Adva-27a anticancer compound to that company.

Effective February 1, 2019, we completed a 20 to 1 reverse split of our $0.001 par value Common Stock reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400 (the “Reverse Stock Split”). All references in this report to our issued and outstanding Common Stock as well as price per share of our Common Stock are presented on a post Reverse Stock Split basis.

We have never been subject to any bankruptcy, receivership or similar proceeding.

Going Concern

Our financial statements accompanying this Report have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The financial statements do not include any adjustment that might result from the outcome of this uncertainty. We have a minimal operating history and minimal revenues or earnings from operations. We have no significant assets or financial resources. We will, in all likelihood, sustain operating expenses without corresponding revenues for the immediate future. See “Financial Statements and Notes.”

Results Of Operations

Comparison of Results of Operations for the fiscal years ended December 31, 2018 and 2017

During our fiscal years ended December 31, 2018 we generated revenues of $447,200 from the operations of our new wholly owned subsidiary, Atlas Pharma Inc. (“Atlas”), which we acquired on January 1, 2018. The direct cost for generating these revenues was $359,300, which is comprised of Atlas related salaries, laboratory supplies, rent and depreciation. We did not generate any revenues in 2017 or prior thereto.

General and administrative expenses for our fiscal year ended December 31, 2018 were $1,222,656, compared to $857,190 during our fiscal year ended December 31, 2017, an increase of $365,466. The expense categories that saw an increase included accounting and legal fees, which increased by $109,406, office expenses by $103,305, and executive compensation by $234,944. These increases were offset to some extent by a decrease in consulting fees by $90,768. The decrease in consulting fees was due to the fact that a substantial amount of the work required for our various operations was performed in-house.

We also incurred $159,420 in interest expense and $871,726 in losses from debt conversion during the year ended December 31, 2018, compared to $104,829 in interest expense and $76,929 in losses from debt conversion during the similar period in 2017. The increase in interest expense and losses from debt conversion in 2018 was due to an increase in issuance of convertible debt instruments in order to finance operations.

As a result, we incurred a net loss of $2,156,155 (approximately $0.04 per share) for the year ended December 31, 2018, compared to a net loss of $1,040,236 (approximately $0.02 per share) during the year ended December 31, 2017.

Liquidity and Capital Resources

As of December 31, 2018, we had cash and cash equivalents of $115,216.

Net cash used in operating activities was $512,806 during our fiscal year ended December 31, 2018, compared to $543,520 during our fiscal year ended December 31, 2017. We anticipate that our cash requirements for our operations will increase in the future before we reach profitability levels.

Cash flows used in investing activities were $13,908 during our fiscal year ended December 31, 2018. For the fiscal year ended December 31, 2017, cash flows used in investing activities were $84,008 arising primarily out of the purchase of laboratory equipment. Net cash flows provided by financing activities totaled $527,640 in 2018, compared to $670,705 during our fiscal year ended December 31, 2017.

We have issued convertible and non-convertible notes to both related and unaffiliated parties in order to fund our operations. Following is a description of our liquidity and capital resources events in 2018:

●

In December 2016, we received monies from our CEO in exchange for a note payable having a principal amount of $90,000 Canadian ($67,032 US) with interest at 12% due March 31, 2017. The note was convertible any time after the date of issuance into shares of our Common Stock at a price 35% below market value. At the time, this note was collateralized by all of our assets. In the event of default, the interest rate will increase to 18% per annum and a penalty of $1,000 Canadian ($752 US) per day will accrue. On March 31, 2017, the note, together with accrued interest of $3,021 Canadian ($2,271 US) and an additional principal amount of $3,000 Canadian ($2,247 US) was renewed for a 90-day period under the same terms and conditions as the original note. The new note then having a face value of $96,021 Canadian ($72,198 US) was due on June 30, 2017. On June 30, 2017, the note, together with accrued interest of $2,873 Canadian ($2,005 US), was renewed for a 90-day period under the same terms and conditions as the original note except that the new note was not- convertible. The new note then having a face value of $98,894 Canadian ($76,072US) was due on September 30, 2017. On September 30, 2017, the note, together with accrued interest of $2,991 Canadian ($2,397 US) was renewed for a 90-day period under the same terms and conditions as the June 2017 note. The note, then having a principal balance of $101,885 Canadian ($81,640 US) matured December 31, 2017. On December 31, 2017 the note was renewed for a 12-month period under the same terms and conditions as the September 2017 note except that this new note is unsecured and nonconvertible. The new note has a face value of $104,942 Canadian ($83,649 US) and matures on December 31, 2018. On December 31, 2018 the note, together with interest of $9,227, was renewed for a 12-month period under the same terms and conditions as the previous note. The new has a face value of $117,535 Canadian ($86,118 US) and matures on December 31, 2019.

●

A note payable held by a private individual who subsequently became a principal shareholder of our Company, having a face value of $100,000 at December 31, 2016 and a maturity date of March 31, 2017, accrues interest at 12%. The Note is convertible any time from the date of issuance into shares of our Common Stock at a 35% discount from market price. On March 31, 2017, the note’s principal balance of $100,000 plus accrued interest of $11,715 was renewed for a period of 90 days under the same terms and conditions as the original note. The new note then having a face value of $111,715 matured on June 30, 2017. On June 30, 2017, the note’s principal balance of $111,715, plus accrued interest of $3,342 was renewed for a period of 90 days under the same terms and conditions as the original note. The new note then had a face value of $115,057 and matured on September 30, 2017. On September 30, 2017, the note’s principal balance of $115.057 plus accrued interest of $3,480 was renewed for a period of 90 days under the same terms and conditions as the original note. The new note then had a principal balance of $118,537, which matured on December 31, 2017. On December 31, 2017 the note was renewed for a 12-month period under the same terms and conditions as before. The new note has a face value of $122,093 and matures on December 31, 2018. On December 31, 2018 the note, together with accrued interest of $14,651was renewed for a 12-month period. The new Note has a face value of $136,744 and matures on December 31, 2019. The new note is nonconvertible.

●

A Note Payable having a Face Value of $21,439 at December 31, 2016 and accruing interest at 12% was due December 31, 2017. On December 31, 2017, we renewed the note, together with accrued interest of $2,573, for a 12-month period. The new note has a Face Value of $24,012 and accrues interest at 12%. This note is convertible anytime from the date of issuance into shares of our Common Stock at a 35% discount from market price and is due December 31, 2018. On December 31, 2018 we renewed this note, together with accrued interest of $2,881, for a 12-month period. The new note has a Face Value of $26,893 and accrues interest at 12%. This new note is not convertible.

●

On January 1, 2018, as part of the acquisition of Atlas Pharma Inc., we issued a note payable in the amount of $450,000 Canadian ($358,407 US) and accruing interest at the rate of 3% per annum. The note is due on December 31, 2023. Payments on this note are $10,000 Canadian (approximately $8,000 US) per quarter. The outstanding principal balance at December 31, 2018 was $310,079. The note is not convertible but is secured by our Atlas Pharma Inc. shares.

●

On January 12, 2018 we received monies in exchange for a Note Payable having a Face Value of $102,000 with interest accruing at 8%, which was due October 30, 2018. The Note is convertible after 180 days from issuance into shares of our Common Stock at a price 35% below market value. The Note, together with accrued interest of $4,080 was converted in 2018 into 3,569,333 shares of our Common Stock. ..

●

On February 7, 2018, we received monies in exchange for a Note Payable having a Face Value of $150,000 with interest accruing at 8%, which became due February 7, 2019. The note was paid off in 2018 in part by cash of $48,000 and the remainder, together with accrued interest of $5,073, was converted into 5,710,642 shares of our Common Stock.

●

On February 20, 2018, we received monies in exchange for a Note Payable having a Face Value of $85,000 with interest accruing at 8%, which became due November 30, 2018. The Note, together with accrued interest of $3,400, was converted in 2018 into 4,376,238 shares of our Common Stock.

●

On May 29, 2018, we received monies in exchange for a Note Payable having a Face Value of $26,750 with interest accruing at 8%, which became due February 29, 2019. The note, together with accrued interest of $1,353, was converted into 4,003,265 shares of our Common Stock.

●

On June 27, 2018, we received monies in exchange for a Note Payable having a Face Value of $53,000 with interest accruing at 8%, which is due April 15, 2019. The Note, together with accrued interest of $5,332, was paid by cash on January 1, 2019.

●

On August 17, 2018, we received monies in exchange for a Note Payable having a Face Value of $53,000 with interest accruing at 8%, which is due April 15, 2019. The Note is convertible after 180 days from issuance into shares of our Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $1,557. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.

●

On September 10, 2018, we received monies in exchange for a Note Payable having a Face Value of $20,000 with interest accruing at 8%, which is due April 15, 2019. The Note is convertible after 180 days from issuance into shares of our Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $487. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.

●

On September 10, 2018, we received monies in exchange for a Note Payable having a Face Value of $16,500 with interest accruing at 8%, which is due April 15, 2019. The Note is convertible after 180 days from issuance into shares of our Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $401. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.

●

On October 23, 2018, we received monies in exchange for a Note Payable having a Face Value of $90,000 with interest accruing at 8%, which is due October 23, 2019. The Note is convertible after 180 days from issuance into shares of our Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $1,361. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.

●

On December 24, 2018, we received monies in exchange for a Note Payable having a Face Value of $87,000 with interest accruing at 8%, which is due October 23, 2019. The Note is convertible after 180 days from issuance into shares of our Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $153. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.

●

During the fiscal year ended December 31, 2018, we issued an aggregate of 39,715,488 shares of our Common Stock as follows:

1,000,000 shares for the acquisition of Atlas Pharma Inc.

1,456,737 shares for the purchase of laboratory and generic drugs warehouse equipment valued at $174,808

9,750,000 shares valued at $600,300 as compensation to our Directors and Officers

632,500 shares for services rendered to us by third parties valued at $83,400

26,876,251 valued at $1,589,099 shares in connection with the conversion of $684,318 in debt and interest of $32,808 resulting in a $871,973 loss on conversion

We relied upon the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended, to issue the respective shares.

We are not generating significant revenue from our operations, and our ability to implement our business plan as set forth herein will depend on the future availability of financing. Such financing will be required to enable us to further develop our proprietary drug development program, generic pharmaceuticals business, dietary supplements sales, and analytical chemistry operations. We intend to raise funds through private placements of our Common Stock and/or debt financing. We estimate that we will require approximately $10 million ($1 million for the generic pharmaceutical operations, $1 million for expansion of the analytical chemistry operations, $1 million for the development of dietary supplements sales and $7 million for the proprietary drug development program) to fully implement our business plan in the future and there are no assurances that we will be able to raise this capital.

In late 2017 we signed an agreement with Jitney Trade Inc. (“Jitney”), a Canadian broker-dealer, to raise up to $10 million Canadian (approximately $8 million US) in a private offering in order to provide the funding we have estimated we need to implement our business plan (the “Offering”). The Offering, including a six-month extension, expired on August 31, 2018 without any funds having been raised. We are currently in discussion with various investment groups for financing. There are no assurances that we will be successful in raising any funds.

Our cost to continue operations are expected to increase as we move forward with implementation of our enhanced business plan. We do not have sufficient funds to cover the anticipated increase in the relevant expenses. We need to raise additional funds in order to continue our existing operations and planned expansions.

Inflation

Although our operations are influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during our fiscal year ended December 31, 2018.

Critical Accounting Policies and Estimates

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Leases

We follow the guidance in ASC 840 “Accounting for Leases,” as amended, which requires us to evaluate the lease agreements we enter into to determine whether they represent operating or capital leases at the inception of the lease.

Recently Adopted Accounting Standards

In February 2017, the FASB issued ASU No. 2017-02, Leases (Topic 842), to provide guidance on recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements, specifically differentiating between different types of leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from all leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. There continues to be a differentiation between finance leases and operating leases. However, the principal difference from previous guidance is that the lease assets and lease liabilities arising from operating leases should be recognized in the balance sheet. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. The amendments will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach.

The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. These practical expedients relate to the identification and classification of leases that commenced before the effective date, initial direct costs for leases that commenced before the effective date, and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset.

An entity that elects to apply the practical expedients will, in effect, continue to account for leases that commence before the effective date in accordance with previous GAAP unless the lease is modified, except that lessees are required to recognize a right-of-use asset and a lease liability for all operating leases at each reporting date based on the present value of the remaining minimum rental payments that were tracked and disclosed under previous GAAP. We are currently evaluating the impact of these amendments on our financial statements.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Reference is made to the Financial Statements, the notes thereto, and the Report of Independent Public Accountants thereon commencing at page F-1 of this Report, which Financial Statements, notes and report are incorporated herein by reference.

Sunshine Biopharma, Inc.

CONSOLIDATED FINANCIAL STATEMENTS

With Independent Accountant’s Audit Report

At December 31, 2018 and 2017

TABLE OF CONTENTS

	Page

Independent Accountant’s Audit Report	F-1

Consolidated Balance Sheet	F-2

Consolidated Statement of Operations	F-3

Consolidated Statement of Cash Flows	F-4

Consolidated Statement of Shareholders’ Equity	F-5

Notes to Consolidated Financial Statements	F-6

Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of Sunshine Biopharma, Inc.:

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Sunshine Biopharma, Inc. (the "Company") as of December 31, 2018 and 2017, the related consolidated statements of operations and comprehensive loss, shareholders' equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017 and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

Going Concern Uncertainty

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company’s limited operations and Working Capital deficit raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ BF Borgers CPA PC

We have served as the Company's auditor since 2013.

Lakewood, CO

April 12, 2019

F-1

Sunshine Biopharma, Inc.
Consolidated Balance Sheet

	December 31,	December 31,
	2018	2017
ASSETS
Current Assets:
Cash and cash equivalents	$115,216	$107,532
Accounts receivable	94,955	-
Prepaid expenses	1,341	9,667

Total Current Assets	211,512	117,199

Equipment (net of $57,964 and $9,132 depreciation)	269,362	59,996

Patents (net of $58,918 amortization and $556,120 impairment)	-	-

Non-Current Asset:
Goodwill	665,697
Deposits	-	80,290

TOTAL ASSETS	$1,146,571	$257,485

LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities:
Current portion of notes payable	419,663	516,867
Current portion of notes payable - Related party	243,094	205,742
Related party advances	49,349
Accounts payable & accrued expenses	191,080	19,314
Interest payable	9,291	9,215

Total Curent Liabilities	912,477	751,138

Long-Term Liabilities - Related party note payable	289,847	79,710

TOTAL LIABILITIES	1,202,324	830,848

SHAREHOLDERS' EQUITY

Preferred Stock, Series A, $0.10 par value per share; Authorized 850,000 shares; Issued and outstanding -0- shares at December 31, 2018 and 2017.	-	-

Preferred Stock, Series B $0.10 par value per share; Authorized 500,000 Shares; Issued and outstanding 500,000 at December 31, 2018 and 2017.	50,000	50,000

Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 85,652,400 and 45,936,825 at December 31, 2018 and 2017, respectively	85,652	45,936
Reserved for issuance 97,321,836 At December 31, 2018

Capital paid in excess of par value	15,586,678	12,948,387

Accumulated other comprehesive Income (Loss)	(3,738)	504

Accumulated (Deficit)	(15,774,345)	(13,618,190)

TOTAL SHAREHOLDERS' DEFICIT	(55,753)	(573,363)

TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$1,146,571	$257,485

See Accompanying Notes To These Financial Statements.

F-2

Sunshine Biopharma, Inc.
Consolidated Statement Of Operations and Comprehensive Loss
	2018	2017

Revenues	$447,200	$-
Cost of Revenues	391,081	-

Gross Profit	56,119	-

General & Administrative Expenses:
Accounting	153,889	81,643
Legal	113,068	75,908
Consulting	36,245	127,013
Office	149,031	45,726
Officer & Director remuneration	755,215	520,271
Research & Development	12,800	-
Amortization & Depreciation	2,408	6,629

Total General & Administative	1,222,656	857,190

Income (Loss) from Operations	(1,166,537)	(857,190)

Other Expenses:
Interest expense	(159,420)	(104,829)
Loss on conversion of notes payable	(871,726)	(76,929)
Gain (Loss) from foreign exchange transactions	41,528	(1,288)

Total Other Expenses	(989,618)	(183,046)

Net (loss)	$(2,156,155)	$(1,040,236)

Basic Gain (Loss) per Common Share	$(0.04)	$(0.02)

Weighted Average Common Shares Outstanding	60,936,164	43,634,280

Net Income (Loss)	$(2,156,155)	$(1,040,236)

Unrealized Comprehensive Gain (Loss) from foreign exchange transactions	(4,242)	110

Comprehensive Income (Loss)	(2,160,397)	(1,040,126)

Basic (Loss) per Common Share	(0.04)	(0.02)

Weighted Average Common Shares Outstanding	60,936,164	43,634,280

See Accompanying Notes To These Financial Statements.

F-3

Sunshine Biopharma, Inc.
Consolidated Statement Of Cash Flows

	December 31,	December 31,
	2018	2017
Cash Flows From Operating Activities:
Net (Loss)	$(2,156,155)	$(1,040,236)
Depreciation and amortization	49,361	6,629
Foreign exchange gain	(42,399)
Stock issued for services	676,100	427,400
Loss on conversion of notes payable	871,973	76,929
Stock issued for payment of interest	33,977	3,022
Interest forgiven	(247)	-
Increase (decrease) in accounts receivable	(15,447)
Increase (decrease) in prepaid expenses	8,326	(8,660)
Increase (decrease) in Accounts Payable	61,629	(8,808)
Increase (decrease) in interest payable	76	204

Net Cash Flows (Used) in Operations	(512,806)	(543,520)

Cash Flows From Investing Activities:
Cash received from purchase of subsidiary	4,942
Purchase equipment	(18,850)	(3,718)
Deposits on business acquisition	-	(80,290)

Net Cash Flows (Used) in Investing Activities	(13,908)	(84,008)

Cash Flows From Financing Activities:
Proceed from note payable	609,885	660,565
Note payable - Interest expense	26,759	33,977
Payment of notes payable	(194,184)	(115,000)
Advances from related parties	29,930	2,251
Note payable used to pay expenses	36,500
Note payable used to pay origination fees & interest	18,750	25,000
Sale of common stock	-	63,912

Net Cash Flows Provided by Financing Activities	527,640	670,705

Net Increase (Decrease) In Cash and Cash Equivalents	926	43,177
Foreign currency translation adjustment	6,758	6,902
Cash and cash equivalents at beginning of period	$107,532	$57,453

Cash and cash equivalents at end of period	$115,216	$107,532

Supplementary Disclosure of Cash Flow Information:
Cash paid for interest	$23,496	$21,900
Stock issued for acquisition of Atlas Pharma Inc.	$238,000	$-
Stock issued for services	$676,100	$427,400
Stock issued for note and accrued interest conversions	$1,589,099	$128,451
Stock issued to buy equipment	$174,808	$56,700
Loan issued for interest	$45,509	$58,977

See Accompanying Notes To These Financial Statements.

F-4

Sunshine Biopharma, Inc.
Statement of Shareholders' Equity

	Number Of		Capital Paid	Number Of
	Common	Common	in Excess	Preferred	Preferred	Comprehensive	Accumulated
	Shares Issued	Stock	of Par Value	Shares Issued	Stock	Income	Deficit	Total
Balance at December 31, 2016	38,469,993	$38,470	$12,279,390	500,000	$50,000	$394	$(12,577,954)	$(209,700)

Common stock issued for cash	1,700,000	1,700	62,212					63,912

Common stock issued for services	3,090,217	3,090	424,310					427,400

Common stock issued for equipment	550,208	550	56,150					56,700

Common stock issued for the reduction of notes payable
and payment of interest	2,126,406	2,126	126,325					128,451


Net Income (Loss)	-	-	-			110	(1,040,236)	(1,040,126)
Balance at December 31, 2017	45,936,825	$45,936	$12,948,387	500,000	$50,000	$504	$(13,618,190)	$(573,363)

Common stock issued for the acquisition of Atlas Pharma, Inc.	1,000,000	1,000	237,000					238,000

Common stock issued for services	10,382,500	10,383	665,718					676,100

Common stock issued for equipment	1,456,737	1,457	173,351					174,808

Common stock issued for the reduction of notes payable and payment of interest	26,876,338	26,876	1,562,223					1,589,099


Net Income (Loss)	-	-	-			(4,242)	(2,156,155)	(2,160,397)
Balance at December 31, 2018	85,652,400	$85,652	$15,586,678	500,000	$50,000	$(3,738)	$(15,774,345)	$(55,753)

See Accompanying Notes To These Financial Statements.

F-5

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2018 and 2017

Note 1 – Description of Business

The Company was originally incorporated under the name Mountain West Business Solutions, Inc. (“MWBS”) on August 31, 2006 in the State of Colorado. Effective October 15, 2009, MWBS acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. MWBS concurrently changed its name to Sunshine Biopharma, Inc. and Sunshine Biopharma, Inc. changed its name to Sunshine Etopo, Inc. In 2015, Sunshine Etopo, Inc. became inactive and was recently dissolved.

On July 25, 2014, the Company formed a Canadian wholly owned subsidiary, Sunshine Biopharma Canada Inc., for the purposes of offering generic prescription drugs and over-the-counter dietary supplements.

On January 1, 2018, the Company acquired Atlas Pharma Inc., a Health Canada certified Canadian company offering chemical analysis of pharmaceutical and other industrial samples.

On March 23, 2018, the Company formed NOX Pharmaceuticals, Inc., a Colorado company that now holds all of the patents and intellectual property pertaining to Sunshine Biopharma Inc.’s proprietary drugs including Adva-27a, a multi-purpose anti-tumor compound targeted for the treatment of multidrug resistant cancer.

On December 17, 2018, the Company launched its first over-the-counter product, Essential 9tm, a dietary supplement comprised of the nine amino acids which the human body cannot synthesize. Essential 9tm has been authorized for marketing by Health Canada under NPN 80089663.

The following are Sunshine Biopharma, Inc.’s subsidiaries:

●

NOX Pharmaceuticals Inc., a wholly owned Colorado company;

●

Sunshine Biopharma Canada Inc., a wholly owned Canadian company; and

●

Atlas Pharma Inc., a wholly owned Canadian company.

Effective February 1, 2019, the Company completed a 20 to 1 reverse split of its $0.001 par value Common Stock reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400 (“Reverse Stock Split”).

The financial statements reflect the Reverse Stock Split on a retroactive basis and represent the consolidated activity of Sunshine Biopharma, Inc. and its subsidiaries (hereinafter collectively referred to as the "Company"). The Company was originally formed for the purposes of conducting research, development and commercialization of drugs for the treatment of various forms of cancer. The Company may also engage in any other business that is permitted by law, as designated by the Board of Directors of the Company.

During the last year the Company has continued to raise money through stock sales and borrowings.

The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company’s generic pharmaceuticals business and proprietary drug development program.

Note 2 – Summary of Significant Accounting Policies

This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the financial statements.

PRINCIPLES OF CONSOLIDATION

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

F-6

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2018 and 2017

USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

CASH AND CASH EQUIVALENTS

For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $115,216 and $107,532 as of December 31, 2018 and December 31, 2017, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 or the equivalent in Canada.

PROPERTY AND EQUIPMENT

Property and equipment is reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2018 and 2017, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.

Property and equipment are stated at cost. Depreciation is calculated using the straight-line method for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows:

Office Equipment:	5-7 Years
Laboratory Equipment	5 Years
Vehicles	5 Years

INTELLECTUAL PROPERTY RIGHTS - PATENTS

The cost of patents acquired is capitalized and is amortized over the remaining life of the patents.

The Company evaluates recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable. Such circumstances include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of cost significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the assets against the estimated undiscounted future cash flows associated with it.

The Company’s management determined that the expected cash flows would be less than the carrying amount of certain intangible assets; therefore an impairment loss was recognized in 2016. The impairment loss was calculated as the amount by which the carrying amount of the intangible assets exceeded fair value.

EARNINGS PER SHARE

The Company has adopted the Financial Accounting Standards Board (FASB) ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.

F-7

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2018 and 2017

INCOME TAXES

In accordance with ASC 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2018 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.

For Canadian and US tax purposes, the Company’s 2015 through 2017 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.

FUNCTIONAL CURRENCY

The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.

The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:

●

Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.

●

Income statement accounts are translated using the weighted average exchange rate for the period.

The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non U.S. currency transactions.

CONCENTRATION OF CREDIT RISKS

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.

FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company applies the provisions of accounting guidance, FASB Topic ASC 825, Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2018 and 2017, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.

The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

F-8

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2018 and 2017

Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.

NOTES PAYABLE

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method.

ACCOUNTING FOR DERIVATIVES LIABILITIES

The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense.

Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. The Company determined that none of the Company’s financial instruments meet the criteria for derivative accounting as of December 31, 2018 and 2017.

EQUITY INSTRUMENTS ISSUED TO NON-EMPLOYEES FOR AQUIRING GOODS OR SERVICES

Issuances of the Company’s common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.

F-9

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2018 and 2017

NONCASH EQUITY TRANSACTIONS

Shares of equity instruments issued for noncash consideration are recorded at the estimated fair market value of the consideration granted based on the estimated market value of the equity instrument, or at the estimated value of the goods or services received whichever is more readily determinable.

RELATED PARTIES

A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.

GENERAL AND ADMINISTRATIVE EXPENSES

General and administrative expenses consisted of professional service fees, rent and utility expenses, meals, travel and entertainment expenses, and other general and administrative overhead costs. Expenses are recognized when incurred.

BASIC AND DILUTED NET GAIN (LOSS) PER SHARE

The Company computes loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.

Basic net income (loss) per share is calculated by dividing net (loss) by the weighted-average common shares outstanding. Diluted net income per share is calculated by dividing net income by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2018 no potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.

Therefore, basic and dilutive net (loss) per share were the same as of December 31, 2018 and 2017.

COMMON STOCK

The Company completed a 20 to 1 reverse stock split of the $.001 par value Common Stock affective February 1, 2019. All shares in this filing have been restated to reflect the 20 to 1 reverse split.

REVENUE RECOGNITION

As of January 1, 2018, the Company adopted ASU No. 201409, “Revenue from Contracts with Customers” (ASU 201409). Under the new guidance, an entity will recognize revenue to depict the transfer of promised goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. A five-step model has been introduced for an entity to apply when recognizing revenue. The new guidance also includes enhanced disclosure requirements. The guidance was effective January 1, 2018 and was applied on a modified retospective basis. The adoption did not have an impact on the Company's financial statements. All of the revenues of the Company are generated by Atlas Pharma Inc., the Company's wholly owned Canadian subsidiary, which provides laboratory testing services. Performance obligations for testing services are recognized as revenue at a point in time on the date results are delivered to a customer which is when control is transferred.

Local governmental regulations require that companies recognize revenues upon completion of the work by issuing an invoice and remitting the applicable sales taxes (GST and QST) to the appropriate government agency. Atlas Pharma Inc.'s revenue recognition policy is in compliance with these local regulations.

F-10

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2018 and 2017

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 will require lessees to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with terms of more than 12 months. Lessor accounting remains substantially similar to current GAAP. In addition, disclosures of leasing activities are to be expanded to include qualitative along with specific quantitative information. ASU 2016-02 will be effective in fiscal years beginning after December 15, 2018 (with early adoption permitted). ASU 2016-02 mandates a modified retrospective transition method. The Company is currently evaluating the potential impact of adopting this guidance on our consolidated financial statements.

DIRECTOR AND OFFICER COMPENSATION

For the period ended December 31, 2018, the Company issued 4,050,000 shares of par value $0.001 Common Stock valued at $429,300 or $0.106 per share and 5,700,000 shares of par value $0.001 Common Stock to the Board of Directors valued at $171,000 or $0.03 per share. During the year ended December 31, 2018 the Directors and officers were paid $154,915 in cash. Of this amount, $85,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

For the period ended December 31, 2017, the Company issued 2,100,000 of par value $0.001 Common Stock to the three Company officers valued at $336,000 or $0.16 per share. During the year ended December 31, 2017 the Directors and officers were paid $184,271 in cash. Of this amount, $147,695 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

LEGAL FEES

During the years ended December 31, 2018 and 2017, the legal fees incurred were related to services provided to the Company to assist with its regulatory requirements with the Securities and Exchange Commission, patenting costs and one ongoing litigation.

DATE OF MANAGEMENT’S REVIEW

Subsequent events have been evaluated through April 12, 2019, which is the date the Financial Statements were available to be issued.

Note 3 – Going Concern

In the course of its life the Company has had limited operations and Working Capital deficit. This raises substantial doubt about the Company’s ability to continue as a going concern. The Company believes it can raise capital through equity sales and borrowing to fund its operations. Management believes this will contribute toward its subsequent profitability. The accompanying Financial Statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

F-12

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2018 and 2017

Note 4 – Patents

The following is a summary of the patents held by the Company at December 31, 2018 and 2017:

On October 8, 2015, the Company acquired U.S. Patent Number 8,236,935 (the “US Patent”) for the Adva-27a anticancer compound from Advanomics Corporation (“Advanomics”), a related party, in exchange for an interest-free note payable for $4,320,000. Effective December 28, 2015, the parties executed an amendment pursuant to which this note payable for $4,320,000 was cancelled and replaced with a new interest-free convertible note having a face value of $210,519, comprised of $155,940 in principal amount which is the Advanomics book value of the US Patent, plus $54,579 as an adjustment for the currency exchange difference. The new note is automatically convertible into 4,048,449 shares of the Company’s Common Stock upon the Company increasing its authorized capital to a level that would permit the issuance of such shares.

On December 28, 2015, the Company acquired the remaining worldwide issued and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 (the “Worldwide Patents”) for the Adva-27a anticancer compound from Advanomics, a related party, in exchange for a note payable for $12,822,499. Effective December 28, 2015, the parties executed an amendment pursuant to which this note payable for $12,822,499 was cancelled and replaced with a new interest-free convertible note having a face value of $624,875, comprised of $462,870 in principal amount, which is the Advanomics book value of the Worldwide Patents, plus $162,005 as an adjustment for the currency exchange difference. The new note is automatically convertible into 12,016,823 shares of the Company’s Common Stock upon the Company increasing its authorized capital to a level that would permit the issuance of such shares.

In July 2016, the Company issued 16,065,271 shares of $0.001 par value Common Stock in exchange for the aforementioned patents related notes payable totaling $835,394. In 2016, the remaining value of these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.

Note 5 – Capital Stock

The Company’s authorized capital is comprised of 3,000,000,000 shares of $0.001 par value Common Stock and 30,000,000 shares of $0.10 par value Preferred Stock, to have such rights and preferences as the Directors of the Company have or may assign from time to time. Out of the authorized Preferred Stock, the Company has designated 850,000 shares as Series “A” Preferred Stock (“Series A”). The Series A is convertible at any time after issuance into 20 shares of the Company's Common Stock with no further consideration, has full voting rights at 20 votes per share, and has superior liquidation rights to the Common Stock. During the year ended December 31, 2015, the Company authorized 500,000 shares of $0.10 par value Series “B” Preferred Stock (“Series B”). The Series B Preferred Stock is non-convertible, non-redeemable and non-retractable. It has superior liquidation rights to the Common Stock at $0.10 per share and gives the holder the right to 1,000 votes per share. All shares of the Series B Preferred Stock are held by the CEO of the Company. Through December 31, 2018 and December 31, 2017, the Company has issued and outstanding a total of 85,652,400 and 45,936,825 shares of Common Stock, respectively. Through the same periods, the Company has issued and outstanding a total of -0- and -0- shares of Series A Preferred Stock and 500,000 and 500,000 shares of Series B Preferred Stock, respectively. Effective February 1, 2019, the Company completed a 20 to 1 reverse split of its $0.001 par value Common Stock. All stock and price per share amounts in this report have been restated to reflect the 20 to 1 reverse split.

During the fiscal year ended December 31, 2018, the Company issued an aggregate of 39,715,575 shares of its Common Stock as follows:

●

1,000,000 shares for the acquisition of Atlas Pharma Inc.

●

1,456,737 shares for the purchase of laboratory and generic drugs warehouse equipment valued at $174,808

●

9,750,000 shares valued at $600,300 as compensation to the Company’s Directors and Officers

●

632,500 shares for services rendered to the Company by third parties valued at $75,800

●

26,876,338 shares valued at $1,589,099 connection with the conversion of $684,318 in debt and interest of $32,808 resulting in a $871,973 loss on conversion

F-13

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2018 and 2017

During the fiscal year ended December 31, 2017, the Company issued an aggregate of 7,466,832 shares of its Common Stock as follows:

●

1,700,000 shares for cash in the amount of $100,000 Canadian or $78,312 US

●

550,208 shares for the purchase of laboratory and generic drugs warehouse equipment valued at $56,700

●

2,400,000 shares valued at $336,000 as compensation to the Company’s Directors and Officers

●

690,218 shares for services rendered to the Company by third parties valued at $77,000

●

2,126,406 shares valued at $128,451 in connection with the conversion of $48,500 in debt and interest of $3,022 resulting in a $76,929 loss on conversion.

The Company has declared no dividends since inception.

Note 6 – Earnings Per Share

The following table sets forth the computation of basic and diluted net income per share for the years ended December 31:

	2018	2017
Net (loss) attributable to Common Stock	$(2,156,155)	$(1,040,236)
Basic weighted average outstanding shares of Common Stock	60,936,164	43,634,280
Dilutive effects of common share equivalents	-0-	-0-
Dilutive weighted average outstanding shares of common stock	60,936,164	43,634,280
Net (loss) attributable to Common Stock	$(0.04)	$(0.02)

Note 7 – Income Taxes

The Company files a United States federal income tax return and a Canadian branch return on a calendar year basis. The Company and its wholly-owned subsidiaries, Sunshine Biopharma Canada Inc. and Atlas Pharma Inc., have not generated taxable income since inception.

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur. The Company accounts for income taxes pursuant to ASC 740.

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses and other items. Loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.

F-14

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2018 and 2017

The Company follows FASB Statement Accounting Standards Codification No. 740, “Accounting for Income Taxes”, which requires, among other things, an asset and liability approach to calculating deferred income taxes. The components of the deferred income tax assets and liabilities arising under ASC No. 740 were as follows:

The types of temporary differences between the tax basis of assets and their financial reporting amounts that give rise to a significant portion of the deferred assets and liabilities are as follows:

	December 31, 2018		December 31, 2017
	Temporary Difference	Tax Effect	Temporary Difference	Tax Effect
Deferred tax assets:
Net operating loss US	$12,156,020	$2,997,675	$10,611,921	$3,932,778
Net operating loss Canada	298,661	80,041	266,498	71,421
Total	12,454,681	3,077,716	10,878,419	4,004,199
Valuation allowance	(12,454,681)	(3,077,716)	(10,878,419)	( 4,004,199)
Total deferred tax asset	-0-	-0-	-0-	-0-
Net deferred tax asset	-0-	-0-	-	-

At December 31, 2018 and December 31, 2017, the Company had approximately $12,454,681 and $10,878,419 respectively, in unused federal net operating loss carryforwards, which begin to expire principally in the year 2029. A deferred tax asset at each date of approximately $3,077,716 and $4,004,199 resulting from the loss carryforwards has been offset by a 100% valuation allowance. The change in the valuation allowance for the period ended December 31, 2018 and December 31, 2017 was approximately $926,483 and $342,693, respectively.

F-15

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2018 and 2017

A reconciliation of the U.S. statutory federal income tax rate to the effective tax rate is as follows:

	December 31,
	2018	2017
U.S. Federal statutory graduated rate	21.00%	34.00%
State income tax rate, net of federal benefit	4.12%	3.06%
Net rate	25.12%	37.06%

Net operating loss used	0.00%	0.00%
Net operating loss for which no tax benefit is currently available	-25.12%	-37.06%
	0.00%	0.00%

Canada Federal statutory rate	15.00%	15.00%
Canada Provincial rate	11.80%	11.80%
Net Canada rate	26.80%	26.80%

Net operating loss used (Canada)	0.00%	0.00%
Net operating loss for which no tax benefit is currently available (Canada)	-26.80%	-26.80%
	0.00%	0.00%

The Company’s income tax filings are subject to audit by various taxation authorities. The Company’s open audit periods are 2015, 2016, and 2017, although, the statute of limitations for the 2015 tax year will expire effective March 15, 2019. In evaluating the Company’s provisions and accruals, future taxable income, and reversal of temporary differences, interpretations and tax planning strategies are considered. The Company believes its estimates are appropriate based on current facts and circumstances.

F-16

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2018 and 2017

Note 8 – Notes Payable

Notes payable consist of the following:

	2018	2017

A Note Payable having a Face Value of $24,012 at December 31, 2016 and accruing interest at 12% was due December 31, 2017 (“2016 Note”). On December 31, 2017, the Company renewed the 2016 Note, together with accrued interest of $2,573, for a 12-month period (“2017 Note”). On December 31, 2018 the Company renewed the 2017 Note, together with accrued interest of $2,881, for a 12-month period (“2018 Note”). The 2018 Note has a Face Value of $26,893 and accrues interest at 12%. The 2018 Note is nonconvertible.	$26,893	$24,012

On January 12, 2018 the Company received monies in exchange for a Note Payable having a Face Value of $102,000 with interest accruing at 8% is due October 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $4,080 was converted in 2018 into 3,569,333 shares of Common Stock valued at $166,085 resulting in a loss of $60,005.	$-0-	-0-

On February 7, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $150,000 with interest accruing at 8% is due February 7, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note was paid off in 2018 in part by cash of $48,000 and the remainder, together with accrued interest of $5,073, was converted into 5,710,642 shares of Common Stock valued at $183,411 resulting in a loss of $76,338.	$-0-	$-0-

On February 20, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $85,000 with interest accruing at 8% is due November 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $3,400, was converted in 2018 into 4,376,238 shares of Common Stock valued at $281,663 resulting in a loss of $193,263.	$-0-	$-0-

On May 29, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $26,750 with interest accruing at 8% is due February 29, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued interest of $1,353, was converted into 4,003,265 shares of Common Stock valued at $192,157 resulting in a loss of $164,054.	$-0-	$-0-

On June 27, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $53,000 with interest accruing at 8% is due April 15, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $2,137. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.	$53,000	$-0-

On August 17, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $53,000 with interest accruing at 8% is due April 15, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $1,557. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.	$53,000	$-0-

On September 10, 2018, the Company received monies in exchange for two Notes Payable having an aggregate Face Value of $36,500 with interest accruing at 8% are due June 20, 2019. Interest accrued at December 31, 2018 was $888.	$36,500	$-0-

On October 23, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $90,000 with interest accruing at 8% is due October 23, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $1,361. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.	$90,000	$-0-

F-17

On December 24, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $87,000 with interest accruing at 8% is due October 23, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $153. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.	$87,000	$-0-

On April 1, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $100,000 Canadian ($73,270US) at December 31, 2018 and ($79,710 US) at December 31, 2017 with interest payable quarterly at 9% is due April 1, 2019. The Note is convertible any time after issuance into $0.001 par value Common Stock at a price of $0.015 Canadian (approximately $0.012 US) per share. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.	$73,270	$79,710

On August 3, 2017 the, Company received monies in exchange for a Note Payable having a Face Value of $ 80,000 with interest accruing at 8% is due August 3, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. A principal amount of $40,000 of this note plus accrued interest of $1,712 was converted in 2018 into 327,788 shares of Common Stock valued at $70,507 resulting in a loss of $28,795. The remaining principal amount of $40,000 together with accrued interest of $1,613 was paid in cash reducing the balance to $-0-	$-0-	$80,000

On August 21, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $ 83,000 with interest accruing at 8% is due May 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, plus accrued interest of $3,419, was paid off in 2018.	$-0-	$83,000

On September 22, 2017 the Company received monies in exchange for a note having a Face Value of $ 62,000 with interest accruing at 8% is due June 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued interest of $2,480 was converted in 2018 into 790,590 shares of Common Stock valued at $107,056 resulting in a loss of $42,576.	$-0-	$62,000

On October 26, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $ 115,000 with interest accruing at 8% is due October 26, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued interest of $6,126, was converted in 2018 into 2,921,146 shares of Common Stock valued at $208,661 resulting in a loss of $87,535.	$-0-	$62,000

On November 14, 2017, the Company received monies in exchange for a Note Payable having a Face Value of $ 113,000 with interest accruing at 8% is due November 14, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $7,018 was converted in 2018 into 4,917,251 shares of Common Stock valued at $351,999 resulting in a loss of $231,981.	$-0-	$115,000

On December 1, 2017, the Company received monies in exchange for a Note Payable having a Face Value of $50,000 Canadian ($38,568 US) at December 31, 2018 and ($39,855 US) at December 31, 2017 with interest accruing at 8% is due November 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $1,566 was converted in 2018 into 260,000 shares of Common Stock valued at $27,560 resulting in a gain of $12,574.	$-0-	$113,000

Total Notes Payable	$419,663	$596,577

Interest expense for the years ended December 31, 2018 and 2017 was $159,420 and $79,674, respectively. The balance of interest payable at December 31, 2018 and 2017 was $9,291 and $9,215, respectively. Loss on conversion of notes payable for the years ended December 31, 2018 and 2017 was $871,973 and $76,929 respectively.

F-18

Note 9 – Notes Payable Related Party

Notes payable to related parties consist of the following:	2018	2017

A Note Payable held by a private individual who became a principal shareholder of the Company having a Face Value of $118,537 at September 30, 2017 and a maturity date of December 31, 2017, accrues interest at 12%. The Note is convertible any time from the date of issuance into $0.001 par value Common Stock at a 35% discount from market price. On December 31, 2017 the Note together with accrued interest was renewed for a 12-month period under the same terms and conditions as before. The new Note has a Face Value of $122,093 and matures on December 31, 2018. On December 31, 2018 the Note, together with accrued interest of $14,651 was renewed for a 12-month period. The new Note has a Face value of $136,744 and matures on December 31, 2019. The new Note is nonconvertible. This individual ceased to be a principal shareholder of the Company in the third quarter of 2018	$136,744	$122,093

In December 2016, the Company received monies from its CEO in exchange for a note payable having a principal amount of $90,000 Canadian ($67,032 US) with interest at 12% due March 31, 2017. The note was convertible any time after the date of issuance into $0.001 par value Common Stock at a price 35% below market value. This note was collateralized by all of the assets of the Company. In the event of default, the interest rate will increased to 18% per annum and a penalty of $1,000 Canadian ($752 US) per day will accrue. On March 31, 2017, the note, together with accrued interest of $3,021 Canadian ($2,271 US) and an additional principal amount of $3,000 Canadian ($2,247 US) paid to the Company on March 28, 2017, was renewed for a 90-day period under the same terms and conditions as the original note. The new note now having a face value of $96,021 Canadian ($72,198 US) was due on June 30, 2017. On June 30, 2017, the note, together with accrued interest of $2,873 Canadian ($2,005 US), was renewed for a 90-day period under the same terms and conditions as the original note except that the new note is nonconvertible. The new note now having a face value of $98,894 Canadian ($76,072US) is due on September 30, 2017. On September 30, 2017, the note, together with accrued interest of $2,991 Canadian ($2,397 US) was renewed for a 90-day period under the same terms and conditions as the original note except that the new note is nonconvertible. The new note now having a principal balance of $101,885 Canadian ($81,640 US) matures December 31, 2017. On December 31, 2017 the note was renewed for a 12month period under the same terms and conditions as before except that this new note is unsecured and nonconvertible. The new note has a face value of $104,942 Canadian ($83,649 US) and matures on December 31, 2018. On December 31, 2018 the note was renewed for a 12-month period under the same terms and conditions as the previous note. The new note together with interest of $9,227, has a face value of $86,118 US ($117,535 CAD) and matures on December 31, 2019.	86,118	83,649

On January 1, 2018 as part of the acquisition of Atlas Pharma Inc., the Company issued a note payable in the amount of $450,000 Canadian ($358,407 US) and accruing interest at the rate of 3% per annum. The note is due on December 31, 2023. Payments on this note are $10,000 Canadian (approximately $8,000 US) per quarter. The outstanding principal balance at December 31, 2018 was $310,079. The note is nonconvertible and is secured by the Atlas Pharma Inc. shares held by the Company. The holder of this note is currently a director and officer of Atlas Pharma Inc.	$310,079	$-0-

Total Notes Payable Related Party	$532,941	$205,742

Long-Term Portion	$289,847	$79,710

F-19

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2018 and 2017

Note 10 – Related Party Transactions

In addition to the transactions specified under Note 9 above, during the period ended December 31, 2018, the Company issued 4,050,000 shares of par value $0.001 Common Stock valued at $429,300 or $0.106 per share and 5,700,000 shares of par value $0.001 Common Stock to the Board of Directors valued at $171,000 or $0.03 per share. During the year ended December 31, 2018 the Directors and Officers were paid $154,915 in cash. Of this amount, $85,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

For the period ended December 31, 2017, the Company issued 2,100,000 of par value $0.001 Common Stock to the three Company officers valued at $336,000 or $0.008 per share. During the year ended December 31, 2017 the Directors and officers were paid $184,271 in cash. Of this amount, $147,695 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

During the year ended December 31, 2018, certain Directors of the Company made interest free cash advances to the Company totaling $49,349.

Note 11 – Royalties Payable

As part of a subscription agreement entered into in 2016, the Company had an obligation to pay a royalty of 5% of net sales on one of its generic products (Anastrozole) for a period of three (3) years from the date of the first sale of that product. In September 2018, 50,000 shares of the Company’s Common Stock valued at $5,900 were issued in exchange for cancellation of this royalty obligation.

Note 12 – Acquisition of Atlas Pharma Inc.

On January 1, 2018 the Company acquired all of the issued and outstanding shares of Atlas Pharma Inc. (“Atlas”), a Canadian privately held company. The purchase price for the shares was Eight Hundred Forty Thousand Dollars $848,000 Canadian ($676,748 US). The purchase price included a cash payment of $100,500 Canadian ($80,289 US), plus the issuance of 1,000,000 shares of the Company’s Common Stock valued at $238,000 or $0.238 per share, and a promissory note in the principal amount of $450,000 Canadian ($358,407 US), with interest payable at the rate of 3% per annum. Atlas is a certified company dedicated to chemical analysis of pharmaceutical and other industrial samples. Atlas’ operations are authorized by a Drug Establishment License issued by Health Canada. Atlas is also registered with the FDA. The Company has performed analysis of the fair market value of Atlas Pharma Inc. assets and liabilities. The following table summarizes the allocation of the purchase price as of the acquisition date:

Cash	$4,942
Accounts receivable	$79,508
Prepaids	$1,428
Property and equipment	$62,990
Goodwill	$665,697
Less: Liabilities assumed ($172,899 Canadian)	$(137,817)
Total consideration	$676,748

Note 13 – Accounts Receivable

Accounts receivable consist of trade accounts arising in the normal course of business and are classified as current assets and carried at original invoice amounts less an estimate for doubtful receivables based on a review of outstanding balances on a monthly basis. The estimate of allowance for doubtful accounts is based on the Company's bad debt experience, market conditions, and aging of accounts receivable, among other factors. If the financial condition of the Company's customers deteriorates resulting in the customer's inability to pay the Company's receivables as they come due, additional allowances for doubtful accounts will be required.

F-20

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2018 and 2017

Note 14 – Commitments

The Company’s subsidiary, Atlas Pharma Inc., has entered into long-term lease agreements for the rental of buildings which call for minimum aggregate lease payments of $150,347 Canadian (approximately $115,767 US) and additional lease payments based on operating expenses. The lease expires on May 21, 2021. Minimum lease payments for the next three years are $62,213 (approximately $47,904 US) in 2019, $62,213 (approximately $47,904 US) in 2020, and $25,921 (approximately $19,959 US) in 2021.

Note 15 – Subsequent Events

On January 1, 2019, the Company paid $69,931 to pay off the principal ($53,000) and accrued interest ($16,931) on a note payable dated June 27, 2018.

On January 8, 2019, the Company received net proceeds of $50,500 in exchange for a note payable having a face value of $54,000 and accruing interest at the rate of 8% per annum. The note, due on January 8, 2020, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.

On January 10, 2019, the Company received net proceeds of $38,000 in exchange for a note payable having a face value of $40,660 and accruing interest at the rate of 8% per annum. The note, due on October 10, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.

On February 5, 2019, the Company received net proceeds of $35,000 in exchange for a note payable having a face value of $37,450 and accruing interest at the rate of 8% per annum. The note, due on October 10, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.

On February 11, 2019, the Company received net proceeds of $50,000 in exchange for a note payable having a face value of $52,000 and accruing interest at the rate of 8% per annum. The note, due on November 30, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.

On March 4 and 13, 2019 the holder of a note payable dated August 17, 2018 elected to convert $25,000 in principal into 3,696,581 shares of Common Stock leaving a principal balance of $28,000.

On March 18, 2019, the Company received net proceeds of $38,000 in exchange for a note payable having a face value of $40,660 and accruing interest at the rate of 8% per annum. The note, due on December 18, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.

On March 18, 2019, the Company received another $38,000 of net proceeds in exchange for a note payable having a face value of $40,660 and accruing interest at the rate of 8% per annum. The note, due on December 18, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.

F-21

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None

ITEM 9A. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Disclosure Controls and Procedures – Our management, with the participation of our Chief Executive Officer, Chief Financial Officer, and Chief Operations Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this Report.

These controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions regarding required disclosure.

Based on this evaluation, our management, including our CEO and CFO, concluded that our disclosure controls and procedures were not effective as of December 31, 2018, at reasonable assurance level, for the following reasons:

●

ineffective control environment and lack of qualified full-time CFO who has SEC experience to focus on our financial affairs;

●

lack of qualified and sufficient personnel, and processes to adequately and timely identify making any and all required public disclosures;

●

deficiencies in the period-end reporting process and accounting policies;

●

inadequate internal controls over the application of new accounting principles or the application of existing accounting principles to new transactions;

●

inadequate internal controls relating to the authorization, recognition, capture, and review of transactions, facts, circumstances, and events that could have a material impact on the company’s financial reporting process;

●

deficient revenue recognition policies;

●

inadequate internal controls with respect to inventory tracking and transactions; and

●

improper and lack of timely accounting for accruals such as prepaid expenses, accounts payable and accrued liabilities.

Our Board of Directors has assigned a priority to the short-term and long-term improvement of our internal control over financial reporting. We are reviewing various potential solutions to remedy the processes that would eliminate the issues that may arise due to the absence of separation of duties within the financial reporting functions. Additionally, the Board of Directors will work with management to continuously review controls and procedures to identified deficiencies and implement remediation within our internal controls over financial reporting and our disclosure controls and procedures.

We believe that our financial statements presented in this annual report on Form 10-K fairly present, in all material respects, our financial position, results of operations, and cash flows for all periods presented herein.

Inherent Limitations – Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple error or mistake. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.

Changes in Internal Control over Financial Reporting – There were no changes in our internal control over financial reporting during our fiscal year ended December 31, 2018, which were identified in conjunction with management’s evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management’s report in this Annual Report.

Management Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act. Those rules define internal control over financial reporting as a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

●

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;

●

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and the receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the Company; and

●

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2018. In making this assessment, our management used the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Based on an assessment carried out April 1-10, 2018, management believes that, as of December 31, 2018, our internal control over financial reporting were ineffective based in part on the issues discussed above.

ITEM 9B. OTHER INFORMATION

None

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Following is a list of our officers and directors:

Name	Age	Position(s)

Dr. Steve N. Slilaty	66	President, Chief Executive Officer, and Chairman

Dr. Abderrazzak Merzouki	55	Chief Operating Officer and Director

Camille Sebaaly	58	Chief Financial Officer, Secretary and Director

Our directors serve as directors until our next Annual Meeting of Stockholders and the election and qualification of the director’s respective successor or until the director’s earlier death, removal or resignation.

Following is biographical information of our current management:

Dr. Steve N. Slilaty was appointed as our CEO, President and Chairman of our Board of Directors on October 15, 2009. Dr. Slilaty is an accomplished scientist and business executive. His scientific publications are widely cited including university textbooks. Sunshine Biopharma is the third in a line of biotechnology companies that Dr. Slilaty founded and managed through their early and mid-stages of development. The first, Quantum Biotechnologies Inc. later known as Qbiogene Inc., was founded in 1991 and grew to over $60 million in annual sales. Today, Qbiogene is a member of a family of companies owned by MP Biomedicals, one of the largest international suppliers of biotechnology reagents and other research products. The second company which Dr. Slilaty founded, Genomics One Corporation, later known as Alert B&C Corporation, conducted an initial public offering (IPO) of its capital stock in 1999 and, on the basis of its ownership of Dr. Slilaty’s patented TrueBlue® Technology, Genomics One became one of the key participants in the Human Genome Project. Formerly a research team leader of the Biotechnology Research Institute, a division of the National Research Council of Canada, Dr. Slilaty also served as a consultant in a management and advisory capacity for a major Canadian biotechnology company between 1995 and 1997 during which time the company completed one of the largest biotechnology IPO‘s in Canada. Dr. Slilaty is one of the pioneers of Gene Therapy having developed the first gene delivery system applicable to humans in 1983 [Science 220:725-727 (1983)]. Dr. Slilaty's other distinguished scientific career accomplishments include the discovery of a new class of enzymes, the S24 Family of Proteases (IUBMB Enzyme Nomenclature: EC 3.4.21.88), development of the first site-directed mutagenesis system applicable to double-stranded DNA, cloning the gene for the first yeast-lytic enzyme (lytic b-1,3-glucanase), developing a new molecular strategy for increasing the rate of enzyme reactions, inventing a powerful new cloning system for genomic cloning and gene discovery (TrueBlue® Technology) and developing a new transcriptomics technology for generating entire RNA profiles. These and other works of Dr. Slilaty are cited in research papers, editorials, review articles and textbooks. Dr. Slilaty received his Ph.D. degree in Molecular Biology from the University of Arizona in 1983 and Bachelor of Science degree in Genetics and Biochemistry from Cornell University in 1976. In addition, Dr. Slilaty holds a position as Adjunct Professor at Université du Québec in the Department of Microbiology and Biotechnology. He devotes approximately 50% of his time to our business affairs.

Dr. Abderrazzak Merzouki was appointed as a Director and our Chief Operating Officer in February 2016. In addition to his new positions with our Company, since January 2016 he has been self-employed as a consultant in the fields of biotechnology and pharmacology. From July 2007 through December 2016, Dr. Merzouki worked at the Institute of Biomedical Engineering in the Department of Chemical Engineering at Ecole Polytechnique de Montreal, where he taught and acted as a senior scientist involved in the research and development of plasmid and siRNA-based therapies. Dr. Merzouki is a molecular biologist and an immunologist with extensive experience in the area of gene therapy where he performed several preclinical studies for pharmaceutical companies involving the use of adenoviral vectors for cancer therapy and plasmid vectors for the treatment of peripheral arterial occlusions. Dr. Merzouki also has extensive expertise in the design of expression vectors, and production and purification of recombinant proteins. He developed technologies for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. Dr. Merzouki obtained his Ph.D. in Virology and Immunology from Institut Armand-Frappier in Quebec and received his post-doctoral training at the University of British Columbia and the BC Center for Excellence in HIV/AIDS research. Dr. Merzouki has over 30 publications and 70 communications in various, highly respected scientific journals in the field of cellular and molecular biology. He will devote approximately 50% of his time to our business affairs.

Camille Sebaaly was appointed as our Chief Financial Officer, Secretary and a Director of our Company on October 15, 2009. Since 2001, Mr. Sebaaly has been self-employed as a business consultant, primarily in the biotechnology and biopharmaceutical sectors. He held a number of senior executive positions in various areas including, financial management, business development, project management and finance. As an executive and an entrepreneur, he combines expertise in strategic planning and finance with strong skills in business development and deal structure and negotiations. In addition, Mr. Sebaaly worked in operations, general management, investor relations, marketing and business development with emphasis on international business and marketing of advanced technologies including hydrogen generation and energy saving. In the area of marketing, Mr. Sebaaly has evaluated market demands and opportunities, created strategic marketing and business development plans, designed marketing communications and launched market penetration programs. Mr. Sebaaly was a cofounder of Advanomics Corporation with Dr. Slilaty. Mr. Sebaaly graduated from State University of New York at Buffalo with an Electrical and Computer Engineering Degree in 1987. He devotes approximately 50% of his time to our business affairs.

There are no family relationships between any of our former or current officers and directors.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934 (the “34 Act”) requires our officers and directors and persons owning more than ten percent of the Common Stock, to file initial reports of ownership and changes in ownership with the Securities and Exchange Commission (“SEC”). Additionally, Item 405 of Regulation S-K under the 34 Act requires us to identify in our Form 10-K and proxy statement those individuals for whom one of the above referenced reports was not filed on a timely basis during the most recent year or prior years. To our best knowledge, all reports that were required to be filed were filed, though some were filed late.

Code of Ethics

Our board of directors has not adopted a code of ethics but plans to do so in the near future.

Committees of the Board of Directors

There are no committees of the Board of Directors but it is anticipated that we will establish an audit committee, nominating committee and governance committee once independent directors are appointed, which is expected to occur at such time as financing for our drug development program is secured, of which there are no assurances.

ITEM 11. EXECUTIVE COMPENSATION

The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to our executive officers. We do not currently have an established policy to provide compensation to members of our Board of Directors for their services in that capacity, although we may choose to adopt a policy in the future.

SUMMARY COMPENSATION TABLE

Name and Principal Position	Year	Salary ($)		Bonus ($)	Stock Awards ($)		All Other Compensation ($)	Total ($)

Dr. Steve N. Slilaty,	2016	1,000		-	164,600	(1)	-	165,600
Chief Executive Officer and Director	2017	155,641	(2)	-	112,000	(3)	-	267,641
	2018	85,000	(4)	-	200,100	(5)	-	285,100

Camille Sebaaly,	2016	4,597		-	164,600	(1)	-	169,197
Chief Financial Officer and Director	2017	16,099		-	112,000	(3)	-	128,099
	2018	37,500		-	200,100	(5)	-	237,600

Dr. Abderrazzak Merzouki,	2016	-0-		-	164,600	(1)	-	164,600
Chief Operating Officer and Director	2017	12,531		-	112,000	(3)	-	124,531
	2018	32,415		-	200,100	(5)	-	232,515

(1)

In 2016, each member of our Board of Directors was issued 1,300,000 and 600,000 shares of our Common Stock valued at $80,600 and $84,000, respectively.

(2)

This includes $147,695 paid to Advanomics Corporation, a company controlled by our CEO.

(3)

In 2017, each member of our Board of Directors was issued 700,000 shares of our Common Stock valued at $112,000.

(4)

This amount was paid to Advanomics Corporation, a company controlled by our CEO.

(5)

In 2018, each member of our Board of Directors was issued 1,350,000 and 1,900,000 shares of our Common Stock valued at $143,100 and $57,000, respectively.

Salaries are established by our Board of Directors. We currently do not have a Compensation Committee but expect to have one in place in the future once we have independent directors. We have not and do not expect to pay any other compensation to our current executive officers or directors until such time as we are able to secure adequate funding for our operations.

Employment Agreements

None of our executive officers is party to an employment agreement with us.

Stock Plan

We have not adopted any stock option or other employee plans as of the date of this Report. We may adopt such plans in the future.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table sets forth certain information regarding the ownership of Common Stock and Preferred Stock voting with the Common Stock as of the date of this Report by (i) each person known to us to own more than 5% of our outstanding Common Stock as of the date of this Report, (ii) each of our directors, (iii) each of our executive officers, and (iv) all of our directors and executive officers as a group. Unless otherwise indicated, all shares are owned directly and the indicated person has sole voting and investment power. The information provided is based upon 87,041,289 Common Shares and 500,000 Series B Preferred Shares issued and outstanding as of the date of this Report.

Title of Class	Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership	Percent of Common Class	Percent of Voting Shares

Common	Dr. Steve N. Slilaty(1) 579 Rue Lajeunesse Laval, Quebec Canada H7X 3K4	16,619,930(2)	19.09%	2.83%
Series B Preferred		500,000,000(3)	0%	85.17%

Common	Camille Sebaaly(1) 14464 Gouin West, #B Montreal, Quebec Canada H9H 1B1	12,335,165(4)	14.17%	2.10%

Common	Dr. Abderrazzak Merzouki(1) 731 Place de l’Eeau Vive Laval, Quebec Canada H7Y 2E1	5,923,350	6.81%	1.01%

Common	All Officers and Directors As Group (3 persons)	534,878,445	40.07%	91.11%

(1)

Officer and Director.

(2)

Includes 10,750,712 shares held in the name of Advanomics Corporation. Dr. Slilaty is an officer, director and principal shareholder of Advanomics Corporation and, as a result, controls the disposition of these shares.

(3)

Comprised of 500,000 shares of $0.10 par value Series “B” Preferred Stock having 1,000 votes per share. The Series “B” Preferred Stock is non-convertible, non-redeemable, non-retractable and has a superior liquidation value of $0.10 per share.

(4)

Includes 6,474,447 shares held in the name of 4019318 Canada, Inc. Mr. Sebaaly is the sole officer and director of this company and, as a result, controls the disposition of these shares.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

Related Party Transactions

On November 27, 2014, we issued a note payable in the principal amount of $128,000 to an individual who subsequently became a principal shareholder. The note accrues interest at 10% per annum and was convertible into shares of our Common Stock at a price of $0.20 per share. On June 30, 2015, we renewed this note with the addition of accrued interest of $7,540 and an origination fee of $25,600. The new Note had a face value of $161,140 and accrued interest at 12% per annum. The new note was due December 31, 2015 and was convertible any time from the date of issuance into shares of our Common Stock at a 35% discount from market price. On December 31, 2015, we again renewed this note with the addition of accrued interest amounting to $9,668 and an origination fee of $32,228. The new note now has a face value of $203,036 and accrues interest at 12% per annum. The new note was due June 30, 2016 and was convertible anytime from the date of issuance into shares of our Common Stock at a 35% discount from market price. In January 2016, $38,036 of the principal was converted, leaving a principal balance of $165,000. In connection therewith, 7,705,186 shares of our Common Stock, valued $231,156 were issued generating a loss on conversion of $193,120. On June 30, 2016, we renewed this note again with the addition of accrued interest amounting to $9,852. The renewed note had a face value of $174,852 and accrues interest at 12% per annum. It was due on March 31, 2017. In October 2016, $74,852 of the principal amount was converted, leaving a principal balance of $100,000. On March 31, 2017, the note’s principal balance of $100,000 plus accrued interest of $11,715 was renewed for a period of 90 days under the same terms and conditions as the previous note. The new note now had a face value of $111,715 and matured on June 30, 2017. On June 30, 2017, the note’s principal balance of $111,715 plus accrued interest of $3,342 was renewed for a period of 90 days under the same terms and conditions as its predecessor. The new note had a face value of $115,057 and matured on September 30, 2017. On September 30, 2017, the note’s principal balance of $115.057 plus accrued interest of $3,480 was renewed for a period of 90 days under the same terms and conditions as the previous note. The new note had a principal balance of $118,537 and matured on December 31, 2017. On December 31, 2017 the note was renewed for a 12-month period under the same terms and conditions as the prior note. The new note has a face value of $122,093 and matures on December 31, 2018. On December 31, 2018 the note, together with accrued interest of $14,651 was renewed for a 12-month period. The new Note has a face value of $136,744 and matures on December 31, 2019. The new note is not convertible. In the third quarter of 2018, this individual ceased to be a principal shareholder of the Company.

In December 2016, we received monies from our CEO in exchange for a note payable having a principal amount of $90,000 Canadian ($67,032 US) with interest at 12%. The note was convertible any time after the date of issuance into shares of our Common Stock at a price 35% below market value. In addition, the note was collateralized by all our assets. On March 31, 2017, the note, together with all accrued interest thereon and an additional principal amount of $3,000 Canadian paid to us in March 2017, was renewed for a 90-day period under the same terms and conditions as the original note. The new note now having a face value of $96,021 Canadian ($72,198 US) was due on June 30, 2017. On June 30, 2017, the note, together with accrued interest of $2,873 Canadian ($2,005 US), was renewed for a 90-day period under the same terms and conditions as the original note except that the new note is nonconvertible. The new note now having a face value of $98,894 Canadian ($76,072US) was due on September 30, 2017. On September 30, 2017, the note, together with accrued interest of $2,991 Canadian ($2,397 US), was renewed for a 90-day period under the same terms and conditions as its predecessor. The new note now having a principal balance of $101,885 Canadian ($81,640 US) matured on December 31, 2017. On December 31, 2017 the note was renewed for a 12-month period under the same terms and conditions as before except that this new note is unsecured and now non-convertible. The new note has a face value of $104,942 Canadian ($83,649 US) and matures on December 31, 2018. On December 31, 2018 the note, together with accrued interest of $9,227, was renewed for a 12-month period under the same terms and conditions as the previous note. The new has a face value of $117,535 Canadian ($86,118 US) and matures on December 31, 2019.

On October 8, 2015, we acquired U.S. Patent Number 8,236,935 (the “US Patent”) for the anticancer compound, Adva-27a from a related entity (Advanomics Corporation), which includes all rights to this intellectual property within the United States, in exchange for an interest-free note payable for $4,320,000 (the “October Patent Purchase Agreement”). On December 28, 2015, we acquired the remaining worldwide issued and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 (the “Worldwide Patents”) for the Adva-27a anticancer compound from the same related entity (Advanomics Corporation) in exchange for a note payable for $12,822,499 (the “December Patent Purchase Agreement”). We believe that purchase of the US Patent and the Worldwide Patents (the “Patents”) would facilitate our ability to obtain the funding necessary to complete the development and FDA approval process for Adva-27a. In related party transactions, purchased patents are required to be recorded at the purchase price or the book value on the seller’s financial statements, whichever is lower. Effective December 28, 2015, the parties agreed to amend the October Patent Purchase Agreement and the December Patent Purchase Agreement. Pursuant to the amendment agreements (the “Amendments”), the Patents were purchased from the related party, Advanomics Corporation, at Advanomics’ cost less the amortization through December 28, 2015, the effective date of the transfer. The Amendments amended the purchase price of the Patents to $835,394, eliminated all cash payments obligations and replaced the non-convertible notes totaling $17,142,499 with two (2) convertible notes totaling $835,394 that automatically convert into an aggregate of 321,305,415 shares of our Common Stock when we successfully amend our Articles of Incorporation to increase our authorized capital of Common Stock to 3 billion. In July 2016, having completed the increase of our authorized capital to 3 billion shares of Common Stock, we issued the 321,305,415 Common Shares to Advanomics thereby completing all aspects of the patent purchase arrangements and securing direct ownership of all worldwide patents and rights pertaining to Adva-27a.

In 2016 and 2017 our principal place of business was located at 469 Jean-Talon West, 3rd Floor, Montreal, Quebec, Canada, H3N 1R4. This was also the location of our former licensor, Advanomics Corporation, who provided this space to us on a rent-free basis. Dr. Steve N. Slilaty, our Chief Executive Officer and a Director, is an Officer, Director and principal shareholder of Advanomics. Starting January 1 2017 we assumed the lease from Advanomics until we moved on June 1, 2017.

During the year ended December 31, 2018, we issued an aggregate of 9,750,000 shares of our Common Stock valued at $600,300 to the members of our Board of Directors in equal amounts. During the year ended December 31, 2018 our Directors and Officers were paid $154,915 in cash. Of this amount, $85,000 was paid to Advanomics Corporation, a company controlled by our CEO.

During the year ended December 31, 2018, certain of our Directors made interest-free cash advances to us totaling $49,349. At December 31, 2018, the outstanding balance of these loans was $49,349.

During the fiscal ended December 31, 2017, we issued 2,100,000 shares of our Common Stock to our Board of Directors in equal amounts. These shares were valued at $336,000 or $0.16 per share. During the same period, our Directors and Officers were paid $184,271 in cash. Of this amount, $147,695 was paid to Advanomics Corporation, a company controlled by our CEO.

On January 1, 2018 as part of the acquisition of Atlas Pharma Inc., we issued a note payable in the amount of $450,000 Canadian ($358,407 US), accruing interest at the rate of 3% per annum. The note is due on December 31, 2023. Payments on this note are $10,000 Canadian (approximately $8,000 US) per quarter. The outstanding principal balance at December 31, 2018 was $310,079. The note is nonconvertible and is secured by the Atlas Pharma Inc. shares held by us. The holder of this note is currently a director and officer of Atlas Pharma Inc., now our wholly owned subsidiary.

There are no other related party transactions that are required to be disclosed pursuant to Regulation S-K promulgated under the Securities Act of 1933, as amended.

Director Independence

None of our current directors are deemed “independent” pursuant to SEC rules. We anticipate appointing independent directors in the foreseeable future.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.

Fees Paid to Independent Registered Public Accounting Firms

The following table presents fees for professional audit services rendered by B F Borgers CPA PC, our independent auditors, during our fiscal years ended December 31, 2018 and 2017:

	December 31, 2018	December 31, 2017
Audit Fees	$81,198	$21,600
Tax Fees
All Other Fees
Total	$81,198	$21,600

Audit Fees. Consist of amounts billed for professional services rendered for the audit of Atlas Pharma Inc. for the years ended December 31, 2018 and 2017 and for our annual financial statements included in our Annual Reports on Forms 10-K for our fiscal years ended December 31, 2018 and 2017 and for reviews of our interim financial statements included in our Quarterly Reports on Form 10-Q..

Tax Fees. Consists of amounts billed for professional services rendered for tax return preparation, tax planning and tax advice.

All Other Fees. Consists of amounts billed for services other than Audit Fees.

We do not have an audit committee and as a result our entire Board of Directors performs the duties of an audit committee. Our Board of Directors evaluates the scope and cost of the engagement of an auditor before the auditor renders audit and non-audit services.

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

The following exhibits are included herewith:

Exhibit No.		Description


31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350

101.INS	XBRL Instances Document

101.SCH	XBRL Taxonomy Extension Schema Document

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document

101.LAB	XBRL Taxonomy Extension Label Linkbase Document

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

Following are a list of exhibits which we previously filed in other reports which we filed with the SEC, including the Exhibit No., description of the exhibit and the identity of the Report where the exhibit was filed.

No.	Description	Filed With	Date
3.1	Articles of Incorporation	Form SB-2 Registration Statement	October 19, 2007
3.2	Bylaws	Form SB-2 Registration Statement	October 19, 2007
3.3	Articles of Amendment (Name Change)	Form 8-K Dated November 2, 2009	November 6, 2009
3.4	Statement of Share and Equity Capital Exchange	Form 10-Q For Quarter Ended 06/30/10	August 4, 2010
3.5	Articles of Amendment (Add Preferred and Series A Preferred to Authorized)	Form 10-Q For Quarter Ended 06/30/10	August 4, 2010
10.1	Share Exchange Agreement with Sunshine Biopharma, Inc.	Form 8-K Dated October 15, 2009	October 20, 2009
10.2	License Agreement with Advanomics, Inc.	Form 8-K/A1 Dated October 15, 2009	January 19, 2010
10.3	Amendment No. 1 to License Agreement with Advanomics, Inc.	Form 8-K/A1 Dated October 15, 2009	January 19, 2010
10.4	Research Agreement with The Research Foundation of the State University of New York	Form 8-K Dated January 17, 2011	January 19, 2011
10.5	Research Agreement with Jewish General Hospital	Form 8-K Dated June 14, 2011	June 17, 2011
10.6	Amendment No. 2 to License Agreement with Advanomics	Form 8-K Dated December 21, 2011	December 27, 2011
10.7	Investment Agreement with Dutchess Investment Group II	Form 8-K dated April 28, 2014	April 28, 2014
10.8	Registration Rights Agreement with Dutchess Investment Group II	“	“
10.9	Patent Purchase Agreement with Advanomics Corporation	Form 8-K dated October 8, 2016	October 9, 2016
10.10	Second Patent Purchase Agreement with Advanomics Corporation	Form 8-K dated December 28, 2015	December 28, 2015
10.11	Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated October 8, 2016, including Secured Convertible Promissory Note.	Form 8-K dated March 14, 2016	March 14, 2016
10.12	Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated December 28, 2016, including Secured Convertible Promissory Note	Form 8-K dated March 14, 2016	March 14, 2016

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned thereunder duly authorized.

	SUNSHINE BIOPHARMA, INC.

Dated: April 12, 2019	By:	/s/ Dr. Steve N. Slilaty
		Dr. Steve N. Slilaty, Principal Executive Officer


		/s/ Camille Sebaaly
		Camille Sebaaly, Principal Financial and Accounting Officer

In accordance with the Exchange Act, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on April 12, 2019.

s/ Dr. Steve N. Slilaty

Dr. Steve N. Slilaty, Director

s/ Camille Sebaaly

Camille Sebaaly, Director

s/ Dr. Abderrazzak Merzouki

Dr. Abderrazzak Merzouki, Director

EX-31.1 2 sbfm_ex311.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 Blueprint

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Steve N. Slilaty, certify that:

1. I have reviewed this annual report on Form 10-K of Sunshine Biopharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: April 12, 2019

s/ Steve N. Slilaty

Steve N. Slilaty, Chief Executive Officer

EX-31.2 3 sbfm_ex312.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 Blueprint

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Camille Sebaaly, certify that:

1. I have reviewed this annual report on Form 10-K of Sunshine Biopharma, Inc.;

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: April 12, 2019

s/ Camille Sebaaly

Camille Sebaaly, Chief Financial Officer

EX-32.1 4 sbfm_ex321.htm CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Blueprint

Exhibit 32

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this annual report of Sunshine Biopharma, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2018, as filed with the Securities and Exchange Commission on April 12, 2019, (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: April 12, 2019	s/ Steve N. Slilaty Steve N. Slilaty, Chief Executive Officer

Dated: April 12, 2019	s/ Camille Sebaaly Camille Sebaaly, Chief Financial Officer

GRAPHIC 5 sbfm_10k000.jpg IMAGE begin 644 sbfm_10k000.jpg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sbfm_10k001.jpg IMAGE begin 644 sbfm_10k001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 Z17AI9@ 34T *@ @ U$0 $ M ! 0 %$1 0 ! %$2 0 ! #_VP!# @&!@<& M!0@'!P<)"0@*#!0-# L+#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_\0 'P$ P$! 0$! 0$! 0 $" P0%!@<("0H+_\0 M1$ @$" M! 0#! <%! 0 0)W $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5 M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! M (1 Q$ /P#V'1]'TZ?1[.:6QMY)'A5F=HP23CJ:N_V%I7_0.MO^_0I="_Y M-A_UP3^5:% &=_86E?\ 0.MO^_0H_L+2O^@=;?\ ?H5HT4 9W]A:5_T#K;_O MT*/["TK_ *!UM_WZ%:-% &=_86E?] ZV_P"_0H_L+2O^@=;?]^A6C10!G?V% MI7_0.MO^_0H_L+2O^@=;?]^A6C10!G?V%I7_ $#K;_OT*/["TK_H'6W_ 'Z% M:-% &=_86E?] ZV_[]"C^PM*_P"@=;?]^A6C10!G?V%I7_0.MO\ OT*/["TK M_H'6W_?H5HT4 9W]A:5_T#K;_OT*/["TK_H'6W_?H5HT4 9W]A:5_P! ZV_[ M]"C^PM*_Z!UM_P!^A6C10!G?V%I7_0.MO^_0H_L+2O\ H'6W_?H5HT4 9W]A M:5_T#K;_ +]"C^PM*_Z!UM_WZ%:-% &=_86E?] ZV_[]"C^PM*_Z!UM_WZ%: M-% &=_86E?\ 0.MO^_0H_L+2O^@=;?\ ?H5HT4 9W]A:5_T#K;_OT*/["TK_ M *!UM_WZ%:-% &=_86E?] ZV_P"_0H_L+2O^@=;?]^A6C10!G?V%I7_0.MO^ M_0H_L+2O^@=;?]^A6C10!G?V%I7_ $#K;_OT*/["TK_H'6W_ 'Z%:-% &=_8 M6E?] ZV_[]"C^PM*_P"@=;?]^A6C10!G?V%I7_0.MO\ OT*/["TK_H'6W_?H M5HT4 9W]A:5_T#K;_OT*/["TK_H'6W_?H5HT4 9W]A:5_P! ZV_[]"C^PM*_ MZ!UM_P!^A6C10!G?V%I7_0.MO^_0H_L+2O\ H'6W_?H5HT4 9W]A:5_T#K;_ M +]"C^PM*_Z!UM_WZ%:-% &=_86E?] ZV_[]"C^PM*_Z!UM_WZ%:-% &=_86 ME?\ 0.MO^_0H_L+2O^@=;?\ ?H5HT4 9W]A:5_T#K;_OT*/["TK_ *!UM_WZ M%:-% &=_86E?] ZV_P"_0H_L+2O^@=;?]^A6C10!G?V%I7_0.MO^_0H_L+2O M^@=;?]^A6C10!G?V%I7_ $#K;_OT*/["TK_H'6W_ 'Z%:-% &=_86E?] ZV_ M[]"C^PM*_P"@=;?]^A6C10!S.M:1IT7D>790)G=G:@&>E%7=>_Y=_P#@7]** M +.A?\@&P_ZX)_*M"L_0O^0#8?\ 7!/Y5H4 %%%% !1110 5S]QXKL;3Q/=: M/=?N!:V"W\MU(X$:H7*8/H.-*T_1)]2L;FVU%;>XBMYEAN%_=EW"_,1G&,YJ>X\56;VUC< M:5/8ZA#!^ZCBVN<>N>W>@#>T+QSIVMZ:9$F MM8M0VS-]A-RN_$;LN3TP#MSR.,TS3OB#I-U?V.EW,L$&IW=H+E8DN$DCY(P@ M<'YF.M:+J7AJ[>RAG6WT?^S;L"8 PMN#;QQ\PXQQ0!T]EXPTT:%9:EK%YI^G& M[W;%:]1T."1\KCAOPZ9J]=>)M"L;@6]UJ]C#,2@$ M)-'M+:2/3[34))-&DTN6WEN H@8RL^\$@AE(;D#GBIIOAUJT>E:U9HL-S)-H MMI8VTSN,O)$#NZ_='2@#U*ZO+:RM9+FZGC@@C&7EE8*JCU)-CZ+HM MMJ%I=6=]]KN5MH0MTJH6)PQ+\X"YR3@]J?XST"_UKPS9VUB(Y+FTNK>Z,,S[ M5F\M@2A.#U]_:N:D\%:W>-+?RVEO!-=^(+;47M%E#"&&,!6^; !8XS@4 =1X MK\:P^$=$LM2N[.2Z%S((REJP;;\A8D$XR %/UINL^/-/TJ^T6UCAENSJIC*- M$1B)'955VSV)8=/0U)XNT&XUN;0A##')!:Z@LURKD#]UL=3QW^]TKB]-^'>O M6UNK7;1SW%OJ=I';$R#Y+"WDW+SZ_,>/84 >E+KVDNJ&/4K1S).UL@$R_/*N MGU+[5]H^9TE5\ )C@C=@\^F.]/T7P=KNC-X1N38P3OIOVJ*Z MC$X4JLKY#@XP<#G% '6P^,+*/0UU'5)[&Q>226.*,WJ.)&1B,!AP3QR.U&B^ M-M)U'2-+O+N[M;&XU&%)8[:6X7>=YP ,XSR,=*XJ#P1XAL/[,G2PLKQHXM0M M9K>:<*J">4LDG0Y&.HZ]N:O^%? U_8:IHEQJEI;LECH2V18LKF.<29^7\.] M'=PZ[I-PMLT.HVLBW2.\!652)57[Q7GD#O4>F^)-$UJXDM],U6SO)HEW.D$R MN5'3)P>E>43^%/$>F^'8(;W3H39Z/I>H6V^&4RR3F4':P0 8'3C.>OMG4^$D MDG]IZBMPAN+@V=L#?12;H@J@A8>(T <9)/7KR: -_5?B-%I6LZI9OH]Y+:Z4 MT(O+N-TQ&)0"IVDACU[5U$FOZ1%J46G2:E:I?2@&.W:91(P/3"YS7G/B'X>Z MGJ7B#Q)K,$$+74DUG/IN^7Y)#$!O5UZ8..XIMWX%UJ?Q1?3SPS3V-_?PWVZ* M^2(0E=O#J8V8E2O&TX/'3F@#N-4\6:?:V6I/8W=C=WE@FZ6V-XD>WD#YF)^7 MKU/TJQ+XGT:U>:*XU.SCN8(//F@\]=Z*!DG&?2O/+WP5XEN+;Q'96ELEKIUY M!*(;:2[64-.\H;=&=H:-2 25)/)K7M_#.M1>,YY[:W6RTRX$C7A:X65+AC'M M5D3;NC?.,\XP* .AL/'OAJ_T"WUK^U;:VLYSM!N950J^,E#SPP'.*O7?BC0; M J+O6+& LBR+YEPJ[E8D*PR>0<'FO/H_#7C*W\':'H]M;1PFR62VNA#=1JTR M[0$<.R-M7/5<9X%1VGP_UA--E@N+6W>7_A%AIB%I%.+@%CC/8I^ M=N?%&KW5KI\4F+XBT5KN:T75 M;,W, 8S1"==T87[Q(SQC/-,B\4:#-ILFHQ:Q8O91MM>X6X4HI]",X D$%]JU^T]M/D;FB^0A&8 D E2,<]:JQ>%/%,-C>WEI!-!J%Q/;>< MD]]#)))%'NSL(B"(WS D$X!Z<4 >@2>*=!ALK>]DUBQ6UN6VPS&X3;(>X4Y MY-5M-\::)JOB/4-"M;M6OK$@.I9!O%%OX:M8[>TVZS% M>WI06Y^T1R &. M2-"I&S&>2TVN76FZ5I%WJ7V*18[R>)XT6%CSM^=@6(')QTR*U(O M$FB2WEQ:1ZK9M,=_2N8L-+\0^&?$.MO8:9;ZC8ZM>?; M%D-UY30,P"L&!4Y'&1CWK!'A#Q==^(_MFHK&Z10WT2LLZ",^:K"/8@0%1]W. MXDYYH ]&L_$FB:B9A9:M97'D1B67RIU;8A&0QP>!CO48\5^'CIQU :WIYLP_ MEF?[2FS=Z9SC->=S_#K6+C1[:RBCMK=QX:.GR-O 'G[T;!QU!PE)83Z;+(KV=I>1AI%:-5#J[(5!!!&".AZT =U-XDT2V^S^=JUE'] MI4/!NG4>8"0 5YYY(''K577_ !-'H]W9V$-G/?ZE>[O(M82JDJHRS%F("@>Y MKE?#_@.6PUOP_-LI MK#6+J+K3FL;BSMK^-#$-['EWC8$%2,[>/ MY0R*1DE23R:R-?\ !FNZEJWB"*&PLOLFL7EK(M\9?WMND00D[<<\J0 #USZT M >AIKVDRPPRQZC:M'/,;>)A*N'D&6X/'L:R_&'C"U\(6=O<3VT]TTSD" M* L$52SN<_PJ!D_6N.T7P_-_P +>U"!7W:/ICMJ428X6YN$"D>G #-QTW>] M;?B'PCJ?B7Q:;E[XV%A;V#6L+QHDK2F7_6Y# [1M"CU/- &]K7BG2M%TK[;< M7UJK20--;1R3!#/A<@+GKGC\Z;I/B[2]0T!-3EN[:VV6T5Q=1O,/]&#J&&\\ M8X/4XS7GD?@CQ5#9V,9R1 P88_O9Y7Z4 >E1>(M&GU+^SH=4LY+[&?LZSJ9,8S]W. M>E1Z]JUUI-GY]KI-SJ+ %F2&1$VJ!DDEB/P S7!/X4\67?CNQOKP)]@L]2EG M1XIHU1861E7;'L#;QGDECGT-:_BO1?$H\.KI&C7-YJ"W_Y=_\ @7]**->_Y=_^ M!?THH LZ%_R ;#_K@G\JT*S]"_Y -A_UP3^5:% !1110 4444 %%%% !1110 M 4444 4-9UFQT#2YM2U&;RK:+&XA2Q))P .223@ 57T_P 0V][;S33VMWIR MP[=WV^+RA@]"#G'Z\=ZS/'VBWVM:):_V=&LUU8WT-\D#MM$WEMDID],@\>XK M%\11ZMXC;2+N7PQ>/86%YYESIURT):X!0@,%WE6VD@X)Y_"@#NGU*RCC622Z M@2-T+JS2 J,9(YZO)M-\!Z@^HZ,=2T M6-M/2349A:2%'2T27!AC(SC(YZ9 -9\'@[4=#\-Z=#CKB@#VE=0M'$I2YA80C,A60'9]?3\::-3L6MUG6\MS"Q*K()5VDC MJ,YQVKQG1_#^LS:6=3TGPU##&^@06Q@G\MEO92ZL9-N<-AZ*XL9?$<-V\#K#&/LWD[68I&=HYX('^- 'L?V^T$D49N80\PW1+Y@R MX]5'?\*S]7\26&D36<$S&2:ZNH[41Q,I9&?.TL,Y XKSC7/ M]-XMOBEC=&Q MF-J+&:RAMR;5(U VAI"&C (S\O4&FMX/U4>(UEDT$S7,?B07YU8O'DVI/RJ. M=QP.-IP!CB@#TW5O$6E:'/90ZC=I!)>S>3 &_B;!//H..IXJZ;VV%R+8SQ"< MC<(BXW$>N.N*X_X@:"^JS:!>QZ.FI_8-062>$(A=H2K @;R 1G:<9[>U3Q!< Z-F\DUY-0BUG>G[NU!'[O.=X( *[<8YH ]'U+Q)I.DZE8:??7B0W M-^S+ C?Q%1DY/0#W/6HM"\3:?KGVD6^89(+J:V,4I4,S1G#, #RN>]<_XW\/ MRZAXD\+ZM'HRZC%8W,GVI%2,OL9"%^^0" V#UXZUS=IX)U*WU"QU!-($=\/% M,]S+[T"%F&MW MDUZ[JA)@;?Y>[GYESMXY^E 'J[ZC9QQK(]U L;)O5C( "O'(.>G(Y]ZA('K7DFB^!+Y_P"Q;?5M$62TM(=24QS;72/?+F$8S_=Z M>GM5>V\ ZY!I5A#IVG_8+Z7PY-:W36A?>#-2@U;4H],T@0Z>VM MZ9=01P[$39&O[U@H.!@CGN: /4UO;5UB9;B)EE.V-@XPY] >_P"'I56[URSL M]*;#48_$_A_7[*QEOHM/%Q'/;PLHDQ(H 9=Q .".1GO0!L:? MXFTS48;Z9)O)CLKQ[*9IR$'F)C."3TY&*T7O;6.2..2XB227_5HS@%_H.]>1 MW_@[5IM FNI])N9-0GUBZU.VMHQ#,L7F* J3(YVL"!S@G':H]6\%:Y?ZW+-J M%C,Z75K:)$]A' WV1T4;U5I"#& _(*]1]* /3-=\4:?H(MQ<$R23W4-L(HBI M=3(VU6(SPN3UHUSQ-:Z#=6%K+:WES<7[.L$5K&'9BB[FZD=J\TU/P;J\FOW+ MG0&NKEO$5OJ$>J%X_EM@4&S).[(P?EQC'/IGLO%]KJ(\4^%M5L],N;Z"PDN3 M<+;E-P#Q;5X9AW- &WI7BG2M7LI+F&*0#)5@>^.?I6@-0LR MK,+J$JNW[U2\W_9K6)I9-@R=H'.!7A^C7>F1^ M/QJ&HB!U35[UX&C6-I@WS/4]JW M3J-F'A0W4 :<9B'F#,@_V>>?PKR_5/#5YJW@=;1-$U66YM+NUG\K5)DE9U5A MYBQ$N0!@'@D YJMKWA+5+^ZUM8?#I>34X[4:5K>)-7CM-&\R[C\1Q2'5]R?N$C",XY.X9&> ,'=[5=TKP?K4.JZV> MJ7-W=ZN'0?:H7W[4# [R2&48( &V@#TN]URUM(!- OVPFX2W=;>1"49CCYLL M.GIU]J9J'B2QT[4M/L&8RSWES]G"Q$$QML9\N,Y PIKS"Q$:Y;:.UC;:*\= MI%JEC+ 9HX4N61)-SF0H<.%'1CR>:FL?!VK0Z]ILCZ%MO+76+FXN-8W)F:*1 M9-AZ[B!E001QCB@#UJ.]M99Y((YXGFC^_&K@LOU':K%>2^ _!NJ:3KNGSZG: MW<=Y9I.L]TL<"Q7._NTBGS),G!&X<5ZR.E "T444 %%%% !1110 4444 %%% M% !1110!C:]_R[_\"_I11KW_ "[_ / OZ44 6="_Y -A_P!<$_E6A6?H7_(! ML/\ K@G\JT* "BBB@ HHHH **** "BHII#&8@!]]]I_(U+0 4444 %%%% !3 M9(UEC:-U5D8896&01[TZB@!L<:Q($10JJ,!5& !3J** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@")+>**21XXD1I&W.54 L?4^M2T44 %%%% !1110 M 4444 55T^T2Z>Y2U@6X<8:41@.WU/6K(&!BEHH **** (HX(H6D:.-$,C;G M*J!N/J?4U+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &-KW M_+O_ ,"_I11KW_+O_P "_I10!9T+_D V'_7!/Y5H5GZ%_P @&P_ZX)_*M"@ MHHHH *3-<3\3KK5;#PE)J.F:K+9&V="RQQJ3+N=% W'H!DG@9-9_BS4M4G\1 M:I8VFJW-A%INAMJ"?9]N9)MS8W9!RH"]/C9I:\2MO&'B#4_"FH>,/[2N M(9M-N+2)+% HAD!$7F;AC)W&0]^,#%>V9RF?:@""Y^_;_P#74?R-3YK@?$GB M6ZT/4_)BE:X57,P1T^:,],'U7G(-267CR&*W6$V6IW4PR6D:)5W$GL,\#VII M7U'8[NDS7*_$;J3C,7A?46'JQ JIJ'B#5KBQF2X\*W<<6W)D^U*I3'.[.., M=:I4Y!9G:Y%+7FL7B37;F6Q2\T>XE0#=&B2",SL.06XYP,';QGKC'%:TWC;4 M;618[CPW603T8$=QZ=ZBT[VY169Z517&Z#XQ@U*9GN+O:^T(MJ MD9[=6)QR3Z#.!^-=+_:*?\\+K_OPW^%-IK<&K%VBJ7]HI_SPNO\ OPW^%']H MI_SPNO\ OPW^%("[15+^T4_YX77_ 'X;_"C^T5_Y][K_ +\-_A0!=HJE_:*_ M\^]U_P!^&_PH_M%?^?>Z_P"_#?X4 7:*I?VBO_/O=?\ ?AO\*/[17_GWNO\ MOPW^% %VBJ7]HK_S[W7_ 'X;_"C^T5_Y][K_ +\-_A0!=HJE_:*_\^]U_P!^ M&_PH_M%/^>%U_P!^&_PH NT52_M%/^>%U_WX;_"C^T4_YX77_?AO\* +M%4O M[17_ )][K_OPW^%']HK_ ,^]U_WX;_"@"[15+^T5_P"?>Z_[\-_A1_:*_P#/ MO=?]^&_PH NT52_M%?\ GWNO^_#?X4?VBO\ S[W7_?AO\* +M%4O[17_ )][ MK_OPW^%']HK_ ,^]U_WX;_"@"[15+^T5_P"?>Z_[\-_A1_:*_P#/O=?]^&_P MH NT52_M%?\ GWNO^_#?X4?VBO\ S[W7_?AO\* +M%4O[13_ )][K_OPW^%6 MH9/-B#A77/9U(/Y&@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M!C:]_P N_P#P+^E%&O?\N_\ P+^E% %G0O\ D V'_7!/Y5H5GZ%_R ;#_K@G M\JT* "BBB@#%\0^%['Q/:+:ZA+=" ?>C@G:,/R"-V.N" 152_P# VCZF(3>- M>22) ;9Y?M3AYXBM_^NH_D:GJ/9PUTW"QB?\(Y'"2;&\N;7/\ "CY7 M\JIZC:ZI;V4AN;RUN[9!N(GBQG'(Z5T]1S017$1CFC61#U5AD5FZ,4OU=I8:+;6)\T;I;AN6FD.6/\ A4HTG3PP M(LH 0<@^6*NU%"@X+WW<25MQ,5AZYX>;6IH&>]:.*$9$7E[E+?WNO7%;M(>E M=,DFK,HX/3/".G3ZGJ-O?(DOEX&W9M//1P1R/I6@?#^MZ3@Z+K#21#I;7HWK MCT#=16A-_HWBRW<\+'/^@I%_WRW^%)_PG7AO_H)H?HC?X5K_ -F6'_/E;?\ ?I?\ M*=]@LQTM8/\ OV*+P\PT,7_A.O#G_023_OV_^%+_ ,)UX<_Z"2?]^W_PK:^P M6G_/K!_W[%'V"T_Y]8/^_8HO#S#0Q?\ A.O#G_023_OV_P#A0?&_AP_\Q6+_ M +Y;_"MK[!9_\^L'_?L4PZ98X_X\K;_OTO\ A1>'F&ARR?$#3H[>99;B*6Y1 ML1&/*I+GH>?NX[YZ>]:=IXNT;[-']HUBS:;:-Y0D+GO@'M0/"=C);3BZB22X MF.YID0*4(^[M'8#]>]7+;0K);=%NK*TEF"X>06ZKN/KCM5-TQZ#1XHT)NFK6 M?XS 4]?$>BMTU6S.?^FZ_P"-*?#VC,,'2K,_]L5_PIA\,Z&W72;/G_IB*GW/ M,6A*-=TD]-2M/^_R_P"-2+J^G/\ =O[4_29?\:HMX2T!NNDVO'HF*C;P7X=; MKI4'X9']:/<\PT-=;^T;[MU"<^D@J19XF^[(A^C5@-X%\.-_S#5&?21A_6HC M\/\ PX?^7)Q])G']:+0[AH=,&!Z$?G2Y%X61T5Q>06@C,\@C$CA%+=,GH,]J);R"&>&"20"68D1IW;')KC=6\/ZS%9&, M^(KN[\X^6EN;=2')]3G '?)]*T=#L[K1KQ(=39KN>= L=Z 3C _U9]!QD'OW MYI\BM>X61U-%%%9B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#&U[_EW M_P"!?THHU[_EW_X%_2B@"SH7_(!L/^N"?RK0K/T+_D V'_7!/Y5H4 %%%% ! M1169JGB+1M$>--4U.UM'E^XLTH4M[_3WH TZ*R[OQ)HEA=6]K=ZK9P3W !B2 M24 N#P"/8UJ9XS0!!<_>M_\ KJ/Y&IZKW)^:#_KJ/Y&K% !1110 4444 %%% M% &'XA_=-I]U_P \KE03Z ]:W!TK)\1Q>=H=T!]Y%#@^F#FK]I+Y]G!+_?C5 MOS%8QTJ-?,74GHHHK884444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 F*,4M% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 8VO?\N__ OZ44:]_P N_P#P+^E% %G0O^0#8?\ 7!/Y5H5G MZ%_R ;#_ *X)_*M"@#)U?Q-HN@H&U75+2SR,A9I0&(]EZFJVE>-O#.N3>1IN MN6-Q,3@1K* Y^BG!/X5G^(IK+1-:M]9FTNPG>2,Q-<87[6A&<; >77YCE5^; MG@'I67X0T^]UYUU+Q!!:7\:!)K6X=(7,4P8EA$4&5087AOFSG- 'H=>.?%%9 MCXIF,,\E@7T9XVE\AI1?Y?\ X]Q@':>O(Y^8>E>QT4 >$:FCII_B?3I]+G@O M=8TO3H]+M3$SG(C"F,-C@J_7./6O<+*.2*PMXY3F1(U5CG/('-3T4 4+I;KS M8=LL(4R_+F,DC@_[52[+S_GO;_\ ?D__ !5.N?O6_P#UU'\C5@=* *NR\_Y[ MV_\ WY/_ ,51LO/^>]O_ -^3_P#%5:HH J[+S_GO;_\ ?D__ !5&R\_Y[V__ M 'Y/_P 55JB@"KLO/^>]O_WY/_Q5&R\_Y[V__?D__%5:HH S[NWNYK2:)IH, M.A4XB/I_O53T)[J;1KU;9&16+X?\][?_OR?_BJ- MEY_SWM_^_)_^*JU10!5V7G_/>W_[\G_XJC9>?\][?_OR?_BJM44 5=EY_P ] M[?\ [\G_ .*HV7G_ #WM_P#OR?\ XJK5% %79>?\][?_ +\G_P"*HV7G_/>W M_P"_)_\ BJM44 5=EY_SWM_^_)_^*HV7G_/>W_[\G_XJK5% %79>?\][?_OR M?_BJ-EY_SWM_^_)_^*JU10!5V7G_ #WM_P#OR?\ XJC9>?\ />W_ ._)_P#B MJM44 5=EY_SWM_\ OR?_ (JC9>?\][?_ +\G_P"*JU10!5V7G_/>W_[\G_XJ MC9>?\][?_OR?_BJM44 5=EY_SWM_^_)_^*J>,.$ D96;N5&!_,T^B@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** ,;7O^7?_@7]**->_P"7?_@7 M]** +.A?\@&P_P"N"?RK0K/T+_D V'_7!/Y5H4 >:_$#^PIM8B771JMG"EN8 MWO8;$30,C-DKNVL4;*CD8//6K>E>+?"USKV[P_;ZC>7%XZIZD#O6[XP\3Q>&-#FNT6":Z4HL<$DPCSN8*&)[*,Y)QT!IGAK5]9U. M6<:I;Z3$B*IC-A?&M_\ MKJ/Y&IZ "BBB@ HHHH **** "L.P'D>)=2A_AE5)1_(UN5AW/^C^*[23HMQ" MT7XCFL:NG*_,3-RBD%+6PPHHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH ***3- "T5 ]W ES';M(!+("57U ZU M-GWI70"T5C:WXEL-!N+""\$Q:]E\M#&FX)RJ[G/\*[G09]6%0ZOXMTG1[^UL M)[J)KR>>./[.LJ^8BN.K2XTZ>[M M]+U69K6=K>ZME@42V[*,G>"P&,8Y!/6KFD>,=$UA;$0WT4-S?1":&SGD59V0 MY(.S.>0,T =!1110 4444 %%%% &-KW_ "[_ / OZ44:]_R[_P# OZ44 6=" M_P"0#8?]<$_E6A6?H7_(!L/^N"?RK0H \\^)D%K;VUK?KX.M-35GP192PZI?S)X-M/#EFT,:H$2,2ROEBV3&<;<;<#US6 MMX[MI+KP?>Q0Z9::E(=I6VNY?+C8AAU;(Z=>H^M<9\(I4^V:I;?VG;(#GV/;I0!ZO7.:YXJ.F:K#I-CITNHZE+$9S"DJ1".,'&YF<@ MCW=W$VD74\6G113:G+&Z8M!)T&"> _ M$<4&K:7;_9KNWUNQM+6XO99BK6[1)L=MI!+Y'(YZ]:]1MH!;6D-NIR(T" GV M&* $N?O0?]=1_(U/6?=6<32PL3+EI><3.!T/O4W]GP>LW_?]_P#&@"U157^S MX/6;_O\ O_C1_9\'K-_W_?\ QH M455_L^#UF_[_ +_XT?V?!ZS?]_W_ ,: M+5%5?[/@]9O^_P"_^-']GP>LW_?]_P#&@"U6'XA__?UJY_9\'K-_W_?_ !JHNZ3&6J*J_P!GP>LW_?\ ?_&C^SX/ M6;_O^_\ C5 6J*J_V?!ZS?\ ?]_\:/[/@]9O^_[_ .- %JBJO]GP>LW_ '_? M_&C^SX/6;_O^_P#C0!:HJK_9\'K-_P!_W_QH_L^#UF_[_O\ XT 6J*J_V?!Z MS?\ ?]_\:/[/@]9O^_[_ .- %JBJO]GP>LW_ '_?_&C^SX/6;_O^_P#C0!:H MJK_9\'K-_P!_W_QH_L^#UF_[_O\ XT 6J*J_V?!ZS?\ ?]_\:/[/@]9O^_[_ M .- %JBJO]GP>LW_ '_?_&C^SX/6;_O^_P#C0!:HJK_9\'K-_P!_W_QH_L^# MUF_[_O\ XT 6J*J_V?!ZS?\ ?]_\:/[/@]9O^_[_ .- %JBJO]GP>LW_ '_? M_&C^SX/6;_O^_P#C0!:HJK_9\'K-_P!_W_QJ>*-8D"+NP/[S%C^9H ?BLB;P MWI\TSRNLVYR2?WK=:UZ2IE",OB0''7'A*Z:[9X)(EAW?(K2-G'UQ]:UAX7T[ M9RDN<=IFK;HK&&%I1;:0E%'"^(? ,WB&\OWEU>XMK>33ULK6*$*=O)9C)N4D MY8(?E(/R=>E5CX$U676X;VXO=/D0WEK>W#- QE,D481E5L\*<9''+.&(W]3D\5V]% ' P>#-53P7=: ]W:1RWDV M;N[B+M),K']ZQ+?QL,@=@#[4R_\ -]=>,M/U2"_ACTVQFADAM &&Q439MP# MM)YR&(SVZ5Z!D49% *6BB@ HHHH **** ,;7O\ EW_X%_2BC7O^7?\ X%_2 MB@"SH7_(!L/^N"?RK0K/T+_D V'_ %P3^5:% '(?$[R_^$$O!+'"T;20J[S1 M^8D2F109"O?:"6P>..:R?AQ+%::AJ6B6.JV6KZ=:Q12QWEI;QQ*KN6S&?+^5 MCP#Z_-S6_P"-Q>77A^2QTK4;>SU.4K)"9Y_*#*C!GZTJNB3%P&.<[AT'04 =I1110 4444 07/WK?_ *ZC^1J>H+G[UO\ M]=1_(U/0 4444 %%%% !1110 4T].>E.HI,##\/L;<7FGL,-;S-M'^R>16Y6 M%=DZ?XDM[G.(KM/)?V8=/\*W!65%V3CV$A:***V&%%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )7.7'C.RM[B2!K'4 MF:-BI*VIP<>E=)1332W&CCCX[MAO466H$[@%;[,> ?49Z_SJ?_A.;';_ ,>& MJ'C_ )]3_C72?9X]CIY8VNF.,QP,0Y9BI MP1P !G/7Y>E=C=>&M*O-575)K4F]553SDE="54D@':0" 2>M5I?!/AZ:-HWT MN(JTSSX#,,._WR,'C=DY P#FH$:!69E\K&5!V. MG\ Z/=:^NHW-M#+!':0VL%H8\)$(W9AT/(Y'RD8^45H'PAH)OI[W^S(?M%P' M$C\\[QA\#. 6 &2,$T <./B3/YUOJ,EN1%_9LTCV,4P93,LT<:@DH < Y MQSP>#4__ G^HZ+::I-JUGOO#JZV-M:+*&2/,*/@R*I)7[QSM)YQCTZT>"_# MWDO$=+A9'BDB?<2Q978,P))R,[#48M6M=8L],FU. MV%E/87-O;NHEC63:?,0-P3E<$>AJK\/-!FL;^]U'^Q3HMH]K!:06L@42R^7N MS+(%X#'=C\*;XY\87N@:[':6WB'0].1K=9##?VDTLA)+#<"AQCC&/8U9\!>* M;OQ%=7L=SKFCZD(D4JNGVTT13)/+%SR/I0!WE%%>E6=Q:Z%=_9;R MTM3?7,_EJ^U-P5$PP(RS$GZ*: /1Z*\L\1^)]=23Q9=66IFVC\/VMM)% (8V M6=W7>_F$@G&. %(]:],M)C<64$Y7:9(U<0L1T/?'-2_;8O[D__?A_\* +-%5_ML7]R?\ [\/_ (4?;8O[D_\ MWX?_ H L457^VQ?W)_^_#_X4?;8O[D__?A_\* +%%5_ML7]R?\ [\/_ (4? M;8O[D_\ WX?_ H L457^VQ?W)_^_#_X4?;8O[D__?A_\* *^LV)U#3Y(5XE M'SQGT8=*;I.I)?6<;,P6<91T)Y##K5G[;%__P"7?_@7]** +.A?\@&P_P"N"?RK0K/T+_D V'_7!/Y5H4 < MYXVFO+3PQ<3Z>9$G5XP\L4(FDCB+@2,J8.2%+'&*Y_X;>(+W7HR7EFGMX;.) M))YH/++7&]]V#@9^79GL*N^*3>Z5XKTKQ"-.N]1T^WMIH)8K1=\D3N5(D"9R MW0J<=,T>$Y+W5/$^L:\VG7FG:?=100PPWJ>7)*Z;MTA3JO55&>N* .VKG_$7 M@S0/$\%Q'J>FV\DTR",W(B7SE .1M?&17044 1V2XAAFBBAN;: M"39%<)']Q74#H.G&..*ZI5"H%48 & !VI:* *]R/FM_^NH_D:GQ4-S]ZW_ZZ MC^1J>@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@!" >U4SI>GYR;*W.>O[I?\*NT4 MG%/<# FTZZTN9KK2@&B;F6U/0^Z^AJ]I^KVNH?(K>7,/O1/PPK1K/OM(M-0^ M:6/$@^[(APP_&L>1P^#[A6+_ !1Q6%]GUO3^(9H[Z$?PR_*X_'O3E\1PQ?)? M6MQ:-WWIE?P(ZTU62^)6"YM\4<55@U.RN5!ANHGSV#C/Y59# C(.:T4D]ACL M48I,TM4 8HQ110 8HQ1FB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1 MBBB@!,4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8VO?\ M+O\ \"_I11KW_+O_ ,"_I10!9T+_ ) -A_UP3^5:%9^A?\@&P_ZX)_*M"@!, M"C ]*6B@ HHJ*6YA@=$EE1&YABE2.25$>0X168 M]/6 MI0F#D]/R_K6W'K&GRC*7T!^K@5C3>$/M$SS27[EW8L3Y M?_UZU(=#LUMTCG@AF=1@R&, M6-/ZQS/F$KEU;F!_NS1M]&%2!@>A%9;>&]) M?K9J/HQ']:C/A?3OX!-'_N2FMKU>R^\>ILYHS6-_PC< ^[>7J_28T?\ "/8^ M[J=^O_;:CGJ?R_B&ILT9K%_X1YO^@K?_ /?VC^P).VK7V/\ KI1SU/Y?Q"[- MK-&:Q?[ E_Z"U]_W\H_L"7_H+7W_ '\HYY_R_B%V;5%8W]@2'KJU_P#A)2?\ M(\W_ $%=0_[^_P#UJ.>I_+^(79M45B_\(\W_ $%=0_[^_P#UJ/\ A'Y!TU:_ M_P"_E'/4_E_$+LV2<5!:7L-[$TD#;E5RA..XKG]4TZ[LK,O!?ZA-(QVA =WY M\55\,F\LKYHI;6X6&88?%AM*OT@\/+'8_P!N:B%"7=P5 M7['"K F4L>1SD \FO3ZJ7.EV%[*)+JRMIW QNEB5CCTR10!XMXK^P^9XTBO M+F.>_BL+%='ED?,K_+PT/QS^M-.GV;20R M-:P%X1B)C&,Q_P"[QQ^%6 ,"@"E=-<^9#B*(J)>"92,\'_9J7?>?\\(/^_Q_ M^)IUS]ZW_P"NH_D:GH K[[S_ )X0?]_C_P#$T;[S_GA!_P!_C_\ $U8HH K[ M[S_GA!_W^/\ \31OO/\ GA!_W^/_ ,35BB@"OOO/^>$'_?X__$T;[S_GA!_W M^/\ \35BB@"OOO/^>$'_ '^/_P 31OO/^>$'_?X__$U8HH K[[S_ )X0?]_C M_P#$T;[S_GA!_P!_C_\ $U8HH K[[S_GA!_W^/\ \31OO/\ GA!_W^/_ ,35 MBB@"OOO/^>$'_?X__$T;[S_GA!_W^/\ \35BB@"OOO/^>$'_ '^/_P 31OO/ M^>$'_?X__$U8HH K[[S_ )X0?]_C_P#$T;[S_GA!_P!_C_\ $U8HH K[[S_G MA!_W^/\ \31OO/\ GA!_W^/_ ,35BB@"OOO/^>$'_?X__$T;[S_GA!_W^/\ M\35BB@"OOO/^>$'_ '^/_P 31OO/^>$'_?X__$U8HH K[[S_ )X0?]_C_P#$ MT;[S_GA!_P!_C_\ $U8HH K[[S_GA!_W^/\ \31OO/\ GA!_W^/_ ,35BB@" MOOO/^>$'_?X__$T;[S_GA!_W^/\ \35BB@"OOO/^>$'_ '^/_P 31OO/^>$' M_?X__$U8HH K[[S_ )X0?]_C_P#$T;[S_GA!_P!_C_\ $U8HH K;KO\ YX0? M]_C_ /$U-'O*#S%56[A6R/SP*?10 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% &-KW_ "[_ / OZ44:]_R[_P# OZ44 6="_P"0#8?]<$_E6A6? MH7_(!L/^N"?RK0H **** "BBB@ HHHH @N?O6_\ UU'\C4]07/WK?_KJ/Y&I MZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH QM>_P"7?_@7]**->_Y=_P#@7]** +.A?\@&P_ZX M)_*M"L_0O^0#8?\ 7!/Y5H4 %%%% !1110!R>M^.[#1+Z\MY+2\GCT^..6_N M(54I:K(?E+9()]<*#@9;$[@ 8/;/%2?V?#_STN?\ P(D_^*H MT54_L^'_GI<_P#@1)_\ M51_9\/\ STN?_ B3_P"*H MT54_L^'_GI<_^!$G_ ,51_9\/_/2Y_P# B3_X MJ@"W153^SX?^>ES_ .!$G_Q5(^GQ[&VR7.<;) M<^9L&_\ TB3KCGO4O]GP_P#/2Y_\")/_ (J@"W153^SX?^>ES_X$2?\ Q5'] MGP_\]+G_ ,")/_BJ +=%5/[/A_YZ7/\ X$2?_%4?V?#_ ,]+G_P(D_\ BJ + M=%5/[/A_YZ7/_@1)_P#%5'%8+YDV^2YV[_D_TA^FT>_KF@"_153^SX?^>ES_ M .!$G_Q5']GP_P#/2Y_\")/_ (J@"W153^SX?^>ES_X$2?\ Q5']GP_\]+G_ M ,")/_BJ +=%5/[/A_YZ7/\ X$2?_%4?V?#_ ,]+G_P(D_\ BJ +=%9TE@/M M,(1[GR\GS/\ 27].._K4W]GP_P#/2Y_\")/_ (J@"W153^SX?^>ES_X$2?\ MQ5']GP_\]+G_ ,")/_BJ +=%5/[/A_YZ7/\ X$2?_%4?V?#_ ,]+G_P(D_\ MBJ +=%5/[/A_YZ7/_@1)_P#%5%0X/$7I7.<5;KP[2MDMSH5I&$_X22+Q-<37J@?OEBW2%F?O MLV%!D\'C%>XCI0 4444 %%%% $5S=6]G \]U/'!"@R\DKA54>Y/ JO/J^F6D M4$MQJ-I#'<$"%Y)E429Y&TD\_A7"?%?[;=:>;,6-Y+I<=I/Z@Y&116 M+X0BNX/!FBQ7VX7264*RANH8(,Y]ZVJ "BBB@ I"0!DG%+7(_$_[9_PKG6OL M._SS!C]WG.W<-W3_ &(WNHS3Z7+9>=87VA6.I::\U[96HBB:$M\Z, M2"%PN>>,\UW7P\$E> :?))_PE=O+;/%(LFKWAM] M.3:+ZVD8,/,E.,F/.3@D8!7DXH ]UM]3T^[NIK6VOK::X@XEBCE5GC_W@#D? MC5NO%O!'V:?5? <>G!/[0M+2[_M<(,2)D 8E[Y,G/S::&*YADEA($J(X+1D]-P[?C4,.L:7<03SP:E9RPV^?.D2=66/'7<0 M>/QKR!9--C/Q(L?#5Q:EY;*,VD5G*K-)B%MY7:VNH6ZW%E1_9GA_P!4["("0IC@C/<=Z[N@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH QM>_Y=_P#@7]**->_Y=_\ @7]** +.A?\ M(!L/^N"?RK0K/T+_ ) -A_UP3^5:% !1110 4444 %%%% #3&C,&9%)'0D=* M=110 4444 %%%% !49@A+;C$A;.<[1FI** &^6F\OL7<>IQS3J** "BBJU_> M1:=IUS?3Y\FVB:9\==J@D_H* +-%<9H_B?59M#C\2ZRNG66B2VYN2@9S-"A& M4R>C$CL .3QFI/\ A9&B)975S=1W]HUJT/FP7%JR2A92 C!>I4GT]* .N(!! M! .>N::8HR "BG;TR.EH B$3W ^QOFTC)P&FX^09!_+/2@#K**Y2Z^(.B6FJ26$GVHM%-' M#+,L#&*,R %"SC@ [@/SK-M/B?:'_A()=2TV]L[71[CRFF,1(8$J!GT;+9V\ M\BTA /4 US$OCO1K;5AITC7+%9U MM9+I+=C;QSMTC9^@;D?F.:98_$+1-0U6'3XA=K)-<26J2R6S+$TR9W('Z$X! M- '4".(+L"*%/8+Q2JJHNU%"@=@*Y[Q/K=UIUWHEA8>5]IU*^6#=(N0L8!>0 MXR.=JX'N:0>--(\I'W3;7U3^RA^[_P"6^3_X[QUH Z3-)D5YYH_Q(DEUOQ!9 MZO;PV]OI_P!HDMI8R?WL<+E7SG^(?*>/6J5C\0];N/#,VLWEE:VWV+5(;>[A M4,3Y$@3.,GA@9![<&@#U&BD'04M !3/*CWE_+7<>K8YI]% #5C16+*B@GJ0. MM.HHH **** "BBB@"-8(D;]UJ*71TM_L\!2U*S@+CRRS;]IVX'89Q45[\/=1UB44 <-??#][N+6HTODC74;JTG0"'B(0A!MQGG.S\,U#J7P^O+R'Q+:Q: MI"EIK5PEUM:W)>*12F>=V"N$Z8[UW]% 'GOBKX<77B37);[^U8UB=H'6.: R M-"8V!(C.\!0W?@U/J7@&[O(O$UK#J<4=IK*4;/XMV"N$Z8[]:[NB M@#@IOA[<27=U;IJB#1+S44U*XM3!F5I058J)-W"ED4],]LU)9^ )K7^S3 M(I1R/ID'Z"N4T_P/XBOI+MI+Z*P@M_$4FIVL,MKO,A#?*2P GRAPHIC 7 sbfm_10k002.jpg IMAGE begin 644 sbfm_10k002.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 Z17AI9@ 34T *@ @ U$0 $ M ! 0 %$1 0 ! %$2 0 ! #_VP!# @&!@<& M!0@'!P<)"0@*#!0-# L+#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_\0 'P$ P$! 0$! 0$! 0 $" P0%!@<("0H+_\0 M1$ @$" M! 0#! <%! 0 0)W $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5 M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! M (1 Q$ /P#RNWAB-K$6C4DCDFI/L\.?]4I_"BV_X](OI4G>OHH0CRK0\.>77*_E1]G@_P">*_E4E%')'L'/+N1_9X/^>*_E1]G@_P"> M*_E4E'XTP<\NY']G@_P">*_E1]G@_YXK^52\^M/A@FN)%CAB>1VX"H,DT MN2/8:E)Z)E?[/!_SQ7\J/L\'_/%?RK6_X1_6O^@5>X_ZY&L]U:-BKJRL#@@C MH:24'M^@VJD=[D/V>#_GBOY4?9X/^>*_E4F:.:KDCV)YY=R/[/!_SQ7\J/L\ M'_/%?RJ2BCDCV#GEW(_L\'_/%?RH^SP?\\5_*I**.2/8.>777#_GBOY4? M9X/^>*_E7B,J4G9 M6_ &JJWN9/V>#_GBOY4?9X/^>*_E4GXT5IR1[$<\NY']G@_YXK^5'V>#_GBO MY5)1S1R1[!SR[D?V>#_GBOY4?9X/^>*_E4O-'XTN6/8.>7#_GBOY4?9X/^>*_E4GXT4P<\NY']G@_Y MXK^5'V>#_GBGY5)11R1[!SR[D?V>#_GBOY4?9X/^>*_E4E%')'L'/+N1_9X/ M^>*_E1]G@_YXK^5244P<\NY']G@_YXK^5'V>#_GBOY5)11R1[!SR[D?V> M#_GBOY4?9X/^>*_E4E%')'L'/+N1_9X/^>*_E1]G@_YXK^5244P<\NY'] MG@_YXK^5'V>#_GBOY5)11R1[!SR[D?V>#_GBOY4?9X/^>*?E4E%')'L'/+N1 M_9X/^>*_E1]G@_YXK^5244P<\NY']G@_YXK^5'V>#_GBOY5)11R1[!SR[ MD?V>#_GBOY4?9X/^>*_E4E%')'L'/+N1_9X/^>*_E1]G@_YXK^5244P<\ MNY']G@_YXK^5'V>#_GBOY5)11R1[!SR[D?V>#_GBOY4?9X?^>2?E4E%')'L' M/+N68((O)7]TGY45+!_J5HK%QC?8M2=MS-MO^/2+_=J3O4=M_P >D7^[4G>M MJ?PKY$3^)A1115$!1110 444=: "BIX+6:Y.(D)YY-;FG^&3<3)'(Y+N$].T"WWP1[KA_OS/RWTSZ5W(&!7-4S!O2" M"&"BOB=SY^F^"GB2*%W2YLI649"*Q!;VY%$H>TOHHZGLXJ[9'& MC.X55W$]JU+;0II>96$8]!R:T+"Q6VR"I\SHVX8(K60<5\WC,[FY.-#1=^I] MYE?"E%04\7J^RV,Z#0K2+!93(P'.X\'\*V;2>>PC2.TD,*I]T*!Q^-1TX5XU M3%UZCO*;^\^II9?A*"M3II?(VK;Q1J]M%L$ZRG\,C.MEN%K?'!$&O^"=/FC:Y\+7+7'EKNEM9/OX]5/? MZ5P3*58JP(8'!!'2O1HY9()1+$[)(O*LO!%=<,NC!U\+JENNOR.>HHZ45[Y\8%%* 68* 2Q. !U-='HW@77 M-9VO';>1">DLWRC\NM88C%44'I7J ME@ $7C->1B<9*3Y8;'J8?#**YI;ERWM8;6(101)&@Z*B@"IL4"EK@.U:"5'+ M!%,A26-)%/564$5(2 ,G@5GW>LVMNK!'$L@Z(I_K0!QOB/X2:#JT4LMA%]@N M]OR&/[A/NM>$ZYH.H^'=1:QU*W,<@^ZP^ZX]0>]?2TFM737.Z M_P"&[3Q3%$FJ;Y'B.4F4X=?49]*[J.2OA8S5XZ,^>:GAL[BY;$49 M(]>U>I7WPI@1S-IT\AVKQ!-SN/\ O5@+#Y#-$R!&0[64=C48W./8JU.-[]3U M,FX>CC;RJSM;HMS"A\.,RYEFVGT49JW'X>M53#L[MZ@XK8J>TM9+RZ2"(?.Q MP#V'UKPI9IC*CLI;]C[.GP_EM"-W3O;OJ8$GARV=1Y;O&>Y/.:HS^')T+>3( MK@#@'@FO8-.\&6XC5KUVDE!R0APOTK8;PII,L;(+-4W#&YE0J9C%7<_D MSQL9A:T/G*:VFMGVRQLISW'%15[MJWP_B>!FM'WX7B*49S^->4:S MX=FL9I#'&PVGYXF'*_\ UJ].AF/O*%=+FN8.@O9T_B?X'U'#^3QQ<_;5E[JZ=S0M84A0*@ %:5I,;6YCG4 E#G% M4HJL#I7R+G+FYKZGZ6J4/9>SMIM8]?\ #FJ07=LCPR!AW'7XGIXH/2L"V\6V,\"R%)E)'(V9Q4%QX[T>WW*YFW#H/+/-=3JP6 MK9XZP.)D^50=R?Q>]G_PC5W%>J&29#&HVACD\ @5YYX7T.TTBV"0K\Y^](W+ M&IM>\3?\)#/ 1;^3%"3M#'))JUITJ[0*VC.\='H=N'POL9>^O>11\7Z3"+-= M1C54D4X? ^_FN26NY\6R#_A&Y!G_ ):+7"(>*\;'Q2JZ'UV52E*A:7F26RY-3:7J*VIR<<5U=AH]QXEQ-*K6]H?X\1B<7/#SYJCM$\^.5ZXIK ,ISC!%>SV/@S1;%DD6T6255P6D.[/X M=*CU+P3HU\)7^S"&9Q@/&<8_#I6GU&I:Z>IQ?ZQ8;FLXNW?_ (!\U:O8_8[K MC_5/RI]*BT[3+G5+I;>U3))Y8]%'J:[WQ-X,U 7LNG1HDUQ&AFC;. R#K^/M M5KPII::=8HO_ "UD^:0^IKU:F7S-3PO MX2L=*B4E%GN.K2.H//MZ5WEO'@9S659@ 5L0G@5^>XS$U:\W.I*["$8QTB6 MT44_%,3K4E<:.R.P4F!@\=:DV'&<4TC%:NE**NQW1P_C#X=Z?X@@,UDB6=^B MG:R+A7]F _G7AFI:;=:3J$MC>Q>5<1'#+G/XU]58K@OB3X/CUK27U"SMU_M& M ;LHOS2+W6OJN'\^J4*BP^(E>#V?9_Y'G8S!J4>>&YX/10002",$<$>E%?HI MX;"BBB@05I^'[>*Z\064$R!XWE 93WK,K7\+_P#(SZ?_ -=145/@9I2^-'M] M@P1P%. .!76V,H('^-<4CF.3-=!870(6OG#W3K%((R*JWU_!I\!EG?'HHZL? M0"LF_P#$4.GJL*#SKM_N0KV]SZ"H-/LY+NX%[?,99SV/W4]@* &/)J^M%C&A MAMR.%)QD58M_#D@13)*J-_=49KH(T55&!BGT 8ZZ'M_Y;_\ CM(=-F3. &&> M,5LT4 831E6P5PP]17 ^.-#\B==4MU^23Y95'8^H KU>2))!AE!]ZQM6TS[3 MI]Q:N6\N5"-R]:QKTO:0<3MR_&2PE=36W7T/$:ZOP9%&6N)BO[Q2%#>@KEYX M7MIY()49'C;:5;J*V_"M\+:\:"1E5).I6#RQQC[3&,A@ M.6'I7127/F-DU6GDS$W/\)_E2J04X.,AX:=2E-36Y\X:WIHLY_,C4B-B01Z& MLBNYU>W:Z@N(T^\6)'&>AKF%T*^89V*#W!;D5>6YC!T+5I)-:''GN258XN^% MIMQDKZ=.YFT5J?V!??W4_P"^JKS:7>0%M\+$#JR\BO2AC>'4RO&T MX\TZ4DO0IT4I4@X((^M)BNF_4X6FMPHHHH$%%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% %Z#_ %*T40?ZE:*P>YJMC-MO^/2+_=J3 MO4=M_P >D7^[4G>M:?PKY$S^)A1115$!3D0R.J#JQQ3:T=!_Y#=MD9^;TJ9R MY8MFE&'/44>[._T718H-)EM8PBRS1X=SSDUR48\J5HR:NQ:V@)&,@MP#^-;&F:):VB@L/.D)SN<=/I701+A< #T%> MI'"RDOWC/DJ^AJQ8707@]:[+4])3 M5K+R$X?/&*[8)0BEV.2CB98AN;^(T?%.HQ?V& M(&8^9*X*#'7%HFF;?AO2'UK6(H"#Y*G=*V#C'I^->WPPI#$L2# M"(H"CVKR;P%="WN[HDX# 5ZG:WD61=N#43D$U&&!HS775QDJD%%EQBN@M-= M0Z,C=&TA:N.[N4SYB\3V<.G^)]2M+92D,4Q5%)SQ6373^/#:3>,[_ .Q0 MRH0^)M[9W/W(]JPX[%V&6;'TK]PRRE5Q&&IR2W2_(^7JP?M'8J45L6NE1W%S M#;@GS)7" D\9->N>'_@YI*6^=9:2YN"V?W4A5 /3WK;&1^II>U>KZ%0P\Y[' MA>1ZU);S207$O(W-BT] ME,S[MRMN7Z;3T%>DD;?4ZD=4S*TK48=5TR&[@.0R@,NJGL:V?[1@U[4;9XV+6K$; M1C!'J#7GUZ/(^9;,[:57G]U[G5:+$\DIN[C)N)CN_BAC+R2HJCJ2U<[KOBB);=K:S;?(XP9 >%'M7 M%,S$8+D_4UT&B^$-1U4Q2.A@M&Y\QNI'L*UGCZM9%M.U#C76D7'ESKE"?DD'1JI8!'3 MK7KNJ:=%J5C+;2#[P^4YQ@]J\JN;*:SN9()5.Z-L9QP?>N'$8;V3NMCZ7*1@]/>M<)C MZN%E=.Z[#S+)L-CH-2C:7=;_ /!/.Z*WM;TI(%^TP*0N?G Z"L'CMTK['"XF M&)I\\#\OS# 5<#7=&K_PX4445TG"%%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 7H/]2M%$'^I6BL'N:K8S;;_CTB_W:D[U';?\>D7^[4G> MM:?PKY$S^)A1115$!4MO,]O<),C%60YR.M144FKJQ49.+370]+M;I+B".XB; MY6&>O2LKQ)N>6"8+A0NTGWKG-)UA]+=QL\R)ARI..?:MG4=5M=1L8?)D_>;L MM&>HKY['X64(2['VN49C3K3BKVEV*,X>%/#]GI%NJ0H#(?OR,/F8UXM+#NJ_(]_%YI'!KEWEV,? MP[\/9F*7&IR!.XB7DCZUW%IX:TVU.1&7!& '.0*U(UVJ!4HZ5Z5.G&FK1/D\ M5BZV*GSU7[MI-;LF598ES<1]/-'KGUKU:JU[:QWEI+;RH'CD4@J>AJ9P4U9FU"O.A4 M52&Y\JTY'*]Z['5?#<'VN>V^6&XBD(9H^0:P+O0+^U4N(O-C')>/G'X5YM3# MRCTN?5X;,Z%:UG9]F5XYR*LI/QR:S7CDB \R-T!Z%E(S2"7!^\*YG ]6%=V. MP\/ZI':WA21@J2C[Y/0UW]KJ2> !U-;>FOXB9S!8QW6 M3RP*D8]^:Z\-6E!)FN AB)^V4U%];GM-OX@7 RV/K5K^W3)D0KO(ZXK M@=*\.ZL[*^K:H3'_ !6\7\0]VKK+.RAM(%@MT"1J>%R3BN^,F^ECYJK3A!VC M)/T(=>W:AILJRR8*C=P/3M7!@]#7I-U;&2QG1%W.R$ #O7 ):$KL;*.O!!]: M\_'X.5;WX;F*'VLY4@%JV;:ZR.M8;6-RARL>X#G*TZ*:2+!=64=B1BOGJV&G M'=6&==!<].:T8K@'O7(V]\/[U:<%Z,9S7GU*.H'2+*/6G>9[BL5+P=C4GVT8 MZUAR2+4VC6,H]:@FN-H&#R3CBLQ[_G"Y)]!UJUIT9EF$DZD,#E 3T_\ KUUX M/ 5,344>G43FSPWQ1&%\6ZGW/G')Q5 #%:OBO_D<-5_Z[FLNOZ-P,%##4XK9 M)?D>1/XF2VD_V6]@N0H8PR!PI[XKZ"\,>+M,U^T5H9TBN,X>"0@,&]O6OG@= M:G@+I,DD3%)$.593@@UQYEED,;%7=FMF72J.#/J6BO$M-\9^*[96;[2MR"!@ M3ID#Z8Q6Z?BS- BK/HQ,@'S$38!/TQ7RE3),5&5HVEZ/_,ZU6C;4Z'XC>'4\ M0>%;A L?GP#S8I'_ (,=N45C$ZNGWE.:]6CDE5X1TZFDMU_P3&52/M%)'JRL00P^M;>G MW? %&%F@FD@=E+QL5)'2O4;S4_M%Q),QP&.0,U MY\?#ES=:E/*\\<<3N6!7DUQ8RC*I;E/=R3'0PO/[1V6Y368>M:EAI-_J##R8 M&"9 +OP /6MS3- T^RE$R*TKXP/-.X#\*Z2)^ !V["LJ>!ZS9WXGB2WNT(W\ MV0Z+X4L+.3=< 74N,8 P!BN4AFP1[5KVNH!, YQ]:[X0C M!6BCYJOB:N(GSU7=FO)$NTFLN3AR*GDU)&3"BJ+2AFR>]6*I MT^28RMDTRO#E)7T/T6$6HI,BFC62-D895A@UPMU%Y-S)'@@*Q SZ5WC'BN0U MW_D)O]!_*O9\JT/8E*I+^*[R\SK8SE:?5.UE!&,U8^/;#['JT5X@ MQ'.,$!>,CWKGX+CFO2/&]@;[07PS Q_,%4^W"V4F8E67@COFDVDKLJ, M92DHQ5V=-NAE ,Z1NH_YZ $#\ZJ3ZGHT(PEK#+)CA4B&/IFN8GO9K\X?(A!X M3^IJYIL*27T,;CY2>>:\^IB[RY8+YGU6#R/EI^TQ$GIK9'2:2++'IUC! M%G*LT0W"NABTFY?E]2N QY. ,?RI]FJJJCBM6$\5Z-*A&WO:G)6E%/W(I?C^ M9#;V,T-N4%PTLG)5Y1G^7:I6DFMANDA+QJF6:/KGV6M&&$N/E%.="O!K=TH; M(\V7)*6J*EC=6U^I:UG27!P0#R#].M<5?V_V+5+BW9]S!MV<8Z\UI^)]*^S+ M_;&G!XKV(@DQ=QW)%8-SXA769;=Y85BN57;(RCB3T-<;JC MK'KW7^?J:4+],5?7;(H$BAL=B,UCP2?E5^.<(,DUY/^-!TNS;_ )8 ?0FKJ@=:=7AO%56[W_!'1&FNI62TBC"^6BK@<''- M0S)+$ZR+GY3G<.U7Z0CCIFN_#9SB*-D]4#I19X7\0-/&G^+YW$PE%VHN 0,; M<]JYQ>E>S>-O! M=8?,L(N1^]%6:>__ QY&(HRIRU'U8MV D!/K584X,0>*^BDKHYUH>@:1>V2 M6NV7!XXK"UR6&24F/K6$ETZKC<<4C2L_)-<-/")?Z>AKK$$@7;,FV0'! K5\$Z2=(\-0 M1NLBRS'S9$D&"I/:M/4=-%TF^(*)AW]17YSF=6%7%SE#;^M3T:2:@KG-*Q#9 M'!JW#?2(1G-,\L*Y25"K#@@T];6-OXVKA-"_%J^!@L15I=97'WJQY=->15^R MSHC9^;S02#^559?#^J3%MNJP1J>-JQG^= &U=>)8;=?F?)]!UKF+_6I+^;/S M%1]U15F7PK:PVP>XOIGG(Y*XP3^-6K"RMK!2T2?,1\SGDF@#*_LO5+F$ND04 M#LYP3]!6QH_A"\N CW3B&/K@EHXK?*E6.XGN,5AB7:E(]'*:3J8RFEWO] MQSX/%+DU=T[1-2U9P+*U=P>-YX4'ZUV%A\,9F96OKX!2O*1#D'ZUX\,/4GLC M[C$9EAVA\CQ%F5/&T(T:0RRL7=N237AYKF+H_NJ>_4^M MX=R98C]_56G0V6U6]GC$*.+> <+%"-H ]/>H0HQ[^]1QXQ4M?)SG*;O)W/T> ME2ITH\L%8Z[29Q/IL94$;!MY[UK6LYC8#I7%:5?BSG(?F%^&P.E=4C+(BNC! ME/0BO9PM95*:75'P6;X&>'Q#=O=>J?Z'765YP,FMN"X5P,FN!M[MX6]O6MFU MU%>FZND\DZX,#TI:QK?45Q][I5Q;U2.HH NT55-X@'4?G5*_UNWLK=I99 / MUH S_%=ZL"Q)YP4#+."W&/>O"=6O8]1UF:>% D.["K_6NYU[59M8^U%1EY$* MJOMZ5YK&#$^QA@KP1Z5Q8R322/HLCH)2=66YJP=.*N*2"&'!'-4(&S5U"/6O M)9]E"SB=AI'B6':L=Y^[<8 ;L?\ "NMM;J*9 T4BNIZ%3FO)>#4MO/+;R*\4 MKHR]"#TKT*&8S@K35SR\3E,*EW!V/;K.]2)-K"BYND<[ON@>M>;:9K\Z$&:= MV^IHUC63=1[!*VWKC-=OU^G;F2U/$_L:?M;&KXL\06S6365I,7F?JT9X ],U MPN2N&7@CI2G&>*3M7DXC$2K3YF?2X3"0P]/V:U[FS8WAD@W-G<.#[UHVK&60 M.<_3TKG+)]LK)S\PK?LG QDUR8_%2J04#X?-,*L-BI06SU1U%G@'BMB'I6#: M2=.U;5O)D5\[56IY\79EU<_$WPT+BR_MJU11+ /WX&!N7U/J17HU5=1MX;O3[BWG MB66-XR&1AD'BM@?#CPF][>1:SGUJGI/@I%E26_E$NTY M,2?=/U-=];//$B) _E*@PJQ#: *^7S7.H2INCAW>^[_R.JE0:=Y'6BTX)/6H MIH=@!_2L9;F][W4O_?52+-=Y),SMD=&YKY(ZAFIV N@9E)$RC\_:L))2IPPP M>XKHUFD&-RY]Q6!JT4<4YEB8E $%YJ\.M+0 4444 % M>W6I)#"TC ML %'KUJ3P[X>.J7*ZEJ*[E?YHX?;L37':%O\1ZQNFD'DVX\PQANOI7L.D[0H MZ#Z5A;VCO):([I3>#BXTW[\EJ^R['164"0Q;$4!1Z5< J&V(V\5/6R.#?<3% M&*6BF A&1BN*\;?#O3O%5L98PMMJ2+^[G1>&]F'<5VU(:J$Y0=XDRBI*S/D7 M6M$O_#^I26&HP&*9.G<,/4'N*SZ^@_BYX6CU7P\VJ0Q,;VR&1Y<>YI%_N_3O M7SY7NX>M[6%^IX]>E[.5@HHHKD7^[4G>H[;_ (](O]VI.]:T_A7R)G\3 M"BBG+C(ST[TV[*XHJ[L:5J@2)??FM[2K.>^E$4*?5CT%8J;=J[3QVKNM!B6T MA1 06;#,?6OBG3>)K2E+N?J=.HL'AX0AV1H/2O7+2XB\IDE 96&"".#7F_C32;?2]0CGL(F2VF M'S8/RAO05R5\*\._:4]D:8;'?7F\+B8ZO9_UU+;7$")YC2J!]:?%<*5#I(,' MWKC3<,>"V0.U7K>?ID_C6^&K^U6NYXF;9=]3FN7X6=='?2(,9ZU935)<< FN M:AN.F3^)J[%<=@"Y/15Y-=)Y!MO>W;QG9MW8X#-BN7N].UC4KDO-/"W]U0QP M*ZBST+5;M59T6",GD,?FQ6Q%X69.MV#_ , H \OC1K6Z:.4@R(<''2N6URR_ ML_424.8YOG3G)]Z[_P 5Z.^CZGG+/%,-P7U>5QMLS#AEQP:OQR9 K%1R#5R&;T->+*)]12JFLK<4_-4TE!' M6IT>LVCL33)PY%*9,]U;5O+L:F7&B3Z#U<^*HS@TIK<^&SK$T\1B>:GJDK7.BM+D9ZFMRUN,BN,M[@JV#6W M9W?'+5Y56D>0=3'*"*L*]8<-T,=<5>CN1MKB<&BXS:-'?FER*J+,#WI_FBI- M%4+&144LJQQLYSM4%C^%1M, *P_$%W(VE7$%M=?9YY$*I*!DJ?I6^&HNM5C3 M75BE4TT/!?$&I1ZEXCU"]A#K%+,2H<8/I5.%I)I4B0$NYPH]:Z2+X?ZG-./W MT8C8Y9VZY^E=+I'P\-A(TCWB32$_*WEXVU^XK,Z&&H*%*5[*R/-]BY.[,+2O M#$K3J]ZZ^6.0J'.[ZUW.G6<-K$$@B6-!_"HJ1="N8!F/$J^W!S]*FA!0E6!# M#J#VKP,3CJ^)=ZLM.W0Z(4XQV+\"8'%:$2X'2J,)X^E7XF!%#NZ0)E# M0!5D'7)P"*UUB8GI3BA7[U SDXY9+.;RY5*E>V*WK/4%(4Y(HU&P6]B #;9% M^Z?Z&N?S/92[)5((H [N"\1P,YJTKANE<;::ED8)K7M]1&/O4 ;M%9Z7ZD,YK;MM1B9<,^WZ MU!1I44U75@,,#FG4 %%%% %#6_\ D!7W_7!_Y&OD1%9V"JI9B> !DFOJ_P 6 M:C'IOAB_GD223,10)&N6);@N/J<5[-;1A8ZGJ)8VL]M!QPE-'FZ_!3PP%&Z2]+ *3%9QQ55.]RWAZ;TL?-^I?"7Q3IUN M)E@@NQSE;=\E1Z\XKAF1HW9'5E93AE88(/O7V3M%>?\ CKX967B96O;$):ZF M!]_&%E]F_P :ZZ./;=JAS5<&K7@?.M%;^H>"O$.G321RZ;*ZHP7S(AN4D^E: MNF?"OQ7J0D+6*V>S&/M+[=WTQFO0=:FE>YQ*C-NUCBZ*]3L_@?JTMO(UYJ5O M!,"=B(I<'ZGC'Y51/P7\4 $A[$_]M3_A4+%47]HMX>KV/.J*U-6\.ZOH4A34 MK":WZD,RY4C.,Y'%9=;)J2NC%Q:=F%%%%,04444 7H/]2M%$'^I6BL'N:K8S M;;_CTB_W:D[U';?\>D7^[4G>M:?PKY$S^)A1THHJB#4@;= N.W%=S9S PQ2( MP9=HY%>=VLP1MK?=/?TKH]+U,6P\F49B8\-GI_\ 6KY6M3>%Q$E+9[,_0<'B M%C<)%Q^*.Z/0K*^&!S6[;W0('-<)#.0 \; KUX-:EMJ13KFMDQJ721VJ3^]< M]XWDWZ5;CN)?Z4B:LB(6=PJCDDGI7,Z]KPU.18H2?)3G)'4^M88RLHT7%]3M MR^@Y5XR6R,WM3DE*5")!3HMTTR1J"2QQ@=:\;#U'3J)H]K,\)'%8>46]M4;V MCP2ZER 9(AO/5CR37-:!9Q62+%&#@U,%W&&7^%NZGU!KRCQ)X5N]++Q.C3VLF0DB@_@ M#BO9332BL,,,@]L4;JQO1Q$Z3T/E*1&BF>-L94XX.:16*]Z]S\6?#2PUPBXT MXQV-X.I"_(X]P._O7E6M>"M>T(.]S8,\"Y/G1?,H [GTKRJM"47Y'U6%S"C6 MBK.S[,R4G-6DGXK,Y!P01]>*,"NX\/_ M _U'4_+GOC]EM77=C_EH?P[55\(Z+;Z<8;Z_C\RY/S(CCB/\/6O4;/5HV R MP-=M'!+XJAX>/S^:?L\/]_\ D.T?PYI^BP(EK N]1CS6&6/XUJXP.E1)=Q.. M&%))=Q1KDN.*[XQ459'S-2I.I+FF[LX'XGJJQ6#!0'9V!8#DC'2N%@O8UVQ3 M.JL3A23C->@^(]%;7[\W$EX\<2Q[8H^P;U->+^,(WL-5;33*',."S*,#)]*Y M)9;4Q>(L]%W['M5ZV%I93RR^-;>K?^1VO2K$%PT9 /2O/M-\575J0ET#<0A< M =&'XUU%EKEA?X6.<+(?X'X.?;UKR\9E&)P_Q1NNZ/G:>(IU%O9G60WW R15 M^*_! YKE0^/NL./0U,MRX(&BJIR:T+_2[_ $[2VO+Z18#D+''@L6)^G2G3R^K5=HQ T+C551>N2:S M:XSZ5F6Y9VW.22:UK<# KZ/+\MCA??EK(5R[!%@C^Z*]4"= M(^>E)<:;!=8+#:X_B7K4\0)(JTL+'M0!S4MM+9R;7&5)X8#BI8GQTK5;UH$:=G*%D&>E<=J]\-0UVXG"%!G9@GTKX'2KT,MT!Q(?R%58EZ"K\:X'% B6&:ZB0JDS M8///-3BYNLY+!^.A%-C0'M4X6@9&+@X_>)M]QTJGJ,0EA\],$KU'J*TEA+G" MKDFICI#D9$BC/48I"1R/EQN=RDJ?:I51U/RS8'O6L?"MP'8I=H 3D94U4FTC M4;<$F'S%!P-AR3[XIC&!INTP_*I%+-@-(Q/<#I5!9A8;Q63%)G&*N12\_2@#J[1%,2GN*G88! M(./J:Q+2_$0 /2K;:DI0XYH =+<5HH0R!AT(JE?EBP'50.:GM'W0@$Y(H MGHI:* (;FUANX&@N88Y8FX9)%# _@:\I\:_".WN&N-4T-O(<(SO:*F0[?[/I MFO7*0UI3JRIN\69SI1FK21\;R))%(T(K1 M%5H1MN0,*"O][W.>*\4[5[E&JJL.9'CUJ3IRL%%%%;&1>@_U*T40?ZE:*P>Y MJMC-MO\ CTB_W:D[U';?\>D7^[4G>M:?PKY$S^)A1115$!5JWN0@V/\ =]:J MT5AB,/3KPY*BT.O!XRKA*GM*3U-RWNY(0'@E8#V/7ZU=_MJ]S]]?^^*YJ"9H M)ED4 [3G!&0:[.PM_#VMQ[(+F2QN%P7$Q&&_W?QKY[$9;7H:TY71]?A,^PN( MTKQM+\#+?4+F8D22N5)Y&>*%N2#C-=!/X&NA)BWNXFCQUD&#^E*G@*^9ES>V MH&1GKG%>9.A5;U1[<,SPT(^[-(PA=5L>&@UWK"%6 $(WM[BM%M \+Z4TB7E[ MIITZ<*BYV77Q%>OAI^QB[6 MW>B_X)Z!8R;9.O)KJ[&<$#FN*5RK@@]ZW;"[X'->N?$,[!&##BG5G6UT#C)K M05@PR* %HHHH *8Z*ZE64$$<@BGTAH \<^).CK*OVNU@3=;,1(%7YF7\.PKS M53&2&Q@]1@]*]MU>57U"[B<*T;,58'N/2O*?$FB?V7=F:W"BSD/R#.=A]*X, M51=^>)]'E&.5O83^1JZ=XM>)$BND,J+_ !@_-[5T=AXAM;J98K6:0R'G&P\? M4UYI)^M/"SJ-\M]#;'8+"_%9J3['>PW=WC M_6 >Y-6HY3G?)*7)]>@KD(M7([GBFW?B:WLHB\TJK@9QGD_2O2BKNR/-5"A3 M7,_Q.GU36(-.LIKJ>0*D:D\G&3Z?6OGS4;V34=1GNY7=VE* MKK7&\D9CLP2A3^%!1TYSTHIT:AY45NC, M ?SKK/*6YZAX!T58=-%U=Q9EN#E26W IVX[5ZCIFGV*.DBVD0D7D-LZ5R6GP M1V-K;V\.?+C0!6*1TR*@&0BY]0*\X^(6I+-J MUO91S.1"N98^0N3T/O7H=O(&3&:\C\:L%\:7?J53^52DEL61VIY'TK5MVXS6 M!#.L:@D_A5N*229N6*K_ '13 WUO8EP 2[>@_P :L1WDS A44>A]*S;:+:!@ M=:U(5 % %N&YN=N XY'7;5NWNKN$,HE+9_OC-01KQQQ5J)JG>;*UD*D<2L!^@K.MH ,9ZGJ3UI")]SSPR1; M2 X*Y)Z"LV'PJH<$W+G_ (#6]%'V J_&@ XIC.<;1I[8%D_>+GH.OY5+#Q@' M((]:Z>.,5#=Z:EP-Z864=#C@T 9\9Z5>0]*SMKPL8Y 5<5HV:WEFT9X88Q..>*[ M6YTZ+4M.,60'QE7(SM-<1<026L[PR<,C8)QUH Z.RO1@ GI6];72LN":X"&Y M:,X[5LVFH@8!- '8@@C@TM8L&H@CK^M7UO%8=10!;I*S;C6((P5C.^0<8'05 M6AU1LDNN3B@#H**13D ^ MHS2T %%%% &=KUK!=Z#?0W$*2Q&%B4<9!P,BOD4_>/U/\Z^N];GBM]#O9)I$ MC00L"SG '!KY%/WC]37J9=M(\[';H2BBBO2//+T'^I6BB#_4K16#W-5L9MM_ MQZ1?[M2=ZCMO^/2+_=J3O6M/X5\B9_$PHHHJB HHHH *.^>XHHH&C3MO$&KV MD?DV]_,J9SC.>?QK6M=6UFZC*W-_,R/QMS6!8P&:88&3G@>IKTSPSH\4*"2> M,-,>N>0*\#,:G//V%))=V?79%A(PBL57U[+]3-L=&U&ZC$D-I(ZGN>/YU+I07:@%@ MDO0J>_TJZ=6S]G4TDOQ/!QN T^L8?6#^]>IU=GJ/&"?PK;MK\''./QKB%8KR M,U:BOG0\YKH/)L=Y'=JV,U-YJGO7%1:OCJ<58_MH8^]0!UIF0?Q5B:]XABTR MS/&Z23Y44']:P[S7;I47[+;23,QQP< >Y-V.U M%5[_ .8ECR3G)-7M&TN37;DI-!)]F09)*<,?09_G74:/X!L+7;)?YNI1C 8_ M*".]=>D:QJ%10J@8 H&FUJCBC\.]%=].FH0DG8J=:K*-N9_>?)C:S MJ3(5:[D(88/(JFSLY^=F;'3)S78^/O DWA"]66.4SV%PQ\MB/F0]<-_C7&5] M!2Y)1YH'@U95+\LV%%%%:F(4JL5=6'53D4E% T>V:->-?Z/:7+%#(\8W[#P# M6W97'EL 2:\H\#:\MA='3KJ0);3'*%C@*W_UZ]*Z'Z^]>!B*3IU&F>W0J*I" MZ.QL[O( S7F?C=]WB^[8>B_RKI[2]9" 78N*NZ;L='!U6M&+K63;N&4%3D>HK1B8%1@UKOL<35G9FFAZ5+^10!EV_S-N8G+')S6M !Z5CV[<#FM M6%LXH U(:N1UG1-W%7XCD \T"N:$2$CBIA _I5C3U7RSGJ?6KI1<8Q0,P[JU M2XC*LOSC[I]*Q"'AD,;C#+UKJ+D!365?VHN$W( )5[GO2$58;C;WQ6QI]R9< MY.0M M5V3/UJ:.X8GTH Z2.XR<"M"!\C.:Y^WE]#6G!-0!N129 JY%+@UC12]#FKD< MV: .DM=0,8 /2N \6ZI/;>+'F0$Q-&H*MT/TKHXY<5A^+K3[7IZ7*!V> _=' M0*>IH$4X=%-%51BR7([DFIAX;TE>EFH_ M$T X)JLWAFW"'9-*&QP2M5Z]ZA15*'*>/6JNI*X4445L8EZ#_4K11!_J5HK![FJV,VV_ MX](O]VI.]1VW_'I%_NU)WK6G\*^1,_B844451 4444 %+[TE% T=!X=A5[N- M9!D9$WC2:";PE+&\GEX=<';G) M]*\OMY-C@^G:NO\ &&IQ?V>MB/FDD8,<'[N/6N*%>)F$E[?W3W\GP[AAFGU9 MORZPQMU$3;77V'-21ZN[8W*O'ZUSF34B3%#S6^$Q//[DMSQL\ROV2^L4]NO^ M9U,=Z6'059CF'&<5SD-S6OIP>]N%C0C:.6)]*[SYDZ'3;>>_F\J$9 ^\QZ 5 MVEAI\-C'A!N<_><]36=IABMXECB4*OM6TC9&: 'T444 %%%% &'XKT.+Q!X= MN]/DB$K.A,2EMHWC[O/UKY4G@DM;B6WFQYL3%'P>,C@U]BMT/TKY$UK_ )#^ MH_\ 7S)_Z%7IY=)ZQ//QT5HRC1117IGG!1110 5V/A?Q=<696RO0\]L.%<W^9]!D65U,95YKVBM_/R.GN M==O;UVV2&&$_=5>OYU7 .223/U##X:EAXVIJPN M*< #6YHWA'5-8"21QB&W;I+)Q^G6NKMOAA$85^U:A)YW?RE&W]:N&&J35TCE MQ&;82A+EE/7RU//X+J>U.8967';M70Z?K\3A4N3LD/&<<'WKJX/AKID:2++< M3REONL<#;5C_ (0'3XH@D.&(/65'4^?S#'Y=B%\+;[K0SHI<@$$$& MN;\0WHFU1(=I!A7!.>N:[5M!EM%"K'E!P"E9>H>'+:_CDDVLD^TA95ZC\.]= M_2Y\W9-V.0.HV]JI\Q\L!D(.IJ!O$=RVY8HDC7'!/)%81MY8;B2.97$JL0P< M16QE23M'0^XP.1X:G#FJ>\_P "^^JZE=;(S\1&Z3[->R#SQQ&QZN/\:YXUY1J> MRJJS,<7E<51^L89WCVZHTM640S"93C?U'O56"[*/D'ZU_! YKADD9,%3Q5R'4'CZYH [Q+E&'6I1(I M_B%<;%JX]:G_ +94#[_ZT =495'<53NK](QM!!)[5S_ MZT",W_A%[3_GZG_2HW\+VO07,_Z5K>94T8).: //_$/AL6MSV('Y4#.3@G]\-6G!<>AK: M;1-.NOF: *^."AQCWJ ^%6ROD7GU,B_X4 113^]7(YQWJ >'M4#LL<:2JO1@ M_7Z"D^P:I!&TDEAAK$6Z[G(]R*F6[' MJ* +MFD=N5CB&U%Z#-=9ITPPHS7((P.&!!]Q6SI]UC S0!VD3 J.:EK*M+K( M'-:BG8UZV&PM.5-2EU/,KX MFHIN*-O4_%>K:H2'N#%$3D1Q' 'MGJ:Q***[HPC#2*..4Y2=Y,****HD**** M +T'^I6BB#_4K16#W-5L9MM_QZ1?[M2=ZCMO^/2+_=J3O6M/X5\B9_$PHHHJ MB HHHH **** +ME)U0_45T]GK:A%CN4((XWKTQ[UQBL5(([&M.&83+D\,.HK MYW,\/.C4=>GL]S[3(L;2Q%%82K\2V\T=W;:I"@#+<)M//+58;Q9%"NV$&1\< M$] :X#OFI4E(&,UY4\9-KW=#Z.E@J497EJ=!-?2WD[3S.6=J ^:R([C@?-TJ MTMP,])73+ER3BXRV985V4Y!KM-,B-K M:1# WD9+#O7 -=*@W$\"NN\/:[;ZW:GRU,) MB.G'H*\^KV<%0=.%WNSR<754Y66R"BBBNTY H[9HHH NV4?!DX]!6O;MS679 M_P"H_&K\38KXK,Y2GB)WZ'ZCD4(TL'3Y5NKFS #(ZH@RS' %>C^%O"T4#I<7 M:B2?L#]U:Y3PA8B5C>N00IVJ/>O4M+P%45.$PZMSR1S9WFL^9X:D[);F];Q* MD8 ] *GJ.+[@YS4E>B?,!1110 G:J5Q9JV7B4!\YJ]10!XMXYT@V&L_:TC M98KGDDMU?OQ7-H1N7ZBO8O'6BKJ6ARR(J":$>8K-_#CKBO&HV#+D=Z\7%T^2 MI?N??9)BOK&%46]8Z'IMC*KPH0000.16O$XKSW0M:6W"VUPQ"Y^5R>![5V=M MSAJ\:D4T>5C,-.E-J2.ILGB,>&(S[TVY*;_ )#6-'/SU-2B M?WKJ2UN>0Z#4KC-9CCFTJY6159=A.#ZUY'&[QNDJ,5=3D$5W/BG7TCM/LMI, MK2R<,R-]T5PG&*\7,JL95$H]#ZG)L/*%&7/LSKX]82?3_M#$ J,./>N;C%[? M2R-:VTTHW?P(3MSZUI>%Y0+B575651N7(Z&N_L+U%&$VIGKM&*Z\/4=2FI,^ M2S+#K#XJ=-;=#$T/PAKCJGVV:.V@R9XS5?Q!IT>MZ'/:[8VD*YCW]%;L:V.$\QCUAG_ .6:@GOFIDNV?[Q MQ7-;I;:9X9@5=&VD,,=*NPW(QG.?>@#I(Y^@-6XY^*P(KG(ZYJTEQQPU &ZL MX]*Q8I,$ MQFB,:N64X4]SVKS9 \$K12#:Z-M8>AKU%+N-U!R :\X\0Q1VNNS"+?Y;_."W M"-T/4%1@UEG3=-'/V*'_ +YI@E']ZG>;_M4 96I6:6TN M^%0L3= .BGTJG'(R'(XJQKVMV^GP>4R^;.XRJ8Z>YK%T_4TNUV/\DWIV/TK+ MVT.?DOJ=BP.(=#VZC[IU=GJ'0$XKH+6]!4#=7"ABO0D5>M]19,9)XK4XSO$N M%8=:D#@]Q7(PZL/[U6QJZC^,4 =)N'J*I:EJ=OIEA/>7+A8H4+NWH*R4U1[B M3RK<&5\=%KS;XRW%];V6E6[S/&L^]I8E;Y6QC&?>M:-/VDU$SJSY(.1YKXCU ME_$'B"\U1UV>>^54$D =NM9='2BOH(Q459'B2DY.["BBBF2%%%% !1110!>@ M_P!2M%$'^I6BL'N:K8S;;_CTB_W:D[U';?\ 'I%_NU)WK6G\*^1,_B844451 M 4444 %%%% !3D=D.5)!IM%)I-69492B[Q=F78KP8Q)^!J[$CSKNB1Y!ZHI( MK%KH/"_B230KKRY&S8R',JAXKQL7E%.5Y4M&?28+B.O32A67,N_4:MK=' M[MM/^$9J46M^!Q971'M"W^%>HZ7K,%]"EQ8W =&[9^8?45T5IKKQC#L17CRP M5G9L]E9])ZQA^)Y+;^$?$UQ"DT6CW#1N,J20,CZ&NFT_X4:W<,?MUW!:H4RI M3YVSZ$<5Z1%X@C(Y.:YOQ+\3M-T>VF2&43W@!58HSD@^]73P$9.R5S"MGV(M MTB>:?$33M*\/FRT:QD>:^C!>ZG)X;/0>V/2N+M;NXL;A9[69HI5Z,IHO;N:_ MO9KRYD\R>9R[N>Y-05]/A\/&C34$CY'%8JIB*KJ3=V>@:'X]C\H0:P&\P$!9 MD'!]VKK+76=-O49K>^@<*<$[]O\ .O$Z./2LJF!A-W6A4,;.*L]3WV*9]H9& MW*>01R#4QU-H #)(L:GNYP/UKP5-1O8T5$N[A548 $A 'ZTR:\N;E0L]Q+*H M.0'A[U\IF^'=.LZBVD?H7#V-C6PRI-^]'\CU30=JZ-9D*!E 3 M@=:['39^!7">%[O[7H,)$>WRCY?)SG'>NEL[GRF )JJ=G!6/%Q2:K33[L[JV MFW*.15NNIV[1SV%>UZO.$"(&^8GD"O._']DUU80WR*[26YVD#H%/4FN3&4^ M>G?L>SD>+]AB>5[2T_R.)!!JW;7]W:(5MYWC4]A67',#WJPDF:\=.47=,^\: MA-6>IO1>*-1AC"?NVQ_$R\FH+GQ!J5UN#7!1&&"J<"LL,#2Y%:.O5:LY&2PE M!/F45<7-(31D4QG SFL=3>R1M^&V!NKA0>0@/ZUTT,3ZS=VVJ-L6^ID8!.#6K!JHZ[J\OC\=Z([JN^="QQEH^!]:D'CK2/-:.-KF1EZ^7$6 MS[_2CZO5_E9R>VIO[1=\:Z?Y6I'48B6CN3\^3DAOZ"N95BG0UT=W>ZSJ=ABQ M\,ZC>6LR;EE9=@SVXZU@VN@^+&9$G\-78)/+@# 'YTO8RM<7M8WLB2.Z(/6K MD%P7[XJI=Z7J&GRB.[LIXFQNPR=JB@F QSU[YK(U.D@EXXK1BEX'K7/03YK1 MBG/K0!NQ2C%6TF(.YJ19P M<=J?(RS0O$_S*XP10!RT-QG S5Z*?'TK!D9[6[DMWP&1L8!SQ5F&YQT- '0Q MS^E6%N/6L%+KBK*W6!DMQ_*@#;$P]:R]5\01V(,4)$EQV'9?K6)?Z\V##:'D M]9/\*Q,DG)))/4FO.Q.,2]V!]-E>1.I:KB59=%_F7#+->W)EGD+NW4GM6S#H M9DM_,4GIP0>17/PR;&!]*W8-=:.'R^Q'(KCIRBW>1]%B*=2,5&DM#M-%T."[ MTF%9"PD .7!Y-+=>&98!^[N%=L]",5F^%-=:826[2'>ARHQVKIFNC(:LPZ+$OS2RM(.H X_.KTDO!S3HF;R M@7/7I]*NI%+8XZU%0CV,5Z?>M-Y$IMFV3[#Y;9QAL<5\WZHMVNK78OLF[,I,IQ]YO6NG 03J< MSZ'E8R;C"R*=%%%>P>4%%%% !1110 4444 7H/\ 4K11!_J5HK![FJV,VV_X M](O]VI.]1VW_ !Z1?[M2=ZUI_"OD3/XF%%%%40%%%% !1110 4444 %%%% $ MD%Q-:R>9;S21/_>1L&MQ?&NO*@47@P!CF,5S]%1*G"6Z+522V9KWGBC6KX() M;Z1=G3R_DS]<5DDEF+$DL3DD]3244XQC'X584IN6["BBBJ)"BBB@ HHHH ** M** "BBB@ HHHH **** "IX;AHN#ROI4%%9U:4*L>2:NC?#XBIAZBJ4G9H[3P MKKB:?=>7+(?LLO!R2=A]<5Z*K!@K*001D$=#7A,;M&X93R#GGI7:^&?&%PK? M9+TK(N?D/3 ]!7C3R^=%-Q=U^)[=3,Z>+:E)-&<$FMRUU $#FN M1M[J&Y7,4RMQDC/(^M64E=.037,([N&_!')JXETC=Q7!Q:DZ8!JVNLX&M/\\>M8PF(/6FM>JO5Q] >:F&'G-VBKG3/'TZ2O4DEZLVFN5 ZFL74M5W*8 M86Y)^8BJ,U_)*I53@?K5.OHCW?^0445V7@ M/PW'JEX;V]B#6L1PBL#AV]?0@5[U2HJ4>9GQE.#J2LBUX.^&UWKTD%Y?L(=. M<;AM/SR>WM7N&@^$M%T&!5T^QBC8 _.1NKT/7IT(4T(% &,4M+16!L,:))%*NBL",$$9S7.ZAX%T._D,OV;R9# MCF([1^72NEHH \XE\)V=K<-"T;?+T8L>11_PC4&[*22(/[HYKLM812(FP-V< M9JE%%NX R30!RLF@7,>XPR*X'16X/YU2?SK9BLL;*<]QUKTB'3U*YD_(5.VG MVCQ^7)!&ZD8(99+=#'45(+D8ZFO0_P"P]+'2PM^/]@5F7G@[3[A&\@O; MR%L[E.1],4 >7Z_#F9;I,8(PV!^IK)2=E-=SJOA#5H R@1SP%23(O\/U'6N8 MU70)[+2VO+1Q-Y8S*C<8'J*3=E;7Q$IJT=CZK+].R*DTL6;2[ELKE+F!L2(;<49QT)'T-=>&Q AB;-Z-=3T?4M9AL[5I&<$X^5 M1SDUJ65TTVG6\K\,\8)'I7F&D6QO]6@BR^Q6W,PYVXKV/2]/\Y%GG!"_PIC% M>E0K3K7DU9'R6'Y:,7>6[$L+ W+>9,I\KL/6LSQG\/\ 3?%EINVK;7\: M_NKA%_1O45V QBEQ75&!**DK,^1]=T#4?#FH/9:E 8Y%/RN/NN/5 M3WK,KZ<^(GAB'Q+X9F0E4N+8&6&1B<*0.WAJ_MHW>YY&(H M^SEIL%%%%=)SA1110 4444 7H/\ 4K11!_J5HK![FJV,VV_X](O]VI.]1VW_ M !Z1?[M2=ZUI_"OD3/XF%%%%40%%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Y 3(H!P20 ?0TV@$J0 MP.".0:&AIGK%CX;ECLH1)>L+@(,E1QGMS6Q9Z%KI'RW]LV?^>@)JOX?NGN]! MLYI)/-D,?SMG)S[UT5A<["%+8KYN:M)GO1^%,IR^&O$T=N98IK.X8?\ +-!@ MG\ZIGPYXIE),EGC/51(N/YUWUI=_**UHY0ZYS4E'EJ^%O$ ZV/\ Y%6M*W\& M:O)"'DDAB8_P,22/RKT2C H X+_A"M4_Y^+;_P >J>V\$3LK?:KQ4;/R^4N? MYUV^!Z4E 'E7Q'\+6>F>"9[V.63N%%%%,@#TKW'P[#%;:38I#&J*8E8@>M>)6\H@N8IBH<1L&*G MOCM7N-GA@4M6=KITHP*WHVW+7&Z?<\"ND MM;@$#FO+/1-&BD!S2T %%%(Q"J22 !0!EZM(&DCB .X?-18Q]^_UK-N+K[1= MO)N)4'"Y[5IV+AE&>: -044@Z4M !1110 A&:YO7-)$>ZZMHUV$'SE]O4"NE MI&4,I##((YH \&U#PO;6%X]Q#&\MK*-P\P9"'/2FVUEIX<+)9PGZK7>:O9K; M7DUI+&3;2'(!/4>M&I3W1 MZ=/&U8;,XVZM[NPD,=W \1!QDC@_0U&LX]:[VYO+6^MFM[I5EB88(/;Z5YO? M0M:WTL,!,B*?EVG.![^]>=7PCIN\=4>MALQ4U:6C1>\_WHB,]W<+;6T;2S.< M*BC)-5[/2]0OG547:&Z;NI^E>W>$/#>GZ%;)*L*F]=!YDI7D>U*EA)2=Y:(Y M\;GE.C'EIZR_K<;X/\'_ -DZ>CWP!N&^9T!R :[$#% QBEKU8Q459'QE6K*K M-U)O5A1115&8UAD8/((KY-\5*%\7:NJ@ "[? ]Z^LG8*I9B H&23VKY+\42 M++XLU:1&#(UTY4@Y!&:]'+OBD<..^%&51117JGF!1110 4444 7H/]2M%$'^ MI6BL'N:K8S;;_CTB_P!VI.]1VW_'I%_NU)WK6G\*^1,_B844451 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110!W'@#65AD?29<*LA+QMCOWR:]"!*GO7@P8JP920PY!'4&N]\- M^-QA;/5WQCA+D_\ LW^->;B\+)OG@>EA<2KE;MM?C@YX^M< M9!-',=>*\MG>=]%>*P'-65F0C.:X>+52N,DBK::P MH'+8H Z[S$_O"J]Q>PV\+R2.H1%+,2<8 KD;_P 56NG6KSW4ZQH@RA/\ A6]'#RJO38QJUHTUKN0?$#Q6GBOQ";F! M98[6%?+C1VZX/WL=LURE%%>[""A%170\>M[*5^A M[A%,T;#!^M;EE?\ 0$UQ.A^(+/7+??"P2=1\\+'E?\16PDC(<@UXQ M%J2O$[NWO00 6J^DR,.M<+!J148-:L&J XRW:I&=3D>M8.OZF(@+.-OG<9<@ M]!6?J?B7['"%AVM._'7[OO7-_;))Y6DGOKK_C"X>)HG MM[8>3%)'GYP.Y]\US5IJE]8E/LUU+&$.X*K'&?I7HQP#E!.^IPO&J,FFCVB6 MRM)MY>$*S?Q+P16;=:--YBFR<&/'(D/(KSS_ (337_\ H('_ +X7_"JUUXEU MF]*F;4)OEZ;#M_E4K+ZG5HV_M.RLKG877GVS%;AEC.<;2XJ"V43W"Q0,AD<] MC^IK@Y)'FD:25V=VY+,YC_:,I/WMC MV33+1--^;.^8_><_TKJ[/4,JO/.*X+1_%.G:O%&!,L%RW!@U;J2,ARI M_6O/E"47:1VQE&2O$[JWOP1G/ZU>2Y1Q7!PZB\?6KT6L8_BQ4C.R\Q/[PI#, M@[URO]M+C[]JA"4W:),YQ@KLW?B1XWMO#^ MC2V4+JVHW*%8XR,@*>"37SGVJYJ>J7NL7KWE_.TTS]ST'L!Z53KW,/05&-NI MX]>LZDKA111708!1110 4444 7H/]2M%$'^I6BL'N:K8S;;_ (](O]VI.]1V MW_'I%_NU)WK6G\*^1,_B844451 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6[75+ZQ" MBUNY8E5MVU6.W/TKH;;X@:M"K">."Y).067;C\JY.BLYT:<_B1I"M.'PL[/_ M (6/?_\ /C;?]]-5*X\>:W+*S1210HPP$5 (JO1LFN+N MXNY/,N9I)7]7;-0T45LDDK(Q;;U84444Q!1110 4444 %%%% $UM=3V=PEQ; MR-'*AR&4UWOA?Q;J>J7GV*>UCN&"ERZD(?\ "O/.U=]\-X8C%?3F-?.5E57Q MR >HKEQ<8^S]E=R0''R(XRH/N:\,]02]' /< M&K2R,F"#0%CN(M1&.N:M"^3'6N%2]E4X_K5&[\9Z?81L9[Z+@[2JMN;/T%4H M2D]$2Y);L](:_C ZUYU\2/'T6G:7+IMA.#?SC:=IYC4]3D=#7$:U\4KNYCDA MTV)H0PQYKGYA[@5P$LLDTK2R.SR.]%%%>J>8%%%% !1110 =_2MW3O%^KZ;#'!'.)($.=DBYR/3/6L*BIG",U: M2N7&]%%;1A&/PHQE.4OB844451(4444 %%% M% !1110!>@_U*T40?ZE:*P>YJMC-MO\ CTB_W:D[U';?\>D7^[4G>M:?PKY$ MS^)A1115$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %=U\.;V-)KNQ*MYD@$@;M@5PM:&C:I-H^IQ7<1.%.'4'&Y>X MK*O#GIN)K0GR5$SV^&3RY,YKHK&[''S5R-I=P7]LES;R+)$XR"IZ'TJ];W#1 M,*^?::=F>WNKH[VVN0RX)JTR1RKM=%8=<$9KD[34 <9-;5O?#UI#'W6@:5>R MB2XL()' P"4[56E\):)+"T?]GQ)N&-R#!'T-::72L/>I?-3U% '+#X>Z(!TN M?^_QIW_"'Z'IB27I%>9?%GQA'8Z*VC6^U[F\&'!& M0J=_H:NE!SFHHBI-0BVSQ/4-1O+K4;F>6[E=FD;YMYY&>/TJEU.3R3W-'; H MKZ*,4E9'ARDV]0HHHIDA1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110!>@_U*T40?ZE:*P>YJMC-MO^/2+_ ':D[U';?\>D/TJ3O6M/ MX%Z(F?Q,****H@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH U]"\0W6@2R- JR1R8W(Y.!]/0UZAI&NV.LV@EM MY0KYPT3'YE/I[UXQ3HY&B=9(W9)%.0RG!%NZ[MQ$GS9_$\UL?\+&U+/\ QY6O_CU<$L!56VIV MK&4WN>QQZP%')(I\FO1Q1[Y) JC^(G KQ2X^(6JS0%(H;>!STD0$D?G6!?ZQ MJ&J-F\NI)/\ 9SA?RIPP$Y?$[$RQL$O=/4_%'Q1BMX&M](D$]PPQYO\ #'_B M:\DNKJ>]N9+BYE>6:0Y9V.2:AHKTJ-"%)61P5:TJCU"BBBMC$**** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"]!_J5HH@_P!2 MM%8/***.9A9"8HQ111S,+(,4444 GRAPHIC 8 sbfm_10k003.jpg IMAGE begin 644 sbfm_10k003.jpg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sbfm_10k004.jpg IMAGE begin 644 sbfm_10k004.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 Z17AI9@ 34T *@ @ U$0 $ M ! 0 %$1 0 ! %$2 0 ! #_VP!# @&!@<& M!0@'!P<)"0@*#!0-# L+#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_\0 'P$ P$! 0$! 0$! 0 $" P0%!@<("0H+_\0 M1$ @$" M! 0#! <%! 0 0)W $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5 M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! M (1 Q$ /P#W^BBB@ K#U+5KB&]>VB"J% R^,GD5N5RFK#_BU7$))Y)/O6?$.#_GM5^/K4C+2=/\ /O4X''X?T%0IT_S[ MU*#Q_GT% $G>EI!2\9IB#UJ-AD?Y]ZD]::W]: *CHN02.X_I5=I9%(Q(_;^( M^A-7'[>^/_9:I28_3_V6@97.LW%J09,2KW!&#CVKH 0R@CH1FN/OP-GX5UT) MS!&?5130A]%%%, HHHH *Y75O^0Q-]%_D*ZJN'\1:M:Z?KLJ7,JQ952N[^+C MM28&C#Z?YZ5?BS6#:ZK%*H:**=U/=86_PK3AOI&'RVD_XIC^=0,UD'^?SJ8# MC\/\*STN+DCBS?\ %E']:F$]YC_CR_\ (BT[@71UIU4O/O?^?(?]_!2^=??\ M^@_[^"F(MGH::>OX_P!:JB>^[V.?I**:T]YC)L"/I(IH D;^'\/Z53E^Y_P' M/_CHHDNYD'S6BBBF 4444 %W%]'=*ZA08H6.-N ,C/;)&:Z2LWQ!N_P"$?O\ 9G<8&''TI,#A[/79+E 8 M;5V![UL0WFI-]VT ^IJKID9$* # K>@1N*@9!')J[=(8Q]35E%UEATA'XU?B M0BK*#WIV$9@BUC_GI *=Y6K8YFA_*M2BG8#,$6J_\]H?R-1R?VHAP6C(^AK7 MICT 8,D^H+U2(_B:H7%YHWVIP- %2WB<8;'S,1Z9_^M6390*BC K9@ &*FX!:VODJ!UK M2C!%11@590"D,D5FQUJ0,WK0B9]*E$8]:8A@8^M&YO6I"@I,"@!FYO6FEF]: MDVYH\L^E %5RU4YXC(I!'6M)X\=14#@4#,6R-UI4[F-C+;OR8F.,'U![5JIX M@LBX28O QXS(ORY^H_KBH95&*R[N%64@@4P.N!! (Z&EKDO#NIO;7HTR=B8I M,F G^$CDK]/\]ZZVF(*\]\0?\C5=9Y^5,>WRBO0J\]\0_P#(TW7T3_T$5,@) MX#Q6A$U9MN>*T(C4C+\;<591JIQG@596F!95C4@8U"M2"@"0-2[JCI: )-Y] M:0R-ZTRDIB!W8CK4#L:D:H'H&02-Q6?<-Q5Z6L^>@#,49U>Q/I>>(2!XJNL^B?^@BO0Z\Y\1_\C7=?[J?^@BE M+8$36[C II\1Z/;S/#-J-LDB':RM( 0:I7-VUEI\EPD0E9,?(6QGD#K@^M>8 M:Y#)/XHU".(;F,[X'3/)K-NR.G"T(UI--V/9(_%6A C_ (FMI_W]%68_%6A' M_F+6?_?X5X8NF7FY%\G)=MBX8.<>OKD?@:GG M?8[UEU)_;/_P#_ E&A?\ 07LO^_Z_XT[_ (2? M0O\ H+V/_@0O^-> ;CZTF3FCVK'_ &1#^8^@?^$FT,_\Q>Q_\"%_QH_X231# M_P Q>P_\"$_QKY_W4;C1[43RB/\ ,>_-XBT7_H+V'_@2G^-1-X@T8]-5L?\ MP(3_ !KP-G('6HRQ!H]J8UX]/6K!\57,PC93'M>V^TY-L1\N'X_UG7Y* MTB[JYYU>FJ51POL=%&P_M>Q&?^7F/_T(5Z'7C-EK5R_B73[>55R+N /B+&,L MF>=YZ;A^M>S5:,0KSCQ)_P C7=?[J?\ H(KT>O-_$G_(V77^['_Z"*4MAHS- M==DT&8H7!+(,H<'EU_2O.]?\U/$U^Z[U87#$$<$@LRA_*>)K>W QBYE&.G[P_Y_P#U5&"/45[LNAVF/]9>?^!DO_Q5176F MZ;9PM+<7-TB@$\W4A)P"3@9R3@'@4N1LM9I!?9/$ 1ZC\Z/Q%>O:?'#?6BW3 M6]]!'(-T:/=-OV]BPZ GTR?KZ:<>D:=+%&WVBY&\X4/.02?3GOP:B'+-M)[% M_P!JQ70\.X/<4GXU[N?#EF>DEP/^VIIA\-V?_/6X_P"^_P#ZU:>S%_:T.QX2 MW3%1GVQ7NS>&[3_GK+']]IF5>,\^2V. 1FH9-)D@UBVTJ&;RW^Q*OFM'\V3YQ['@=1C/>N\^P1:> MUND3.P:LEU Y^7D?.,#KTPA_P ]?::\DMO^0[HY]9K7^;5ZW6B, M6%>;^)?^1KNO]U/_ $$5Z17FWB4Y\677^ZG_ *"*4M@1SVLM")9 2/,-NF_7\.E=C%]VH!%V*K*&O.8?$ M7B34_$U]:Z6=*CL[*Y$#+=,PD?G#$8Z]#Z=JW+7XA^&KB_>SCO\ YT#G<8V" M$(I9B&QC )S[4687.Q7I5/5K 7^GRH$#3JC- 2Q 63:0#Q]?0UBZ7X]\.:M M).EKJ*[H(FFD\Q&0*BXRV6 '&14MCXX\.ZG'=FUU-6^S1-++E&4A%'+ $<@> MV::NG<'9G+:781:BDT4UQ+;:FLN9['R 75@>",8!4_WNG)KN=$T9-.C\Z4*U MY)N,KKD EB">,XZBLBV\8^#;JXM[:&_MFEQNBW1-P>Y[54FWL)*QWW:@UR-OX\TFSTNP?6 MM3M$O+F$2G[.DA1@20"!C('!Z^E*?%:^)O^1MNO\ =3_T$42V!&!JEK/< M7,QC1G'V>)=NTD,?.!^G SGGH:ZZ/I7*WEU*S945=V.&&EVUCXUU!]6\.ZC>O-?" M:TN;97*("V[)P0."1GKT--TV9[76+NSL-*UO^P+B"=K^PN+;!C^1O]6<]3P M.#]>H[F+4='4+_IEX"QPH+3')P#@9^H^M2+K.G"VFG6]O/*B3<6P<-UQC<.^ M.">#FGSFGL'_ $CS>!=8OM&UC0])BOKK2DMUEA-U!LEC*RHQC!'7(#?+WQP! MW9:16VHPF8ZA?2WUII%Q"(&T]8U11!(-A93T&XX)&37K+7=M#3]!^E6]0N;:P\3^.;.X4QW5[9$VJ^6?G A9F(.,# MBO0I+B*&6U1M]:7@ .?$W MALD-QI4_4?\ 3>?_ !KTOSE-VENNL73%D63>%AV!6)"\[.Y&!COBCS[8=/$; MGD#AH.IZ#[G?!HY@]CY_@S@_'S:-;:_?NESK-MK$UJ(REGQ'9R!D_P"JD[5Y MM+>30B.X36VECY,@'([D^E M>?QPQS):QF6)%%M;HZ+M)+K&^1G.>,A?Q]JKH8OO"M+A"^)=+;RKC+WD!R8CM^\G?''W1U].U>ZTX@PKS7Q,?^*MNO\ M=3_T$5Z57FOB;_D;+K_=3_T$42V!'.ZQ&-TTA<8$$89?;S1S_.NBOU3[%O:- MW9'4H$D9#N)VCE>?XJY?6I/]+DBW(NZWC*$@?>\T=^I&!TZ5TUU]O!7[$(R< M8(<\#D<@?3-0P3MJ9$3=1V%UA'"EFE)VX\O&2.5)+&!58'@A2,Y^O.1CKZ?G,UM(L*QG M0;*1,8QM4!?F/;!XQSQSDT:%*O/NR":3PU>3M=2RRI(RD/(L3 MYJ$ 'Y?[O MW?TS4Y@\/+<7<7VRW>%O#L;(=I8)@9 M*?=YQVZ?ACI4\ZI;9G.C"0%0[M\VY<'<#N(SD-O)/')!ZGDT&L1/N5IUT&_M M)X;M[C"P>9N=D#89]S%A)QR>*L)Y-VJM-H,RQ,,'[QPH . ,?=)QQT)&>U,N=-5&FM!H4;P/;F M,R+G! &\J!@X&\< XR<=N " M03C[N1TJE;1:.(EW:I<"&&1H\/& 64KN(^[GD'D^QQBM*V1&-NDVA3%0-N^3 M)*J5\LD@#&=O!QV '84^[7?=.T^B?:&E0,Y (7@#Y6ZACQCIC@?@:#CB9I:, MREC\/6EM-Y;7;^67AD01@2*3N;!^4'DH<9SC<.E6=/M-"FE$%E,YD5UD4*NW M!CSCG:,XW'DY)]3BKL!D,4BII(B=OG)?)#-@;LY Y(9AG/.#VQ5>-+FWG4V^ MC6L>UV59-FT[<\-CMP3Q]>E&@OK$WNR[K-Z;&VCD"!]\R1X.?XF KG](U2[U M%RLVPQ^6S!A@'/FNHZ'I@#M6KKK-)868DC7<]Q'O#$C;W['KD#VKEX'C@MUD MMI@HE3[.HN&^<+YDF6.!UR#@D8^M,@OF]+:_I4<1VE=1B1MW!($B@X]N3U]* M]@KP'24\KQ7I,(0 _:;;#D$%AYQ.>?IZ=Z]^JT#"O*O&D_D^*YP"=[&(@ X. M,*#Z\P[&M'51IIO8VNY9(9E"%'49( ;/H>,X^N,5!49YQQP/3% M(U]O'^5&FVIZK+'9E8WA)!DFVVCY;:')7!/R_=4OZG+$)#9-%B M;RRK1/\ =Z>8>/N]\ ]NN*AAC%K)9AM67EF0!7< M\-NZ?=QQG&<]!D=N:2/Q-?7"R/%IN5C)R6++N'EL_ V_[)7ZX^E9Z?VS$KP1 M:O:S28D;=YX.&WJ0.5ZX+#_@6>-H%78X-9\R8S:Q:LFP^4GF<*Q963) !("Y M&>_!Q18/:P;^$2/Q!JCVUIOL&5I@I\PL1T)W!LK@$XX^OKBK,NO7ZV]NZ:?N M:17,G7"D$CCUZ?0Y'(J-X]2^R[_[6MQ*H)(\P[=N!Z#.0-W/TZU'"-2$ZM+J MUN8XV'F;9B3U_P!W&.<$8[]1M%%ANK3_ )0_M[5Y)8XDTYAOE"^8T#[54D#) MY[ Y/3J1VYSQJ_B&14S:%6=MQS;. @W9 _+'/<<=15F:VNO+>-/$42AFRK>? MRO7'?G@CC(SM]ZJWEJS3M*WB Q1J4RL>YOESE1NW?-][K]* ]O!;11I:F\LN MEV$DC/#*TT);#!"K$C((W#Z8Y^AK@I8I/*AB9L.D8*L.0?WDIS\O&>IKM=5= M3H^E@,+E6N8%WDD;CGJ.<]NF3^-<4L.VVAB^T)A%Y42I@'?* M?^^?Y\C%*6P&1JUG/-K-HT%Z())$VA-Q&[:23R/K5*_\6O:ZM=6\GG,DK*PYR2,$>V,]:PGAA?7M8DE:16:Y^S1 ME%#%&D9ANQ[!2/\ @58]6>K"*<(^T6EOU--/%]JQ!>"'(.07L03GZB0>U6AX MGTN1-LEO:$ 8 -NRC [<,U<_=PB*TN;7RHP+6W@E1T49WMLWWU[0K9B\4%FC,VXG[1.WMVJFO*EAT'!(I>I)NICWSWC]JF?6]#DF6 M5TMBZ1>4I-W+P#UP=G7M^ KSD9HQ1S#_ ++H'H@UG04+.L-KN)9B?M4NCQ!H<(PEM9@% M2F!+,>#G/_+,>M5I/%6F*V5@MCR#GR&?D=.K+Z"N)-1FES,?]G4%T/2%U@:I MH=M+$XC1-2A@^2+RP!\IP!N;U_\ K=ZP(Y$-G A58VVC!7C;\TXY/WCT/'XU M/X=#+X9@(./^)U$3CJ1M3BJ^V-[**2-"GR+\A8[N#<*]'=8G,(NDR2._VCN? MPKWVM(F(5YKXE7/BV[(S]U/_ $$5Z57G'B3_ )&NZ_W4_P#012EL!5%NDH E MCCD Z!EZ5RE]X2UPZI=WMC/&OGNS )*RM@G.#Q_6NSAJ[%461M3K2IO0\Q?P MSXG^R+;&VD>%3D*LJ8'7WSW/YT?V1XEA4C[!,N2&/EQ+U'^[7K*586CE1TQQ M\UT1Y$4\0(Z-_9EV"K!O^/=R"=N/R[XIJ_VTB*)-+G<@DYDMG).<]3^->RJ! MZ5*!1R%+,'_*CP0Z;?CK970QZPM_A1_9]YG_ (]+C_OTW^%>^ #TI=H]!2]F MC7^U)?RG@?\ 9E\W(L;D_2%O\*<-'U(\#3KP_P#;N_\ A7O>!Z4F!1[-"_M2 M?\IX2GA_5I7 _LV\ /P;S8B?]6S M89?Q/45FE+FW_P!=#)'[LI&:[_O2-]TU+B.YPRSD5,MSBF7W^M_$U$*G8"\M MV*E6[6L[O3J5P-+[4GK2_:U]:S1TI:=P-'[6OK2&[6J%+WH3 M-=>E1-<^]0 MTU/]8/I3 ?ODE.(T>0^B*3_*K$.BW]X1N46\9ZL_)_ ?XXKIK3_CUB^E3"FD ;%RKI^FV^FPE(%)9N7=CEF/O_ (5 EX-101.INS 10 sbfm-20181231.xml XBRL INSTANCE DOCUMENT 0001402328 2018-01-01 2018-12-31 0001402328 2018-12-31 0001402328 2017-12-31 0001402328 2017-01-01 2017-12-31 0001402328 2016-12-31 0001402328 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001402328 us-gaap:CommonStockMember 2016-12-31 0001402328 us-gaap:CommonStockMember 2017-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001402328 us-gaap:PreferredStockMember 2016-12-31 0001402328 us-gaap:PreferredStockMember 2017-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2016-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2017-12-31 0001402328 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001402328 us-gaap:RetainedEarningsMember 2016-12-31 0001402328 us-gaap:RetainedEarningsMember 2017-12-31 0001402328 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001402328 us-gaap:CommonStockMember 2018-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001402328 us-gaap:PreferredStockMember 2018-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2018-01-01 2018-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2018-12-31 0001402328 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001402328 us-gaap:RetainedEarningsMember 2018-12-31 0001402328 SBFM:TemporaryDifferenceMember 2018-12-31 0001402328 SBFM:TemporaryDifferenceMember 2017-12-31 0001402328 SBFM:TaxEffectMember 2018-12-31 0001402328 SBFM:TaxEffectMember 2017-12-31 0001402328 us-gaap:OfficeEquipmentMember 2018-01-01 2018-12-31 0001402328 us-gaap:EquipmentMember 2018-01-01 2018-12-31 0001402328 us-gaap:VehiclesMember 2018-01-01 2018-12-31 0001402328 2018-06-30 0001402328 us-gaap:SeriesAPreferredStockMember 2018-12-31 0001402328 us-gaap:SeriesAPreferredStockMember 2017-12-31 0001402328 us-gaap:SeriesBPreferredStockMember 2018-12-31 0001402328 us-gaap:SeriesBPreferredStockMember 2017-12-31 0001402328 SBFM:Note1Member 2018-12-31 0001402328 SBFM:Note1Member 2017-12-31 0001402328 SBFM:Note2Member 2018-12-31 0001402328 SBFM:Note2Member 2017-12-31 0001402328 SBFM:Note3Member 2018-12-31 0001402328 SBFM:Note3Member 2017-12-31 0001402328 SBFM:Note4Member 2018-12-31 0001402328 SBFM:Note4Member 2017-12-31 0001402328 SBFM:Note5Member 2018-12-31 0001402328 SBFM:Note5Member 2017-12-31 0001402328 SBFM:Note6Member 2018-12-31 0001402328 SBFM:Note6Member 2017-12-31 0001402328 SBFM:Note7Member 2018-12-31 0001402328 SBFM:Note7Member 2017-12-31 0001402328 SBFM:Note8Member 2018-12-31 0001402328 SBFM:Note8Member 2017-12-31 0001402328 SBFM:Note9Member 2018-12-31 0001402328 SBFM:Note9Member 2017-12-31 0001402328 SBFM:Note10Member 2018-12-31 0001402328 SBFM:Note10Member 2017-12-31 0001402328 SBFM:Note11Member 2018-12-31 0001402328 SBFM:Note11Member 2017-12-31 0001402328 SBFM:RelatedEntityNote1Member 2018-12-31 0001402328 SBFM:RelatedEntityNote1Member 2017-12-31 0001402328 SBFM:RelatedEntityNote2Member 2018-12-31 0001402328 SBFM:RelatedEntityNote2Member 2017-12-31 0001402328 SBFM:Note12Member 2018-12-31 0001402328 SBFM:Note12Member 2017-12-31 0001402328 SBFM:Note13Member 2018-12-31 0001402328 SBFM:Note14Member 2018-12-31 0001402328 SBFM:Note15Member 2018-12-31 0001402328 SBFM:Note16Member 2018-12-31 0001402328 SBFM:Note13Member 2017-12-31 0001402328 SBFM:Note14Member 2017-12-31 0001402328 SBFM:Note15Member 2017-12-31 0001402328 SBFM:Note16Member 2017-12-31 0001402328 SBFM:Note17Member 2018-12-31 0001402328 SBFM:Note17Member 2017-12-31 0001402328 SBFM:RelatedEntityNote3Member 2018-12-31 0001402328 SBFM:RelatedEntityNote3Member 2017-12-31 0001402328 2019-04-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Sunshine Biopharma, Inc 0001402328 10-K 2018-12-31 false --12-31 No No Yes FY 2018 0.001 0.001 3000000000 3000000000 5-7 Years 5 Years 5 Years 0.10 0.10 0.10 0.10 5000000 5000000 500000 500000 Non-accelerated Filer true true false 115216 107532 1341 9667 211512 117199 269362 59996 0 0 0 80290 1146571 257485 419663 516867 243094 205742 191080 19314 9291 9215 912477 751138 289847 79710 1202324 830848 0 0 50000 50000 85652 45936 15586678 12948387 -3738 504 -15774345 -13618190 1146571 257485 57964 9132 58918 58918 0 0 500000 500000 0 0 500000 500000 85652400 45936825 85652400 45936825 447200 0 153889 81643 113068 75908 36245 127013 149031 45726 755215 520271 12800 0 2408 6629 1222656 857190 -1166537 -857190 159420 104829 871726 76929 41528 -1288 -989618 -183046 -2156155 -1040236 -0.04 -0.02 60936164 43634280 -4242 110 -2160397 -1040126 49361 6629 676100 427400 871973 76929 33977 3022 -247 0 -8326 8660 61629 -8808 76 204 -512806 -543520 18850 3718 0 80290 -13908 -84008 609885 660565 26759 33977 194184 115000 18750 25000 29930 2251 0 63912 527640 670705 926 43177 6758 6902 115216 107532 57453 23496 21900 676100 427400 1589099 128451 174808 56700 45509 58977 -2156155 -1040236 0 0 60936164 872685608 12156020 10611921 2997675 3932778 298661 266498 80041 71421 3077716 4004199 12454681 10878419 3077716 4004199 12454681 10878419 3077716 4004199 0 0 0 0 0 0 0 0 0.2100 0.3400 0.0412 0.0306 0.2512 0.3706 0.0000 0.0000 -0.2512 -0.3706 0.0000 0.0000 12454681 10611921 926483 342693 532941 205742 136744 122093 86118 83649 310079 0 3970144 94955 0 665697 0 49349 0 556120 97321836 -15447 0 -42399 0 4942 0 36500 0 -55753 -573363 -209700 38470 45936 12279390 12948387 50000 50000 394 504 -12577954 -13618190 85652 15586678 50000 -3738 -15774345 38469993 45936825 500000 500000 85652400 500000 63912 1700 62212 1700000 676100 427400 3090 424310 10383 665718 3090217 10382500 174808 56700 550 56150 1457 173351 550208 1456737 1589099 128451 2126 126325 26876 1562223 2126406 26876338 -2160397 -1040126 -1040236 -4242 -2156155 238000 1000 237000 1000000 The Company was originally incorporated under the name Mountain West Business Solutions, Inc. (“MWBS”) on August 31, 2006 in the State of Colorado. Effective October 15, 2009, MWBS acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. MWBS concurrently changed its name to Sunshine Biopharma, Inc. and Sunshine Biopharma, Inc. changed its name to Sunshine Etopo, Inc. In 2015, Sunshine Etopo, Inc. became inactive and was recently dissolved.   On July 25, 2014, the Company formed a Canadian wholly owned subsidiary, Sunshine Biopharma Canada Inc., for the purposes of offering generic prescription drugs and over-the-counter dietary supplements.   On January 1, 2018, the Company acquired Atlas Pharma Inc., a Health Canada certified Canadian company offering chemical analysis of pharmaceutical and other industrial samples.   On March 23, 2018, the Company formed NOX Pharmaceuticals, Inc., a Colorado company that now holds all of the patents and intellectual property pertaining to Sunshine Biopharma Inc.’s proprietary drugs including Adva-27a, a multi-purpose anti-tumor compound targeted for the treatment of multidrug resistant cancer.   On December 17, 2018, the Company launched its first over-the-counter product, Essential 9tm, a dietary supplement comprised of the nine amino acids which the human body cannot synthesize. Essential 9tm has been authorized for marketing by Health Canada under NPN 80089663.   The following are Sunshine Biopharma, Inc.’s subsidiaries:   <table cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 12pt Times New Roman, Times, Serif">●</td> <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify">NOX Pharmaceuticals Inc., a wholly owned Colorado company;</td></tr> </table>   <table cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 12pt Times New Roman, Times, Serif">●</td> <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify">Sunshine Biopharma Canada Inc., a wholly owned Canadian company; and</td></tr> </table>   <table cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 12pt Times New Roman, Times, Serif">●</td> <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify">Atlas Pharma Inc., a wholly owned Canadian company.</td></tr> </table>   Effective February 1, 2019, the Company completed a 20 to 1 reverse split of its $0.001 par value Common Stock reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400 (“Reverse Stock Split”).   The financial statements reflect the Reverse Stock Split on a retroactive basis and represent the consolidated activity of Sunshine Biopharma, Inc. and its subsidiaries (hereinafter collectively referred to as the "Company"). The Company was originally formed for the purposes of conducting research, development and commercialization of drugs for the treatment of various forms of cancer. The Company may also engage in any other business that is permitted by law, as designated by the Board of Directors of the Company.    During the last year the Company has continued to raise money through stock sales and borrowings.   The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company’s generic pharmaceuticals business and proprietary drug development program. This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements.  The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting  policies conform to generally accepted accounting principles and  have  been  consistently  applied  in  the  preparation  of  the  financial statements.   PRINCIPLES OF CONSOLIDATION   The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.   USE OF ESTIMATES   The preparation of financial statements in conformity with U.S. generally accepted accounting  principles  requires  management  to  make  estimates  and assumptions  that  affect the  reported amounts of assets and  liabilities  and disclosure of  contingent  assets and  liabilities  at the date of the financial statements  and the  reported  amounts  of  revenues  and  expenses  during  the reporting  period.  The  more  significant  estimates  and  assumptions  made by management  are valuation of equity  instruments,  depreciation  of property and equipment,  and deferred tax asset  valuation.  Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.   CASH AND CASH EQUIVALENTS   For  the  Balance  Sheets  and  Statements of Cash Flows,  all  highly  liquid investments with maturity of 90 days or less are  considered  to be cash equivalents.  The Company had a cash balance of $115,216 and $107,532 as of December 31, 2018 and December 31, 2017, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 or the equivalent in Canada.   PROPERTY AND EQUIPMENT   Property and equipment is reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2018 and 2017, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.   Property and equipment are stated at cost. Depreciation is calculated using the straight-line method for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 58%; text-align: justify">Office Equipment:</td> <td style="width: 42%; text-align: justify">5-7 Years</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">Laboratory Equipment</td> <td style="text-align: justify">5 Years</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">Vehicles</td> <td style="text-align: justify">5 Years</td></tr> </table>   INTELLECTUAL PROPERTY RIGHTS - PATENTS   The cost of patents acquired is capitalized and is amortized over the remaining life of the patents.   The Company evaluates recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable. Such circumstances include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of cost significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the assets against the estimated undiscounted future cash flows associated with it.   The Company’s management determined that the expected cash flows would be less than the carrying amount of certain intangible assets; therefore an impairment loss was recognized in 2016. The impairment loss was calculated as the amount by which the carrying amount of the intangible assets exceeded fair value.   EARNINGS PER SHARE   The Company has adopted the Financial Accounting Standards Board (FASB) ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.   INCOME TAXES   In accordance with ASC 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements.  The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur.  A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.   The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2018 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.   For Canadian and US tax purposes, the Company’s 2015 through 2017 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.   FUNCTIONAL CURRENCY   The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.   The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:   <table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr> <td style="vertical-align: top; width: 48px; padding-left: 0.25in">●</td> <td style="padding: 0.75pt; text-align: justify">Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.</td></tr> </table>   <table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr> <td style="vertical-align: top; width: 48px; padding-left: 0.25in">●</td> <td style="padding: 0.75pt; text-align: justify">Income statement accounts are translated using the weighted average exchange rate for the period.</td></tr> </table>   The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non U.S. currency transactions.   CONCENTRATION OF CREDIT RISKS   Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.   FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS   The Company applies the provisions of accounting guidance, FASB Topic ASC 825, Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2018 and 2017, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.   The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).   Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.   Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.   Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.   The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.   NOTES PAYABLE   Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method.   ACCOUNTING FOR DERIVATIVES LIABILITIES   The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense.   Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. The Company determined that none of the Company’s financial instruments meet the criteria for derivative accounting as of December 31, 2018 and 2017.   EQUITY INSTRUMENTS ISSUED TO NON-EMPLOYEES FOR AQUIRING GOODS OR SERVICES   Issuances of the Company’s common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.   NONCASH EQUITY TRANSACTIONS   Shares of equity instruments issued for noncash consideration are recorded at the estimated fair market value of the consideration granted based on the estimated market value of the equity instrument, or at the estimated value of the goods or services received whichever is more readily determinable.   RELATED PARTIES   A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.   GENERAL AND ADMINISTRATIVE EXPENSES   General and administrative expenses consisted of professional service fees, rent and utility expenses, meals, travel and entertainment expenses, and other general and administrative overhead costs. Expenses are recognized when incurred.   BASIC AND DILUTED NET GAIN (LOSS) PER SHARE   The Company computes loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.   Basic net income (loss) per share is calculated by dividing net (loss) by the weighted-average common shares outstanding. Diluted net income per share is calculated by dividing net income by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2018 no potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.   Therefore, basic and dilutive net (loss) per share were the same as of December 31, 2018 and 2017.   COMMON STOCK   The Company completed a 20 to 1 reverse stock split of the $.001 par value Common Stock affective February 1, 2019. All shares in this filing have been restated to reflect the 20 to 1 reverse split.   REVENUE RECOGNITION   As of January 1, 2018, the Company adopted ASU No. 201409, “Revenue from Contracts with Customers” (ASU 201409). Under the new guidance, an entity will recognize revenue to depict the transfer of promised goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. A five-step model has been introduced for an entity to apply when recognizing revenue. The new guidance also includes enhanced disclosure requirements. The guidance was effective January 1, 2018 and was applied on a modified retrospective basis. The adoption did not have an impact on the Company's financial statements. All of the revenues of the Company are generated by Atlas Pharma Inc., the Company's wholly owned Canadian subsidiary, which provides laboratory testing services. Performance obligations for testing services are recognized as revenue at a point in time on the date results are delivered to a customer which is when control is transferred.   Local governmental regulations require that companies recognize revenues upon completion of the work by issuing an invoice and remitting the applicable sales taxes (GST and QST) to the appropriate government agency. Atlas Pharma Inc.'s revenue recognition policy is in compliance with these local regulations.    RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS   In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 will require lessees to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with terms of more than 12 months. Lessor accounting remains substantially similar to current GAAP. In addition, disclosures of leasing activities are to be expanded to include qualitative along with specific quantitative information. ASU 2016-02 will be effective in fiscal years beginning after December 15, 2018 (with early adoption permitted). ASU 2016-02 mandates a modified retrospective transition method. The Company is currently evaluating the potential impact of adopting this guidance on our consolidated financial statements.    DIRECTOR AND OFFICER COMPENSATION   For the period ended December 31, 2018, the Company issued 4,050,000 shares of par value $0.001 Common Stock valued at $429,300 or $0.106 per share and 5,700,000 shares of par value $0.001 Common Stock to the Board of Directors valued at $171,000 or $0.03 per share. During the year ended December 31, 2018 the Directors and officers were paid $154,915 in cash. Of this amount, $85,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.   For the period ended December 31, 2017, the Company issued 2,100,000 of par value $0.001 Common Stock to the three Company officers valued at $336,000 or $0.16 per share. During the year ended December 31, 2017 the Directors and officers were paid $184,271 in cash. Of this amount, $147,695 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.   LEGAL FEES   During the years ended December 31, 2018 and 2017, the legal fees incurred were related to services provided to the Company to assist with its regulatory requirements with the Securities and Exchange Commission, patenting costs and one ongoing litigation.   DATE OF MANAGEMENT’S REVIEW   Subsequent events have been evaluated through April 12, 2019, which is the date the Financial Statements were available to be issued.   In the course of its life the Company has had limited operations and Working Capital deficit. This raises substantial doubt about the Company’s ability to continue as a going concern. The Company believes it can raise capital through equity sales and borrowing to fund its operations. Management believes this will contribute toward its subsequent profitability. The accompanying Financial Statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.   The following is a summary of the patents held by the Company at December 31, 2018 and 2017:   On October 8, 2015, the Company acquired U.S. Patent Number 8,236,935 (the “US Patent”) for the Adva-27a anticancer compound from Advanomics Corporation (“Advanomics”), a related party, in exchange for an interest-free note payable for $4,320,000. Effective December 28, 2015, the parties executed an amendment pursuant to which this note payable for $4,320,000 was cancelled and replaced with a new interest-free convertible note having a face value of $210,519, comprised of $155,940 in principal amount which is the Advanomics book value of the US Patent, plus $54,579 as an adjustment for the currency exchange difference. The new note is automatically convertible into 4,048,449 shares of the Company’s Common Stock upon the Company increasing its authorized capital to a level that would permit the issuance of such shares.   On December 28, 2015, the Company acquired the remaining worldwide issued and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 (the “Worldwide Patents”) for the Adva-27a anticancer compound from Advanomics, a related party, in exchange for a note payable for $12,822,499. Effective December 28, 2015, the parties executed an amendment pursuant to which this note payable for $12,822,499 was cancelled and replaced with a new interest-free convertible note having a face value of $624,875, comprised of $462,870 in principal amount, which is the Advanomics book value of the Worldwide Patents, plus $162,005 as an adjustment for the currency exchange difference. The new note is automatically convertible into 12,016,823 shares of the Company’s Common Stock upon the Company increasing its authorized capital to a level that would permit the issuance of such shares.   In July 2016, the Company issued 16,065,271 shares of $0.001 par value Common Stock in exchange for the aforementioned patents related notes payable totaling $835,394. In 2016, the remaining value of these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.   The Company’s authorized capital is comprised of 3,000,000,000 shares of $0.001 par value Common Stock and 30,000,000 shares of $0.10 par value Preferred Stock, to have such rights and preferences as the Directors of the Company have or may assign from time to time. Out of the authorized Preferred Stock, the Company has designated 850,000 shares as Series “A” Preferred Stock (“Series A”). The Series A is convertible at any time after issuance into 20 shares of the Company's Common Stock with no further consideration, has full voting rights at 20 votes per share, and has superior liquidation rights to the Common Stock. During the year ended December 31, 2015, the Company authorized 500,000 shares of $0.10 par value Series “B” Preferred Stock (“Series B”). The Series B Preferred Stock is non-convertible, non-redeemable and non-retractable. It has superior liquidation rights to the Common Stock at $0.10 per share and gives the holder the right to 1,000 votes per share. All shares of the Series B Preferred Stock are held by the CEO of the Company. Through December 31, 2018 and December 31, 2017, the Company has issued and outstanding a total of 85,652,400312 and 45,936,825 shares of Common Stock, respectively. Through the same periods, the Company has issued and outstanding a total of -0- and -0- shares of Series A Preferred Stock and 500,000 and 500,000 shares of Series B Preferred Stock, respectively. Effective February 1, 2019, the Company completed a 20 to 1 reverse split of its $0.001 par value Common Stock. All stock and price per share amounts in this report have been restated to reflect the 20 to 1 reverse split.   During the fiscal year ended December 31, 2018, the Company issued an aggregate of 39,715,575 shares of its Common Stock as follows:   ●1,000,000 shares for the acquisition of Atlas Pharma, Inc. ●1,456,737 shares for the purchase of laboratory and generic drugs warehouse equipment valued at $174,808 ●9,750,000 shares valued at $600,300 as compensation to the Company’s Directors and Officers ●632,500 shares for services rendered to the Company by third parties valued at $75,800 ●26,876,338 shares valued at $1,589,099 in connection with the conversion of $684,318 in debt and interest of $32,808 resulting in a $871,973 loss on conversion   During the fiscal year ended December 31, 2017, the Company issued an aggregate of 7,466,832 shares of its Common Stock as follows:   ●1,700,000 shares for cash in the amount of $100,000 Canadian or $78,312 US ●550,208 shares for the purchase of laboratory and generic drugs warehouse equipment valued at $56,700 ●2,400,000 shares valued at $336,000 as compensation to the Company’s Directors and Officers ●690,218 shares for services rendered to the Company by third parties valued at $77,000 ●2,126,406 shares valued at $128,451 in connection with the conversion of $48,500 in debt and interest of $3,022 resulting in a $76,929 loss on conversion.   The Company has declared no dividends since inception.   The following table sets forth the computation of basic and diluted net income per share for the years ended December 31:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%">Net (loss) attributable to Common Stock</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(2,156,155</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(1,040,236</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom"> <td>Basic weighted average outstanding shares of Common Stock                                        </td> <td> </td> <td> </td> <td style="text-align: right">60,936,164</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">43,634,280</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Dilutive effects of common share equivalents</td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Dilutive weighted average outstanding shares of common stock         </td> <td> </td> <td> </td> <td style="text-align: right">60,936,164</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">43,634,280</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Net (loss) attributable to Common Stock</td> <td> </td> <td>$</td> <td style="text-align: right">(0.04</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.02</td> <td>)</td></tr> </table>                         The Company files a United States federal income tax return and a Canadian branch return on a calendar year basis.  The Company and its wholly-owned subsidiaries, Sunshine Biopharma Canada Inc. and Atlas Pharma Inc., have not generated taxable income since inception.   Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur. The Company accounts for income taxes pursuant to ASC 740.   Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses and other items. Loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.   The Company follows FASB Statement Accounting Standards Codification No. 740, “Accounting for Income Taxes”, which requires, among other things, an asset and liability approach to calculating deferred income taxes. The components of the deferred income tax assets and liabilities arising under ASC No. 740 were as follows:   The types of temporary differences between the tax basis of assets and their financial reporting amounts that give rise to a significant portion of the deferred assets and liabilities are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"> December 31, 2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"> December 31, 2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> Temporary Difference</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> Tax Effect</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> Temporary Difference</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> Tax Effect</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Deferred tax assets:</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 50%">Net operating loss US</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">12,156,020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">2,997,675</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">10,611,921</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">3,932,778</td> <td style="width: 2%"> </td></tr> <tr style="vertical-align: bottom"> <td>Net operating loss Canada</td> <td> </td> <td> </td> <td style="text-align: right">298,661</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">80,041</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">266,498</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">71,421</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td> </td> <td> </td> <td style="text-align: right">12,454,681</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,077,716</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,878,419</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,004,199</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Valuation allowance</td> <td> </td> <td> </td> <td style="text-align: right">(12,454,681</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(3,077,716</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(10,878,419</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">( 4,004,199</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td>Total deferred tax asset</td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Net deferred tax asset</td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> </table>      Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.   At December 31, 2018 and December 31, 2017, the Company had approximately $12,454,681 and $10,878,419 respectively, in unused federal net operating loss carryforwards, which begin to expire principally in the year 2029. A deferred tax asset at each date of approximately $3,077,716 and $4,004,199 resulting from the loss carryforwards has been offset by a 100% valuation allowance. The change in the valuation allowance for the period ended December 31, 2018 and December 31, 2017 was approximately $926,483 and $342,693, respectively.   A reconciliation of the U.S. statutory federal income tax rate to the effective tax rate is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">December 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 75%">   U.S. Federal statutory graduated rate   </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">21.00</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">34.00</td> <td style="width: 2%">%</td></tr> <tr style="vertical-align: bottom"> <td>   State income tax rate, net of federal benefit   </td> <td> </td> <td> </td> <td style="text-align: right">4.12</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">3.06</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td>   Net rate  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">25.12</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">37.06</td> <td style="padding-bottom: 1.5pt">%</td></tr> <tr style="vertical-align: bottom"> <td>   Net operating loss used  </td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td>   Net operating loss for which no tax benefit is currently available   </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-25.12</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-37.06</td> <td style="padding-bottom: 1.5pt">%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">0.00</td> <td style="padding-bottom: 3pt">%</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">0.00</td> <td style="padding-bottom: 3pt">%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>   Canada Federal statutory rate    </td> <td> </td> <td> </td> <td style="text-align: right">15.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">15.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td>   Canada Provincial rate    </td> <td> </td> <td> </td> <td style="text-align: right">11.80</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">11.80</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td>   Net Canada rate  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">26.80</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">26.80</td> <td style="padding-bottom: 1.5pt">%</td></tr> <tr style="vertical-align: bottom"> <td>   Net operating loss used  </td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td>   Net operating loss for which no tax benefit is currently available (Canada)  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-26.80</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-26.80</td> <td style="padding-bottom: 1.5pt">%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">0.00</td> <td style="padding-bottom: 3pt">%</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">0.00</td> <td style="padding-bottom: 3pt">%</td></tr> </table>     The Company’s income tax filings are subject to audit by various taxation authorities. The Company’s open audit periods are 2015, 2016, and 2017, although, the statute of limitations for the 2015 tax year will expire effective March 15, 2019. In evaluating the Company’s provisions and accruals, future taxable income, and reversal of temporary differences, interpretations and tax planning strategies are considered. The Company believes its estimates are appropriate based on current facts and circumstances.   Notes payable consist of the following:     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%">A Note Payable having a Face Value of $24,012 at December 31, 2016 and accruing interest at 12% was due December 31, 2017 (“2016 Note”). On December 31, 2017, the Company renewed the 2016 Note, together with accrued interest of $2,573, for a 12-month period (“2017 Note”). On December 31, 2018 the Company renewed the 2017 Note, together with accrued interest of $2,881, for a 12-month period (“2018 Note”). The 2018 Note has a Face Value of $26,893 and accrues interest at 12%. The 2018 Note is nonconvertible.  </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">26,893</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">24,012</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>On January 12, 2018 the Company received monies in exchange for a Note Payable having a Face Value of $102,000 with interest accruing at 8% is due October 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $4,080 was converted in 2018 into 3,569,333 shares of Common Stock valued at $166,085 resulting in a loss of $60,005.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> On February 7, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $150,000 with interest accruing at 8% is due February 7, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note was paid off in 2018 in part by cash of $48,000 and the remainder, together with accrued interest of $5,073, was converted into 5,710,642 shares of Common Stock valued at $183,411 resulting in a loss of $76,338.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On February 20, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $85,000 with interest accruing at 8% is due November 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $3,400, was converted in 2018 into 4,376,238 shares of Common Stock valued at $281,663 resulting in a loss of $193,263.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> On May 29, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $26,750 with interest accruing at 8% is due February 29, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued interest of $1,353, was converted into 4,003,265 shares of Common Stock valued at $192,157 resulting in a loss of $164,054.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On June 27, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $53,000 with interest accruing at 8% is due April 15, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $2,137. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. </td> <td> </td> <td>$</td> <td style="text-align: right">53,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On August 17, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $53,000 with interest accruing at 8% is due April 15, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $1,557. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.</td> <td> </td> <td>$</td> <td style="text-align: right">53,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On September 10, 2018, the Company received monies in exchange for two Notes Payable having an aggregate Face Value of $36,500 with interest accruing at 8% are due June 20, 2019. Interest accrued at December 31, 2018 was $888.</td> <td> </td> <td>$</td> <td style="text-align: right">36,500</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On October 23, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $90,000 with interest accruing at 8% is due October 23, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $1,361. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.</td> <td> </td> <td>$</td> <td style="text-align: right">90,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 76%">On December 24, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $87,000 with interest accruing at 8% is due October 23, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $153. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">87,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-0-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>On April 1, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $100,000 Canadian ($73,270US) at December 31, 2018 and ($79,710 US) at December 31, 2017 with interest payable quarterly at 9% is due April 1, 2019. The Note is convertible any time after issuance into $0.001 par value Common Stock at a price of $0.015 Canadian (approximately $0.012 US) per share. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.</td> <td> </td> <td>$</td> <td style="text-align: right">73,270</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">79,710</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On August 3, 2017 the, Company received monies in exchange for a Note Payable having a Face Value of $ 80,000 with interest accruing at 8% is due August 3, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. A principal amount of $40,000 of this note plus accrued interest of $1,712 was converted in 2018 into 327,788 shares of Common Stock valued at $70,507 resulting in a loss of $28,795. The remaining principal amount of $40,000 together with accrued interest of $1,613 was paid in cash reducing the balance to $-0-</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">80,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On August 21, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $ 83,000 with interest accruing at 8% is due May 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, plus accrued interest of $3,419, was paid off in 2018.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">83,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On September 22, 2017 the Company received monies in exchange for a note having a Face Value of $ 62,000 with interest accruing at 8% is due June 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued interest of $2,480 was converted in 2018 into 790,590 shares of Common Stock valued at $107,056 resulting in a loss of $42,576.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">62,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On October 26, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $ 115,000 with interest accruing at 8% is due October 26, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued interest of $6,126, was converted in 2018 into 2,921,146 shares of Common Stock valued at $208,661 resulting in a loss of $87,535.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">62,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On November 14, 2017, the Company received monies in exchange for a Note Payable having a Face Value of $ 113,000 with interest accruing at 8% is due November 14, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $7,018 was converted in 2018 into 4,917,251 shares of Common Stock valued at $351,999 resulting in a loss of $231,981.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">115,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> On December 1, 2017, the Company received monies in exchange for a Note Payable having a Face Value of $50,000 Canadian ($38,568 US) at December 31, 2018 and ($39,855 US) at December 31, 2017 with interest accruing at 8% is due November 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $1,566 was converted in 2018 into 260,000 shares of Common Stock valued at $27,560 resulting in a gain of $12,574.</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid">$</td> <td style="text-align: right; border-bottom: Black 1pt solid">-0-</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid">$</td> <td style="text-align: right; border-bottom: Black 1pt solid">113,000</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total Notes Payable</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">419,663</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">596,577</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   Interest expense for the years ended December 31, 2018 and 2017 was $159,420 and $79,674, respectively. The balance of interest payable at December 31, 2018 and 2017 was $9,291 and $9,215, respectively. Loss on conversion of notes payable for the years ended December 31, 2018 and 2017 was $871,973 and $76,929 respectively.   Notes payable to related parties consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td></td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%"> A Note Payable held by a private individual who became a principal shareholder of the Company having a Face Value of $118,537 at September 30, 2017 and a  maturity date of December 31, 2017, accrues interest at 12%. The Note is convertible any time from the date of issuance into $0.001 par value Common Stock at a 35% discount from market price. On December 31, 2017 the Note together with accrued interest was renewed for a 12-month period under the same terms and conditions as before. The new Note has a Face Value of $122,093 and matures on December 31, 2018. On December 31, 2018 the Note, together with accrued interest of $14,651 was renewed for a 12-month period. The new Note has a Face value of $136,744 and matures on December 31, 2019. The new Note is nonconvertible. This individual ceased to be a principal shareholder of the Company in the third quarter of 2018</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">136,744</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">122,093</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> In December 2016, the Company received monies from its CEO in exchange for a note payable having a principal amount of $90,000 Canadian ($67,032 US) with interest at 12% due March 31, 2017. The note was convertible any time after the date of issuance into $0.001 par value Common Stock at a price 35% below market value. This note was collateralized by all of the assets of the Company. In the event of default, the interest rate will increased to 18% per annum and a penalty of $1,000 Canadian ($752 US) per day will accrue. On March 31, 2017, the note, together with accrued interest of $3,021 Canadian ($2,271 US) and an additional principal amount of $3,000 Canadian ($2,247 US) paid to the Company on March 28, 2017, was renewed for a 90-day period under the same terms and conditions as the original note. The new note now having a face value of $96,021 Canadian ($72,198 US) was due on June 30, 2017. On June 30, 2017, the note, together with accrued interest of $2,873 Canadian ($2,005 US), was renewed for a 90-day period under the same terms and conditions as the original note except that the new note is nonconvertible. The new note now having a face value of $98,894 Canadian ($76,072US) is due on September 30, 2017. On September 30, 2017, the note, together with accrued interest of $2,991 Canadian ($2,397 US) was renewed for a 90-day period under the same terms and conditions as the original note except that the new note is nonconvertible. The new note now having a principal balance of $101,885 Canadian ($81,640 US) matures December 31, 2017. On December 31, 2017 the note was renewed for a 12month period under the same terms and conditions as before except that this new note is unsecured and nonconvertible. The new note has a face value of $104,942 Canadian ($83,649 US) and matures on December 31, 2018. On December 31, 2018 the note was renewed for a 12-month period under the same terms and conditions as the previous note. The new note together with interest of $9,227, has a face value of $86,118 US ($117,535 CAD) and matures on December 31, 2019.</td> <td> </td> <td> </td> <td style="text-align: right">86,118</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">83,649</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> On January 1, 2018 as part of the acquisition of Atlas Pharma Inc., the Company issued a note payable in the amount of $450,000 Canadian ($358,407 US) and accruing interest at the rate of 3% per annum. The note is due on December 31, 2023. Payments on this note are $10,000 Canadian (approximately $8,000 US) per quarter. The outstanding principal balance at December 31, 2018 was $310,079. The note is nonconvertible and is secured by the Atlas Pharma Inc. shares held by the Company. The holder of this note is currently a director and officer of Atlas Pharma Inc.</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">310,079</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-0-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">Total Notes Payable Related Party</td> <td style="padding-bottom: 1pt"> </td> <td>$</td> <td style="text-align: right">532,941</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td>$</td> <td style="text-align: right">205,742</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">Long-Term Portion </td> <td style="padding-bottom: 1pt"> </td> <td>$ </td> <td style="text-align: right"> 289,847</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td>$ </td> <td style="text-align: right"> 79,710</td> <td style="padding-bottom: 1pt"> </td></tr> </table>   In addition to the transactions specified under Note 9 above, during the period ended December 31, 2018, the Company issued 4,050,000 shares of par value $0.001 Common Stock valued at $429,300 or $0.106 per share and 5,700,000 shares of par value $0.001 Common Stock to the Board of Directors valued at $171,000 or $0.03 per share. During the year ended December 31, 2018 the Directors and Officers were paid $154,915 in cash. Of this amount, $85,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.   For the period ended December 31, 2017, the Company issued 2,100,000 of par value $0.001 Common Stock to the three Company officers valued at $336,000 or $0.008 per share. During the year ended December 31, 2017 the Directors and officers were paid $184,271 in cash. Of this amount, $147,695 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.   During the year ended December 31, 2018, certain Directors of the Company made interest free cash advances to the Company totaling $49,349. As part of a subscription agreement entered into in 2016, the Company had an obligation to pay a royalty of 5% of net sales on one of its generic products (Anastrozole) for a period of three (3) years from the date of the first sale of that product. In September 2018, 50,000 shares of the Company’s Common Stock valued at $5,900 were issued in exchange for cancellation of this royalty obligation. On January 1, 2018 the Company acquired all of the issued and outstanding shares of Atlas Pharma Inc. (“Atlas”), a Canadian privately held company. The purchase price for the shares was Eight Hundred Forty Eight Thousand Dollars $848,000 Canadian ($676,748 US). The purchase price included a cash payment of $100,500 Canadian ($80,289 US), plus the issuance of 1,000,000 shares of the Company’s Common Stock valued at $238,000 or $0.238 per share, and a promissory note in the principal amount of $450,000 Canadian ($358,407 US), with interest payable at the rate of 3% per annum. Atlas is a certified company dedicated to chemical analysis of pharmaceutical and other industrial samples. Atlas’ operations are authorized by a Drug Establishment License issued by Health Canada. Atlas is also registered with the FDA. The Company has performed analysis of the fair market value of Atlas Pharma Inc. assets and liabilities. The following table summarizes the allocation of the purchase price as of the acquisition date:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 88%">Cash</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">4,942</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Accounts receivable</td> <td> </td> <td>$</td> <td style="text-align: right">79,508</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Prepaids</td> <td> </td> <td>$</td> <td style="text-align: right">1,428</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Property and equipment</td> <td> </td> <td>$</td> <td style="text-align: right">62,990</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Goodwill</td> <td> </td> <td>$</td> <td style="text-align: right">665,697</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Less: Liabilities assumed ($172,899 Canadian)</td> <td> </td> <td>$</td> <td style="text-align: right">(137,817</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td>Total consideration</td> <td> </td> <td>$</td> <td style="text-align: right">676,748</td> <td> </td></tr> </table>   Accounts receivable consist of trade accounts arising in the normal course of business and are classified as current assets and carried at original invoice amounts less an estimate for doubtful receivables based on a review of outstanding balances on a monthly basis. The estimate of allowance for doubtful accounts is based on the Company's bad debt experience, market conditions, and aging of accounts receivable, among other factors. If the financial condition of the Company's customers deteriorates resulting in the customer's inability to pay the Company's receivables as they come due, additional allowances for doubtful accounts will be required. The Company’s subsidiary, Atlas Pharma Inc., has entered into long-term lease agreements for the rental of buildings which call for minimum aggregate lease payments of $150,347 Canadian (approximately $115,767 US) and additional lease payments based on operating expenses. The lease expires on May 21, 2021. Minimum lease payments for the next three years are $62,213 (approximately $47,904 US) in 2019, $62,213 (approximately $47,904 US) in 2020, and $25,921 (approximately $19,959 US) in 2021. On January 1, 2019, the Company paid $69,931 to pay off the principal ($53,000) and accrued interest ($16,931) on a note payable dated June 27, 2018.   On January 8, 2019, the Company received net proceeds of $50,500 in exchange for a note payable having a face value of $54,000 and accruing interest at the rate of 8% per annum. The note, due on January 8, 2020, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.   On January 10, 2019, the Company received net proceeds of $38,000 in exchange for a note payable having a face value of $40,660 and accruing interest at the rate of 8% per annum. The note, due on October 10, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.   On February 5, 2019, the Company received net proceeds of $35,000 in exchange for a note payable having a face value of $37,450 and accruing interest at the rate of 8% per annum. The note, due on October 10, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.   On February 11, 2019, the Company received net proceeds of $50,000 in exchange for a note payable having a face value of $52,000 and accruing interest at the rate of 8% per annum. The note, due on November 30, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.   On March 4 and 13, 2019 the holder of a note payable dated August 17, 2018 elected to convert $25,000 in principal into 3,696,581 shares of Common Stock leaving a principal balance of $28,000.   On March 18, 2019, the Company received net proceeds of $38,000 in exchange for a note payable having a face value of $40,660 and accruing interest at the rate of 8% per annum. The note, due on December 18, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.   On March 18, 2019, the Company received another $38,000 of net proceeds in exchange for a note payable having a face value of $40,660 and accruing interest at the rate of 8% per annum. The note, due on December 18, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.       The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. generally accepted accounting  principles  requires  management  to  make  estimates  and assumptions  that  affect the  reported amounts of assets and  liabilities  and disclosure of  contingent  assets and  liabilities  at the date of the financial statements  and the  reported  amounts  of  revenues  and  expenses  during  the reporting  period.  The  more  significant  estimates  and  assumptions  made by management  are valuation of equity  instruments,  depreciation  of property and equipment,  and deferred tax asset  valuation.  Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.   For  the  Balance  Sheets  and  Statements of Cash Flows,  all  highly  liquid investments with maturity of 90 days or less are  considered  to be cash equivalents.  The Company had a cash balance of $115,216 and $107,532 as of December 31, 2018 and December 31, 2017, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 or the equivalent in Canada. Property and equipment is reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2018 and 2017, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.   Property and equipment are stated at cost. Depreciation is calculated using the straight-line method for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 58%; text-align: justify">Office Equipment:</td> <td style="width: 42%; text-align: justify">5-7 Years</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">Laboratory Equipment</td> <td style="text-align: justify">5 Years</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">Vehicles</td> <td style="text-align: justify">5 Years</td></tr> </table>   The cost of patents acquired is capitalized and is amortized over the remaining life of the patents.   The Company evaluates recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable. Such circumstances include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of cost significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the assets against the estimated undiscounted future cash flows associated with it.   The Company’s management determined that the expected cash flows would be less than the carrying amount of certain intangible assets; therefore an impairment loss was recognized in 2016. The impairment loss was calculated as the amount by which the carrying amount of the intangible assets exceeded fair value. The Company has adopted the Financial Accounting Standards Board (FASB) ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share. In accordance with ASC 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements.  The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur.  A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.   The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2018 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.   For Canadian and US tax purposes, the Company’s 2015 through 2017 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.   The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.   The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:   <table cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 12pt Times New Roman, Times, Serif">●</td> <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify">Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.</td></tr> </table>   <table cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 12pt Times New Roman, Times, Serif">●</td> <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify">Income statement accounts are translated using the weighted average exchange rate for the period.</td></tr> </table>   The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non U.S. currency transactions. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions. The Company applies the provisions of accounting guidance, FASB Topic ASC 825, Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2018 and 2017, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.   The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).   Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.   Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.   Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.   The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method. The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense.   Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. The Company determined that none of the Company’s financial instruments meet the criteria for derivative accounting as of December 31, 2018 and 2017. Issuances of the Company’s common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates. Shares of equity instruments issued for noncash consideration are recorded at the estimated fair market value of the consideration granted based on the estimated market value of the equity instrument, or at the estimated value of the goods or services received whichever is more readily determinable.  A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party. General and administrative expenses consisted of professional service fees, rent and utility expenses, meals, travel and entertainment expenses, and other general and administrative overhead costs. Expenses are recognized when incurred. The Company computes loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.   Basic net income (loss) per share is calculated by dividing net (loss) by the weighted-average common shares outstanding. Diluted net income per share is calculated by dividing net income by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2018 no potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.   Therefore, basic and dilutive net (loss) per share were the same as of December 31, 2018 and 2017.   The Company completed a 20 to 1 reverse stock split of the $.001 par value Common Stock affective February 1, 2019. All shares in this filing have been restated to reflect the 20 to 1 reverse split. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 will require lessees to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with terms of more than 12 months. Lessor accounting remains substantially similar to current GAAP. In addition, disclosures of leasing activities are to be expanded to include qualitative along with specific quantitative information. ASU 2016-02 will be effective in fiscal years beginning after December 15, 2018 (with early adoption permitted). ASU 2016-02 mandates a modified retrospective transition method. The Company is currently evaluating the potential impact of adopting this guidance on our consolidated financial statements.    For the period ended December 31, 2018, the Company issued 4,050,000 shares of par value $0.001 Common Stock valued at $429,300 or $0.106 per share and 5,700,000 shares of par value $0.001 Common Stock to the Board of Directors valued at $171,000 or $0.03 per share. During the year ended December 31, 2018 the Directors and officers were paid $154,915 in cash. Of this amount, $85,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.   For the period ended December 31, 2017, the Company issued 2,100,000 of par value $0.001 Common Stock to the three Company officers valued at $336,000 or $0.16 per share. During the year ended December 31, 2017 the Directors and officers were paid $184,271 in cash. Of this amount, $147,695 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.   During the years ended December 31, 2018 and 2017, the legal fees incurred were related to services provided to the Company to assist with its regulatory requirements with the Securities and Exchange Commission, patenting costs and one ongoing litigation.   Subsequent events have been evaluated through April 12, 2019, which is the date the Financial Statements were available to be issued. <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 58%; text-align: justify">Office Equipment:</td> <td style="width: 42%; text-align: justify">5-7 Years</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">Laboratory Equipment</td> <td style="text-align: justify">5 Years</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">Vehicles</td> <td style="text-align: justify">5 Years</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"> December 31, 2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"> December 31, 2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> Temporary Difference</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> Tax Effect</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> Temporary Difference</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> Tax Effect</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Deferred tax assets:</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 50%">Net operating loss US</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">12,156,020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">2,997,675</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">10,611,921</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">3,932,778</td> <td style="width: 2%"> </td></tr> <tr style="vertical-align: bottom"> <td>Net operating loss Canada</td> <td> </td> <td> </td> <td style="text-align: right">298,661</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">80,041</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">266,498</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">71,421</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td> </td> <td> </td> <td style="text-align: right">12,454,681</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,077,716</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,878,419</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,004,199</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Valuation allowance</td> <td> </td> <td> </td> <td style="text-align: right">(12,454,681</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(3,077,716</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(10,878,419</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">( 4,004,199</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td>Total deferred tax asset</td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Net deferred tax asset</td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> </table> 0.15 0.15 0.118 0.118 0.268 0.268 0.00 0.00 -0.268 -0.268 419663 596577 26893 24012 0 0 0 0 0 0 0 0 53000 0 53000 0 36500 0 90000 0 87000 0 73270 79710 0 80000 0 0 0 0 83000 62000 62000 115000 0 113000 62990 1428 79508 4942 676748 137817 <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">December 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 75%">   U.S. Federal statutory graduated rate   </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">21.00</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">34.00</td> <td style="width: 2%">%</td></tr> <tr style="vertical-align: bottom"> <td>   State income tax rate, net of federal benefit   </td> <td> </td> <td> </td> <td style="text-align: right">4.12</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">3.06</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td>   Net rate  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">25.12</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">37.06</td> <td style="padding-bottom: 1.5pt">%</td></tr> <tr style="vertical-align: bottom"> <td>   Net operating loss used  </td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td>   Net operating loss for which no tax benefit is currently available   </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-25.12</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-37.06</td> <td style="padding-bottom: 1.5pt">%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">0.00</td> <td style="padding-bottom: 3pt">%</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">0.00</td> <td style="padding-bottom: 3pt">%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>   Canada Federal statutory rate    </td> <td> </td> <td> </td> <td style="text-align: right">15.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">15.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td>   Canada Provincial rate    </td> <td> </td> <td> </td> <td style="text-align: right">11.80</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">11.80</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td>   Net Canada rate  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">26.80</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">26.80</td> <td style="padding-bottom: 1.5pt">%</td></tr> <tr style="vertical-align: bottom"> <td>   Net operating loss used  </td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td>   Net operating loss for which no tax benefit is currently available (Canada)  </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-26.80</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-26.80</td> <td style="padding-bottom: 1.5pt">%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">0.00</td> <td style="padding-bottom: 3pt">%</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">0.00</td> <td style="padding-bottom: 3pt">%</td></tr> </table> true 391081 0 56119 0 238000 0 As of January 1, 2018, the Company adopted ASU No. 201409, “Revenue from Contracts with Customers” (ASU 201409). Under the new guidance, an entity will recognize revenue to depict the transfer of promised goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. A five-step model has been introduced for an entity to apply when recognizing revenue. The new guidance also includes enhanced disclosure requirements. The guidance was effective January 1, 2018 and was applied on a modified retrosspective basis. The adoption did not have an impact on the Company's financial statements. All of the revenues of the Company are generated by Atlas Pharma Inc., the Company's wholly owned Canadian subsidiary, which provides laboratory testing services. Performance obligations for testing services are recognized as revenue at a point in time on the date results are delivered to a customer which is when control is transferred.   Local governmental regulations require that companies recognize revenues upon completion of the work by issuing an invoice and remitting the applicable sales taxes (GST and QST) to the appropriate government agency. Atlas Pharma Inc.'s revenue recognition policy is in compliance with these local regulations.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%">Net (loss) attributable to Common Stock</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(2,156,155</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(1,040,236</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom"> <td>Basic weighted average outstanding shares of Common Stock                                        </td> <td> </td> <td> </td> <td style="text-align: right">60,936,164</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">43,634,280</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Dilutive effects of common share equivalents</td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Dilutive weighted average outstanding shares of common stock         </td> <td> </td> <td> </td> <td style="text-align: right">60,936,164</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">43,634,280</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Net (loss) attributable to Common Stock</td> <td> </td> <td>$</td> <td style="text-align: right">(0.04</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.02</td> <td>)</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td></td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%"> A Note Payable held by a private individual who became a principal shareholder of the Company having a Face Value of $118,537 at September 30, 2017 and a  maturity date of December 31, 2017, accrues interest at 12%. The Note is convertible any time from the date of issuance into $0.001 par value Common Stock at a 35% discount from market price. On December 31, 2017 the Note together with accrued interest was renewed for a 12-month period under the same terms and conditions as before. The new Note has a Face Value of $122,093 and matures on December 31, 2018. On December 31, 2018 the Note, together with accrued interest of $14,651 was renewed for a 12-month period. The new Note has a Face value of $136,744 and matures on December 31, 2019. The new Note is nonconvertible. This individual ceased to be a principal shareholder of the Company in the third quarter of 2018</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">136,744</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">122,093</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> In December 2016, the Company received monies from its CEO in exchange for a note payable having a principal amount of $90,000 Canadian ($67,032 US) with interest at 12% due March 31, 2017. The note was convertible any time after the date of issuance into $0.001 par value Common Stock at a price 35% below market value. This note was collateralized by all of the assets of the Company. In the event of default, the interest rate will increased to 18% per annum and a penalty of $1,000 Canadian ($752 US) per day will accrue. On March 31, 2017, the note, together with accrued interest of $3,021 Canadian ($2,271 US) and an additional principal amount of $3,000 Canadian ($2,247 US) paid to the Company on March 28, 2017, was renewed for a 90-day period under the same terms and conditions as the original note. The new note now having a face value of $96,021 Canadian ($72,198 US) was due on June 30, 2017. On June 30, 2017, the note, together with accrued interest of $2,873 Canadian ($2,005 US), was renewed for a 90-day period under the same terms and conditions as the original note except that the new note is nonconvertible. The new note now having a face value of $98,894 Canadian ($76,072US) is due on September 30, 2017. On September 30, 2017, the note, together with accrued interest of $2,991 Canadian ($2,397 US) was renewed for a 90-day period under the same terms and conditions as the original note except that the new note is nonconvertible. The new note now having a principal balance of $101,885 Canadian ($81,640 US) matures December 31, 2017. On December 31, 2017 the note was renewed for a 12month period under the same terms and conditions as before except that this new note is unsecured and nonconvertible. The new note has a face value of $104,942 Canadian ($83,649 US) and matures on December 31, 2018. On December 31, 2018 the note was renewed for a 12-month period under the same terms and conditions as the previous note. The new note together with interest of $9,227, has a face value of $86,118 US ($117,535 CAD) and matures on December 31, 2019.</td> <td> </td> <td> </td> <td style="text-align: right">86,118</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">83,649</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> On January 1, 2018 as part of the acquisition of Atlas Pharma Inc., the Company issued a note payable in the amount of $450,000 Canadian ($358,407 US) and accruing interest at the rate of 3% per annum. The note is due on December 31, 2023. Payments on this note are $10,000 Canadian (approximately $8,000 US) per quarter. The outstanding principal balance at December 31, 2018 was $310,079. The note is nonconvertible and is secured by the Atlas Pharma Inc. shares held by the Company. The holder of this note is currently a director and officer of Atlas Pharma Inc.</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">310,079</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-0-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">Total Notes Payable Related Party</td> <td style="padding-bottom: 1pt"> </td> <td>$</td> <td style="text-align: right">532,941</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td>$</td> <td style="text-align: right">205,742</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">Long-Term Portion </td> <td style="padding-bottom: 1pt"> </td> <td>$ </td> <td style="text-align: right"> 289,847</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td>$ </td> <td style="text-align: right"> 79,710</td> <td style="padding-bottom: 1pt"> </td></tr> </table> 289847 79710 <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 88%">Cash</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">4,942</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Accounts receivable</td> <td> </td> <td>$</td> <td style="text-align: right">79,508</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Prepaids</td> <td> </td> <td>$</td> <td style="text-align: right">1,428</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Property and equipment</td> <td> </td> <td>$</td> <td style="text-align: right">62,990</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Goodwill</td> <td> </td> <td>$</td> <td style="text-align: right">665,697</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Less: Liabilities assumed ($172,899 Canadian)</td> <td> </td> <td>$</td> <td style="text-align: right">(137,817</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td>Total consideration</td> <td> </td> <td>$</td> <td style="text-align: right">676,748</td> <td> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%">A Note Payable having a Face Value of $24,012 at December 31, 2016 and accruing interest at 12% was due December 31, 2017 (“2016 Note”). On December 31, 2017, the Company renewed the 2016 Note, together with accrued interest of $2,573, for a 12-month period (“2017 Note”). On December 31, 2018 the Company renewed the 2017 Note, together with accrued interest of $2,881, for a 12-month period (“2018 Note”). The 2018 Note has a Face Value of $26,893 and accrues interest at 12%. The 2018 Note is nonconvertible.  </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">26,893</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">24,012</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>On January 12, 2018 the Company received monies in exchange for a Note Payable having a Face Value of $102,000 with interest accruing at 8% is due October 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $4,080 was converted in 2018 into 3,569,333 shares of Common Stock valued at $166,085 resulting in a loss of $60,005.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> On February 7, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $150,000 with interest accruing at 8% is due February 7, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note was paid off in 2018 in part by cash of $48,000 and the remainder, together with accrued interest of $5,073, was converted into 5,710,642 shares of Common Stock valued at $183,411 resulting in a loss of $76,338.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On February 20, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $85,000 with interest accruing at 8% is due November 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $3,400, was converted in 2018 into 4,376,238 shares of Common Stock valued at $281,663 resulting in a loss of $193,263.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> On May 29, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $26,750 with interest accruing at 8% is due February 29, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued interest of $1,353, was converted into 4,003,265 shares of Common Stock valued at $192,157 resulting in a loss of $164,054.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On June 27, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $53,000 with interest accruing at 8% is due April 15, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $2,137. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. </td> <td> </td> <td>$</td> <td style="text-align: right">53,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On August 17, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $53,000 with interest accruing at 8% is due April 15, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $1,557. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.</td> <td> </td> <td>$</td> <td style="text-align: right">53,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On September 10, 2018, the Company received monies in exchange for two Notes Payable having an aggregate Face Value of $36,500 with interest accruing at 8% are due June 20, 2019. Interest accrued at December 31, 2018 was $888.</td> <td> </td> <td>$</td> <td style="text-align: right">36,500</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On October 23, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $90,000 with interest accruing at 8% is due October 23, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $1,361. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.</td> <td> </td> <td>$</td> <td style="text-align: right">90,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 76%">On December 24, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $87,000 with interest accruing at 8% is due October 23, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $153. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">87,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-0-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>On April 1, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $100,000 Canadian ($73,270US) at December 31, 2018 and ($79,710 US) at December 31, 2017 with interest payable quarterly at 9% is due April 1, 2019. The Note is convertible any time after issuance into $0.001 par value Common Stock at a price of $0.015 Canadian (approximately $0.012 US) per share. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.</td> <td> </td> <td>$</td> <td style="text-align: right">73,270</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">79,710</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On August 3, 2017 the, Company received monies in exchange for a Note Payable having a Face Value of $ 80,000 with interest accruing at 8% is due August 3, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. A principal amount of $40,000 of this note plus accrued interest of $1,712 was converted in 2018 into 327,788 shares of Common Stock valued at $70,507 resulting in a loss of $28,795. The remaining principal amount of $40,000 together with accrued interest of $1,613 was paid in cash reducing the balance to $-0-</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">80,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On August 21, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $ 83,000 with interest accruing at 8% is due May 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, plus accrued interest of $3,419, was paid off in 2018.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">83,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On September 22, 2017 the Company received monies in exchange for a note having a Face Value of $ 62,000 with interest accruing at 8% is due June 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued interest of $2,480 was converted in 2018 into 790,590 shares of Common Stock valued at $107,056 resulting in a loss of $42,576.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">62,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On October 26, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $ 115,000 with interest accruing at 8% is due October 26, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued interest of $6,126, was converted in 2018 into 2,921,146 shares of Common Stock valued at $208,661 resulting in a loss of $87,535.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">62,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>On November 14, 2017, the Company received monies in exchange for a Note Payable having a Face Value of $ 113,000 with interest accruing at 8% is due November 14, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $7,018 was converted in 2018 into 4,917,251 shares of Common Stock valued at $351,999 resulting in a loss of $231,981.</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">115,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> On December 1, 2017, the Company received monies in exchange for a Note Payable having a Face Value of $50,000 Canadian ($38,568 US) at December 31, 2018 and ($39,855 US) at December 31, 2017 with interest accruing at 8% is due November 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $1,566 was converted in 2018 into 260,000 shares of Common Stock valued at $27,560 resulting in a gain of $12,574.</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid">$</td> <td style="text-align: right; border-bottom: Black 1pt solid">-0-</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid">$</td> <td style="text-align: right; border-bottom: Black 1pt solid">113,000</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total Notes Payable</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">419,663</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">596,577</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   89348981 EX-101.SCH 11 sbfm-20181231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheet link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statement Of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statement Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statement of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 1. Description of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 2. Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 3. Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 4. Patents link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 5. Capital Stock link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 6. Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 7. Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 8. Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 9. Notes Payable Related Party link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 10. Related Transactions link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 11. Royalties Payable link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 12. Acquisition of Atlas Pharma Inc. link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 13. Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 14. Commitments link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 15. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 2. Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 6. Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 7. Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 8. Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 9. Notes Payable Related Party (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 12. Acquisition of Atlas Pharma Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 2. Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 6. Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 7. Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 7. Income Taxes (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 7. Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 8. Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 9. Notes Payable Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - 12. Acquisition of Atlas Pharma Inc. (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 sbfm-20181231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 13 sbfm-20181231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 14 sbfm-20181231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Equity Components [Axis] Common Stock Capital Paid In Excess Of Par Value Preferred Shares Comprehensive Income Accumulated Deficit Temporary Difference Tax Effect Property, Plant and Equipment, Type [Axis] Office Equipment Laboratory Equipment Vehicles Class of Stock [Axis] Series A Preferred Stock Series B Preferred Stock Debt Instrument [Axis] Note 1 Note 2 Note 3 Note 4 Note 5 Note 6 Note 7 Note 8 Note 9 Note 10 Note 11 Related Entity Note 1 Related Entity Note 2 Note 12 Note 13 Note 14 Note 15 Note 16 Note 17 Related Entity Note 3 Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Ex Transition Period Entity Shell Company Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS Current Assets: Cash and cash equivalents Accounts receivable Prepaid expenses Total Current Assets Equipment (net of $57,964 and $9,132 depreciation) Patents (net of $58,918 amortization and $556,120 impairment) Non-current asset - Goodwill Non-current asset - Deposits TOTAL ASSETS LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities: Current portion of note payable Current portion of notes payable - related party Related party advances Accounts payable Interest payable Total Curent Liabilities Long-term liabilities - relaed party note payable TOTAL LIABILITIES SHAREHOLDERS' EQUITY Preferred Stock Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 85,652,400 and 45,936,825 at December 31, 2018 and 2017, respectively Capital paid in excess of par value Accumulated other comprehensive income Accumulated (Deficit) TOTAL SHAREHOLDERS' DEFICIT TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT Equipment depreciation Patent amortization Patent impairment Preferred stock, par value Preferred stock shares authorized Preferred stock shares issued Preferred stock shares outstanding Common stock, par value Common stock shares authorized Common stock shares issued Common stock shares outstanding Common stock shares reserved for issuance Income Statement [Abstract] Revenue Cost of Revenues Gross Profit General & Administrative Expenses: Accounting Legal Consulting Office Officer & Director remuneration Research & development Amortization & Depreciation Total General & Administrative Income (Loss) from Operations Other (expense): Interest expense Loss on conversion of notes payable Gain (Loss) from foreign exchange transactions Total Other Expenses Net (loss) Basic (Loss) per common share Weighted Average Common Shares Outsanding Net Income (Loss) Unrealized Comprehensive Gain (Loss) from foreign exchange transactions Comprehensive Income (Loss) Basic (Loss) per common shares Weighted Average Common Shares Outstanding Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Net (Loss) Amortization & Depreciation Foreign exchange gain Stock issued for services Loss on conversion of notes payable Stock issued for payment of interest Interest forgiven Increase (decrease) in accounts receivable (Increase) decrease in prepaid expenses Increase (decrease) in Accounts Payable Increase (decrease) in interest payable Net Cash Flows (Used) in Operations Cash Flows From Investing Activities: Cash received from purchase of subsidiary Purchase equipment Deposits on business acquisition Net Cash Flows (Used) in Investing Activities Cash Flows From Financing Activities: Proceed from note payable Notes Payable - Interest expense Payment of notes payable Note payable - related party Note payable used to pay expenses Note payable used to pay origination fees & interest Sale of common stock Net Cash Flows Provided by Financing Activities Net Increase (Decrease) In Cash and cash equivalents Foreign currency translation adjustment Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplementary Disclosure Of Cash Flow Information: Cash paid for interest Stock issued for acquisition of Atlas Pharma Inc. Stock issued for services Stock issued for note and accrued interest conversions Stock issued to buy equipment Loan issued for interest Begining Balance, Shares Begining Balance, Amount Stock issued for acquisition, Shares Stock issued for acquisition, Amount Stock issued for cash, Shares Stock issued for cash, Amount Stock issued for services, Shares Stock issued for services, Amount Common stock issued for equipment, Shares Common stock issued for equipment, Amount Common stock issued for the reduction of notes payable and payment of interest, shares Common stock issued for the reduction of notes payable and payment of interest, amount Net Income (Loss) Ending balance, Shares Ending balance, Amount Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business Summary of Significant Accounting Policies Going Concern Going Concern Goodwill and Intangible Assets Disclosure [Abstract] Patents Notes to Financial Statements Capital Stock Earnings Per Share [Abstract] Earnings per share Income Taxes Income Taxes Notes Payable [Abstract] Notes Payable Notes Payable Related Party Related Party Transactions [Abstract] Related Party Transactions Royalties Payable Royalties Payable Business Combinations [Abstract] Acquisition of Atlas Pharma Inc. Accounts Receivable Accounts Receivable Commitments Commitments Subsequent Events [Abstract] Subsequent Events Summary Of Significant Accounting Policies PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES CASH AND CASH EQUIVALENTS PROPERTY AND EQUIPMENT INTELLECTUAL PROPERTY RIGHTS - PATENTS EARNINGS PER SHARE INCOME TAXES FUNCTIONAL CURRENCY CONCENTRATION OF CREDIT RISKS FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS NOTES PAYABLE ACCOUNTING FOR DERIVATIVES LIABILITIES EQUITY INSTRUMENTS ISSUED TO NON-EMPLOYEES FOR AQUIRING GOODS OR SERVICES NONCASH EQUITY TRANSACTIONS RELATED PARTIES GENERAL AND ADMINISTRATIVE EXPENSES BASIC AND DILUTED NET GAIN (LOSS) PER SHARE COMMON STOCK REVENUE RECOGNITION RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS DIRECTOR AND OFFICER COMPENSATION LEGAL FEES DATE OF MANAGEMENT'S REVIEW Summary Of Significant Accounting Policies Estimated useful lives of property plant and equipment Earnings Per Share Schedule of earnings per share computation Income Taxes Temporary differences Income tax reconciliation Notes Payable Notes payable Notes Payable Related Party Summary of notes payable related party Acquisition Of Atlas Pharma Inc. Acquisition Estimated useful lives Summary Of Significant Accounting Policies Cash Earnings Per Share Net (loss) attributable to common stockholders Basic weighted average outstanding shares of common stock Dilutive effects of common share equivalents Dilutive weighted average outstanding shares of common stock Net loss per share of common stock - basic and diluted Deferred tax assets: Net operating loss US Net operating loss Canada Total Valuation allowance Total deferred tax asset Net deferred tax asset Income Taxes U.S. Federal statutory graduated rate State income tax rate, net of federal benefit Net rate Net operating loss used Net operating loss for which no tax benefit is currently available Income tax rate Canada Federal statutory rate Canada Provincial rate Net rate Net operating loss used (Canada) Net operating loss for which no tax benefit is currently available (Canada) Income Taxes Federal net operating loss carryforwards Deferred tax asset net operating loss carryforwards Change in the valuation allowance Notes payable Notes payable related party Long-term portion Acquisition Of Atlas Pharma Inc. Cash Accounts receivable Prepaids Property and equipment Goodwill Less: Liabilities assumed ($172,899 Canadian) Total consideration Custom Element. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit General and Administrative Expense Operating Income (Loss) Interest Expense Induced Conversion of Convertible Debt Expense Nonoperating Income (Expense) Depreciation, Depletion and Amortization, Nonproduction Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments for Other Deposits Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Shares, Issued Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Substantial Doubt about Going Concern [Text Block] Income Tax Disclosure [Text Block] RoyaltiesPayableDisclosureTextBlock AccountsReceivableDisclosureTextBlock Commitments and Contingencies Disclosure [Text Block] Deferred Tax Assets, Valuation Allowance CanadaNetStatutoryTaxRate Notes Payable [Default Label] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities EX-101.PRE 15 sbfm-20181231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 16 R1.htm IDEA: XBRL DOCUMENT v3.19.1

Document and Entity Information - USD ($)
12 Months Ended

Dec. 31, 2018

Apr. 11, 2019

Jun. 30, 2018

Document And Entity Information

Entity Registrant Name Sunshine Biopharma, Inc

Entity Central Index Key 0001402328

Document Type 10-K

Document Period End Date Dec. 31, 2018

Amendment Flag false

Current Fiscal Year End Date --12-31

Is Entity a Well-known Seasoned Issuer? No

Is Entity a Voluntary Filer? No

Is Entity's Reporting Status Current? Yes

Entity Filer Category Non-accelerated Filer

Entity Emerging Growth Company true

Entity Small Business true

Entity Ex Transition Period true

Entity Shell Company false

Entity Public Float $ 3,970,144

Entity Common Stock, Shares Outstanding 89,348,981

Document Fiscal Period Focus FY

Document Fiscal Year Focus 2018

X

- References
No definition available.
+ Details

Name: SBFM_DocumentAndEntityInformationAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

XML 17 R2.htm IDEA: XBRL DOCUMENT v3.19.1

Balance Sheet - USD ($)

Dec. 31, 2018

Dec. 31, 2017

Current Assets:

Cash and cash equivalents $ 115,216 $ 107,532

Accounts receivable 94,955 0

Prepaid expenses 1,341 9,667

Total Current Assets 211,512 117,199

Equipment (net of $57,964 and $9,132 depreciation) 269,362 59,996

Patents (net of $58,918 amortization and $556,120 impairment) 0 0

Non-current asset - Goodwill 665,697 0

Non-current asset - Deposits 0 80,290

TOTAL ASSETS 1,146,571 257,485

Current Liabilities:

Current portion of note payable 419,663 516,867

Current portion of notes payable - related party 243,094 205,742

Related party advances 49,349 0

Accounts payable 191,080 19,314

Interest payable 9,291 9,215

Total Curent Liabilities 912,477 751,138

Long-term liabilities - relaed party note payable 289,847 79,710

TOTAL LIABILITIES 1,202,324 830,848

SHAREHOLDERS' EQUITY

Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 85,652,400 and 45,936,825 at December 31, 2018 and 2017, respectively 85,652 45,936

Capital paid in excess of par value 15,586,678 12,948,387

Accumulated other comprehensive income (3,738) 504

Accumulated (Deficit) (15,774,345) (13,618,190)

TOTAL SHAREHOLDERS' DEFICIT (55,753) (573,363)

TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT 1,146,571 257,485

Series A Preferred Stock

SHAREHOLDERS' EQUITY

Preferred Stock 0 0

Series B Preferred Stock

SHAREHOLDERS' EQUITY

Preferred Stock $ 50,000 $ 50,000

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DepositsAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R3.htm IDEA: XBRL DOCUMENT v3.19.1

Balance Sheet (Parenthetical) - USD ($)
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Equipment depreciation $ 57,964 $ 9,132

Patent amortization 58,918 $ 58,918

Patent impairment $ 556,120

SHAREHOLDERS' EQUITY

Common stock, par value $ 0.001 $ 0.001

Common stock shares authorized 3,000,000,000 3,000,000,000

Common stock shares issued 85,652,400 45,936,825

Common stock shares outstanding 85,652,400 45,936,825

Common stock shares reserved for issuance 97,321,836

Series A Preferred Stock

SHAREHOLDERS' EQUITY

Preferred stock, par value $ 0.10 $ 0.10

Preferred stock shares authorized 5,000,000 5,000,000

Preferred stock shares issued 0 0

Preferred stock shares outstanding 0 0

Series B Preferred Stock

SHAREHOLDERS' EQUITY

Preferred stock, par value $ 0.10 $ 0.10

Preferred stock shares authorized 500,000 500,000

Preferred stock shares issued 500,000 500,000

Preferred stock shares outstanding 500,000 500,000

X

- References
No definition available.
+ Details

Name: SBFM_PatentAccumulatedAmortization

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R4.htm IDEA: XBRL DOCUMENT v3.19.1

Statement Of Operations and Comprehensive Loss - USD ($)
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Income Statement [Abstract]

Revenue $ 447,200 $ 0

Cost of Revenues 391,081 0

Gross Profit 56,119 0

General & Administrative Expenses:

Accounting 153,889 81,643

Legal 113,068 75,908

Consulting 36,245 127,013

Office 149,031 45,726

Officer & Director remuneration 755,215 520,271

Research & development 12,800 0

Amortization & Depreciation 2,408 6,629

Total General & Administrative 1,222,656 857,190

Income (Loss) from Operations (1,166,537) (857,190)

Other (expense):

Interest expense (159,420) (104,829)

Loss on conversion of notes payable (871,726) (76,929)

Gain (Loss) from foreign exchange transactions 41,528 (1,288)

Total Other Expenses (989,618) (183,046)

Net (loss) $ (2,156,155) $ (1,040,236)

Basic (Loss) per common share $ (0.04) $ (0.02)

Weighted Average Common Shares Outsanding 60,936,164 43,634,280

Net Income (Loss) $ (2,156,155) $ (1,040,236)

Unrealized Comprehensive Gain (Loss) from foreign exchange transactions (4,242) 110

Comprehensive Income (Loss) $ (2,160,397) $ (1,040,126)

Basic (Loss) per common shares $ (0.04) $ (0.02)

Weighted Average Common Shares Outstanding 60,936,164 43,634,280

X

- Definition
Custom Element.
+ References
No definition available.
+ Details

Name: SBFM_FinancialConsulting

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_OfficeExpense

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GeneralAndAdministrativeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 40
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=99385385&loc=d3e6835-112609
+ Details

Name: us-gaap_InducedConversionOfConvertibleDebtExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_LegalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 35
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82918529&loc=d3e30304-110892

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b,d)
-URI http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.2(a),(b),(c),(d))
-URI http://asc.fasb.org/extlink&oid=114873854&loc=SL114874292-224272

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section 45
-Paragraph 3
-Subparagraph (k)
-URI http://asc.fasb.org/extlink&oid=114873831&loc=SL114874205-224268
+ Details

Name: us-gaap_ProfessionalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 20 R5.htm IDEA: XBRL DOCUMENT v3.19.1

Statement Of Cash Flows - USD ($)
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Cash Flows From Operating Activities:

Net (Loss) $ (2,156,155) $ (1,040,236)

Amortization & Depreciation 49,361 6,629

Foreign exchange gain (42,399) 0

Stock issued for services 676,100 427,400

Loss on conversion of notes payable 871,973 76,929

Stock issued for payment of interest 33,977 3,022

Interest forgiven (247) 0

Increase (decrease) in accounts receivable (15,447) 0

(Increase) decrease in prepaid expenses 8,326 (8,660)

Increase (decrease) in Accounts Payable 61,629 (8,808)

Increase (decrease) in interest payable 76 204

Net Cash Flows (Used) in Operations (512,806) (543,520)

Cash Flows From Investing Activities:

Cash received from purchase of subsidiary 4,942 0

Purchase equipment (18,850) (3,718)

Deposits on business acquisition 0 (80,290)

Net Cash Flows (Used) in Investing Activities (13,908) (84,008)

Cash Flows From Financing Activities:

Proceed from note payable 609,885 660,565

Notes Payable - Interest expense 26,759 33,977

Payment of notes payable (194,184) (115,000)

Note payable - related party 29,930 2,251

Note payable used to pay expenses 36,500 0

Note payable used to pay origination fees & interest 18,750 25,000

Sale of common stock 0 63,912

Net Cash Flows Provided by Financing Activities 527,640 670,705

Net Increase (Decrease) In Cash and cash equivalents 926 43,177

Foreign currency translation adjustment 6,758 6,902

Cash and cash equivalents at beginning of period 107,532 57,453

Cash and cash equivalents at end of period 115,216 107,532

Supplementary Disclosure Of Cash Flow Information:

Cash paid for interest 23,496 21,900

Stock issued for acquisition of Atlas Pharma Inc. 238,000 0

Stock issued for services 676,100 427,400

Stock issued for note and accrued interest conversions 1,589,099 128,451

Stock issued to buy equipment 174,808 56,700

Loan issued for interest $ 45,509 $ 58,977

X

- References
No definition available.
+ Details

Name: SBFM_LoanIssuedForInterest

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_LossOnConversionOfNotesPayable

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_StockIssuedForPaymentInterestOnNotesPayable

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_StockIssuedToBuyEquipment

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_DebtInstrumentDecreaseForgiveness

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount owed by the reporting entry in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInNotesPayableRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Expenses paid for obtaining loans which includes expenses such as application and origination fees.
+ References
No definition available.
+ Details

Name: us-gaap_LoanProcessingFee

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow for deposits classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsForOtherDeposits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash inflow representing an adjustment to the purchase price of a previous acquisition.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromPreviousAcquisition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R6.htm IDEA: XBRL DOCUMENT v3.19.1

Statement of Shareholders' Equity - USD ($)

Common Stock

Capital Paid In Excess Of Par Value

Preferred Shares

Comprehensive Income

Accumulated Deficit

Total

Begining Balance, Shares at Dec. 31, 2016 38,469,993 500,000

Begining Balance, Amount at Dec. 31, 2016 $ 38,470 $ 12,279,390 $ 50,000 $ 394 $ (12,577,954) $ (209,700)

Stock issued for cash, Shares 1,700,000

Stock issued for cash, Amount $ 1,700 62,212 63,912

Stock issued for services, Shares 3,090,217

Stock issued for services, Amount $ 3,090 424,310 427,400

Common stock issued for equipment, Shares 550,208

Common stock issued for equipment, Amount $ 550 56,150 56,700

Common stock issued for the reduction of notes payable and payment of interest, shares 2,126,406

Common stock issued for the reduction of notes payable and payment of interest, amount $ 2,126 126,325 128,451

Net Income (Loss) (1,040,236) (1,040,126)

Ending balance, Shares at Dec. 31, 2017 45,936,825 500,000

Ending balance, Amount at Dec. 31, 2017 $ 45,936 12,948,387 $ 50,000 504 (13,618,190) (573,363)

Stock issued for acquisition, Shares 1,000,000

Stock issued for acquisition, Amount $ 1,000 237,000 238,000

Stock issued for services, Shares 10,382,500

Stock issued for services, Amount $ 10,383 665,718 676,100

Common stock issued for equipment, Shares 1,456,737

Common stock issued for equipment, Amount $ 1,457 173,351 174,808

Common stock issued for the reduction of notes payable and payment of interest, shares 26,876,338

Common stock issued for the reduction of notes payable and payment of interest, amount $ 26,876 1,562,223 1,589,099

Net Income (Loss) (4,242) (2,156,155) (2,160,397)

Ending balance, Shares at Dec. 31, 2018 85,652,400 500,000

Ending balance, Amount at Dec. 31, 2018 $ 85,652 $ 15,586,678 $ 50,000 $ (3,738) $ (15,774,345) $ (55,753)

X

- References
No definition available.
+ Details

Name: SBFM_CommonStockIssuedForReductionOfNotePayableAmount

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_CommonStockIssuedForReductionOfNotePayableShares

Namespace Prefix: SBFM_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of stock issued during the period pursuant to acquisitions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued pursuant to acquisitions during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 22 R7.htm IDEA: XBRL DOCUMENT v3.19.1

1. Description of Business
12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business
The Company was originally incorporated under the name Mountain West Business Solutions, Inc. (“MWBS”) on August 31, 2006 in the State of Colorado. Effective October 15, 2009, MWBS acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. MWBS concurrently changed its name to Sunshine Biopharma, Inc. and Sunshine Biopharma, Inc. changed its name to Sunshine Etopo, Inc. In 2015, Sunshine Etopo, Inc. became inactive and was recently dissolved.

On July 25, 2014, the Company formed a Canadian wholly owned subsidiary, Sunshine Biopharma Canada Inc., for the purposes of offering generic prescription drugs and over-the-counter dietary supplements.

On January 1, 2018, the Company acquired Atlas Pharma Inc., a Health Canada certified Canadian company offering chemical analysis of pharmaceutical and other industrial samples.

On March 23, 2018, the Company formed NOX Pharmaceuticals, Inc., a Colorado company that now holds all of the patents and intellectual property pertaining to Sunshine Biopharma Inc.’s proprietary drugs including Adva-27a, a multi-purpose anti-tumor compound targeted for the treatment of multidrug resistant cancer.

On December 17, 2018, the Company launched its first over-the-counter product, Essential 9tm, a dietary supplement comprised of the nine amino acids which the human body cannot synthesize. Essential 9tm has been authorized for marketing by Health Canada under NPN 80089663.

The following are Sunshine Biopharma, Inc.’s subsidiaries:

● NOX Pharmaceuticals Inc., a wholly owned Colorado company;

● Sunshine Biopharma Canada Inc., a wholly owned Canadian company; and

● Atlas Pharma Inc., a wholly owned Canadian company.

Effective February 1, 2019, the Company completed a 20 to 1 reverse split of its $0.001 par value Common Stock reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400 (“Reverse Stock Split”).

The financial statements reflect the Reverse Stock Split on a retroactive basis and represent the consolidated activity of Sunshine Biopharma, Inc. and its subsidiaries (hereinafter collectively referred to as the "Company"). The Company was originally formed for the purposes of conducting research, development and commercialization of drugs for the treatment of various forms of cancer. The Company may also engage in any other business that is permitted by law, as designated by the Board of Directors of the Company.

During the last year the Company has continued to raise money through stock sales and borrowings.

The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company’s generic pharmaceuticals business and proprietary drug development program.

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R8.htm IDEA: XBRL DOCUMENT v3.19.1

2. Summary of Significant Accounting Policies
12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Significant Accounting Policies
This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the financial statements.

PRINCIPLES OF CONSOLIDATION

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

CASH AND CASH EQUIVALENTS

For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $115,216 and $107,532 as of December 31, 2018 and December 31, 2017, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 or the equivalent in Canada.

PROPERTY AND EQUIPMENT

Property and equipment is reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2018 and 2017, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.

Property and equipment are stated at cost. Depreciation is calculated using the straight-line method for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows:

Office Equipment: 5-7 Years

Laboratory Equipment 5 Years

Vehicles 5 Years

INTELLECTUAL PROPERTY RIGHTS - PATENTS

The cost of patents acquired is capitalized and is amortized over the remaining life of the patents.

The Company evaluates recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable. Such circumstances include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of cost significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the assets against the estimated undiscounted future cash flows associated with it.

The Company’s management determined that the expected cash flows would be less than the carrying amount of certain intangible assets; therefore an impairment loss was recognized in 2016. The impairment loss was calculated as the amount by which the carrying amount of the intangible assets exceeded fair value.

EARNINGS PER SHARE

The Company has adopted the Financial Accounting Standards Board (FASB) ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.

INCOME TAXES

In accordance with ASC 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2018 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.

For Canadian and US tax purposes, the Company’s 2015 through 2017 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.

FUNCTIONAL CURRENCY

The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.

The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:

● Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.

● Income statement accounts are translated using the weighted average exchange rate for the period.

The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non U.S. currency transactions.

CONCENTRATION OF CREDIT RISKS

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.

FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company applies the provisions of accounting guidance, FASB Topic ASC 825, Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2018 and 2017, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.

The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.

NOTES PAYABLE

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method.

ACCOUNTING FOR DERIVATIVES LIABILITIES

The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense.

Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. The Company determined that none of the Company’s financial instruments meet the criteria for derivative accounting as of December 31, 2018 and 2017.

EQUITY INSTRUMENTS ISSUED TO NON-EMPLOYEES FOR AQUIRING GOODS OR SERVICES

Issuances of the Company’s common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.

NONCASH EQUITY TRANSACTIONS

Shares of equity instruments issued for noncash consideration are recorded at the estimated fair market value of the consideration granted based on the estimated market value of the equity instrument, or at the estimated value of the goods or services received whichever is more readily determinable.

RELATED PARTIES

A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.

GENERAL AND ADMINISTRATIVE EXPENSES

General and administrative expenses consisted of professional service fees, rent and utility expenses, meals, travel and entertainment expenses, and other general and administrative overhead costs. Expenses are recognized when incurred.

BASIC AND DILUTED NET GAIN (LOSS) PER SHARE

The Company computes loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.

Basic net income (loss) per share is calculated by dividing net (loss) by the weighted-average common shares outstanding. Diluted net income per share is calculated by dividing net income by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2018 no potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.

Therefore, basic and dilutive net (loss) per share were the same as of December 31, 2018 and 2017.

COMMON STOCK

The Company completed a 20 to 1 reverse stock split of the $.001 par value Common Stock affective February 1, 2019. All shares in this filing have been restated to reflect the 20 to 1 reverse split.

REVENUE RECOGNITION

As of January 1, 2018, the Company adopted ASU No. 201409, “Revenue from Contracts with Customers” (ASU 201409). Under the new guidance, an entity will recognize revenue to depict the transfer of promised goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. A five-step model has been introduced for an entity to apply when recognizing revenue. The new guidance also includes enhanced disclosure requirements. The guidance was effective January 1, 2018 and was applied on a modified retrospective basis. The adoption did not have an impact on the Company's financial statements. All of the revenues of the Company are generated by Atlas Pharma Inc., the Company's wholly owned Canadian subsidiary, which provides laboratory testing services. Performance obligations for testing services are recognized as revenue at a point in time on the date results are delivered to a customer which is when control is transferred.

Local governmental regulations require that companies recognize revenues upon completion of the work by issuing an invoice and remitting the applicable sales taxes (GST and QST) to the appropriate government agency. Atlas Pharma Inc.'s revenue recognition policy is in compliance with these local regulations.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 will require lessees to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with terms of more than 12 months. Lessor accounting remains substantially similar to current GAAP. In addition, disclosures of leasing activities are to be expanded to include qualitative along with specific quantitative information. ASU 2016-02 will be effective in fiscal years beginning after December 15, 2018 (with early adoption permitted). ASU 2016-02 mandates a modified retrospective transition method. The Company is currently evaluating the potential impact of adopting this guidance on our consolidated financial statements.



DIRECTOR AND OFFICER COMPENSATION

For the period ended December 31, 2018, the Company issued 4,050,000 shares of par value $0.001 Common Stock valued at $429,300 or $0.106 per share and 5,700,000 shares of par value $0.001 Common Stock to the Board of Directors valued at $171,000 or $0.03 per share. During the year ended December 31, 2018 the Directors and officers were paid $154,915 in cash. Of this amount, $85,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

For the period ended December 31, 2017, the Company issued 2,100,000 of par value $0.001 Common Stock to the three Company officers valued at $336,000 or $0.16 per share. During the year ended December 31, 2017 the Directors and officers were paid $184,271 in cash. Of this amount, $147,695 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

LEGAL FEES

During the years ended December 31, 2018 and 2017, the legal fees incurred were related to services provided to the Company to assist with its regulatory requirements with the Securities and Exchange Commission, patenting costs and one ongoing litigation.

DATE OF MANAGEMENT’S REVIEW

Subsequent events have been evaluated through April 12, 2019, which is the date the Financial Statements were available to be issued.

X

- Definition
The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R9.htm IDEA: XBRL DOCUMENT v3.19.1

3. Going Concern
12 Months Ended

Dec. 31, 2018

Going Concern

Going Concern
In the course of its life the Company has had limited operations and Working Capital deficit. This raises substantial doubt about the Company’s ability to continue as a going concern. The Company believes it can raise capital through equity sales and borrowing to fund its operations. Management believes this will contribute toward its subsequent profitability. The accompanying Financial Statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

X

- References
No definition available.
+ Details

Name: SBFM_GoingConcernAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 40
-URI http://asc.fasb.org/subtopic&trid=51888271
+ Details

Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R10.htm IDEA: XBRL DOCUMENT v3.19.1

4. Patents
12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Patents
The following is a summary of the patents held by the Company at December 31, 2018 and 2017:

On October 8, 2015, the Company acquired U.S. Patent Number 8,236,935 (the “US Patent”) for the Adva-27a anticancer compound from Advanomics Corporation (“Advanomics”), a related party, in exchange for an interest-free note payable for $4,320,000. Effective December 28, 2015, the parties executed an amendment pursuant to which this note payable for $4,320,000 was cancelled and replaced with a new interest-free convertible note having a face value of $210,519, comprised of $155,940 in principal amount which is the Advanomics book value of the US Patent, plus $54,579 as an adjustment for the currency exchange difference. The new note is automatically convertible into 4,048,449 shares of the Company’s Common Stock upon the Company increasing its authorized capital to a level that would permit the issuance of such shares.

On December 28, 2015, the Company acquired the remaining worldwide issued and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 (the “Worldwide Patents”) for the Adva-27a anticancer compound from Advanomics, a related party, in exchange for a note payable for $12,822,499. Effective December 28, 2015, the parties executed an amendment pursuant to which this note payable for $12,822,499 was cancelled and replaced with a new interest-free convertible note having a face value of $624,875, comprised of $462,870 in principal amount, which is the Advanomics book value of the Worldwide Patents, plus $162,005 as an adjustment for the currency exchange difference. The new note is automatically convertible into 12,016,823 shares of the Company’s Common Stock upon the Company increasing its authorized capital to a level that would permit the issuance of such shares.

In July 2016, the Company issued 16,065,271 shares of $0.001 par value Common Stock in exchange for the aforementioned patents related notes payable totaling $835,394. In 2016, the remaining value of these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R11.htm IDEA: XBRL DOCUMENT v3.19.1

5. Capital Stock
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Capital Stock
The Company’s authorized capital is comprised of 3,000,000,000 shares of $0.001 par value Common Stock and 30,000,000 shares of $0.10 par value Preferred Stock, to have such rights and preferences as the Directors of the Company have or may assign from time to time. Out of the authorized Preferred Stock, the Company has designated 850,000 shares as Series “A” Preferred Stock (“Series A”). The Series A is convertible at any time after issuance into 20 shares of the Company's Common Stock with no further consideration, has full voting rights at 20 votes per share, and has superior liquidation rights to the Common Stock. During the year ended December 31, 2015, the Company authorized 500,000 shares of $0.10 par value Series “B” Preferred Stock (“Series B”). The Series B Preferred Stock is non-convertible, non-redeemable and non-retractable. It has superior liquidation rights to the Common Stock at $0.10 per share and gives the holder the right to 1,000 votes per share. All shares of the Series B Preferred Stock are held by the CEO of the Company. Through December 31, 2018 and December 31, 2017, the Company has issued and outstanding a total of 85,652,400312 and 45,936,825 shares of Common Stock, respectively. Through the same periods, the Company has issued and outstanding a total of -0- and -0- shares of Series A Preferred Stock and 500,000 and 500,000 shares of Series B Preferred Stock, respectively. Effective February 1, 2019, the Company completed a 20 to 1 reverse split of its $0.001 par value Common Stock. All stock and price per share amounts in this report have been restated to reflect the 20 to 1 reverse split.

During the fiscal year ended December 31, 2018, the Company issued an aggregate of 39,715,575 shares of its Common Stock as follows:

●1,000,000 shares for the acquisition of Atlas Pharma, Inc.

●1,456,737 shares for the purchase of laboratory and generic drugs warehouse equipment valued at $174,808

●9,750,000 shares valued at $600,300 as compensation to the Company’s Directors and Officers

●632,500 shares for services rendered to the Company by third parties valued at $75,800

●26,876,338 shares valued at $1,589,099 in connection with the conversion of $684,318 in debt and interest of $32,808 resulting in a $871,973 loss on conversion

During the fiscal year ended December 31, 2017, the Company issued an aggregate of 7,466,832 shares of its Common Stock as follows:

●1,700,000 shares for cash in the amount of $100,000 Canadian or $78,312 US

●550,208 shares for the purchase of laboratory and generic drugs warehouse equipment valued at $56,700

●2,400,000 shares valued at $336,000 as compensation to the Company’s Directors and Officers

●690,218 shares for services rendered to the Company by third parties valued at $77,000

●2,126,406 shares valued at $128,451 in connection with the conversion of $48,500 in debt and interest of $3,022 resulting in a $76,929 loss on conversion.

The Company has declared no dividends since inception.

X

- References
No definition available.
+ Details

Name: SBFM_CapitalStockTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_NotesToFinancialStatementsAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R12.htm IDEA: XBRL DOCUMENT v3.19.1

6. Earnings Per Share
12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Earnings per share
The following table sets forth the computation of basic and diluted net income per share for the years ended December 31:

2018 2017

Net (loss) attributable to Common Stock $ (2,156,155 ) $ (1,040,236 )

Basic weighted average outstanding shares of Common Stock 60,936,164 43,634,280

Dilutive effects of common share equivalents -0- -0-

Dilutive weighted average outstanding shares of common stock 60,936,164 43,634,280

Net (loss) attributable to Common Stock $ (0.04 ) $ (0.02 )



X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R13.htm IDEA: XBRL DOCUMENT v3.19.1

7. Income Taxes
12 Months Ended

Dec. 31, 2018

Income Taxes

Income Taxes
The Company files a United States federal income tax return and a Canadian branch return on a calendar year basis. The Company and its wholly-owned subsidiaries, Sunshine Biopharma Canada Inc. and Atlas Pharma Inc., have not generated taxable income since inception.

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur. The Company accounts for income taxes pursuant to ASC 740.

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses and other items. Loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.

The Company follows FASB Statement Accounting Standards Codification No. 740, “Accounting for Income Taxes”, which requires, among other things, an asset and liability approach to calculating deferred income taxes. The components of the deferred income tax assets and liabilities arising under ASC No. 740 were as follows:

The types of temporary differences between the tax basis of assets and their financial reporting amounts that give rise to a significant portion of the deferred assets and liabilities are as follows:

December 31,
2018 December 31,
2017

Temporary Difference Tax Effect Temporary Difference Tax Effect

Deferred tax assets:

Net operating loss US $ 12,156,020 $ 2,997,675 $ 10,611,921 $ 3,932,778

Net operating loss Canada 298,661 80,041 266,498 71,421

Total 12,454,681 3,077,716 10,878,419 4,004,199

Valuation allowance (12,454,681 ) (3,077,716 ) (10,878,419 ) ( 4,004,199 )

Total deferred tax asset -0- -0- -0- -0-

Net deferred tax asset -0- -0- - -



Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.

At December 31, 2018 and December 31, 2017, the Company had approximately $12,454,681 and $10,878,419 respectively, in unused federal net operating loss carryforwards, which begin to expire principally in the year 2029. A deferred tax asset at each date of approximately $3,077,716 and $4,004,199 resulting from the loss carryforwards has been offset by a 100% valuation allowance. The change in the valuation allowance for the period ended December 31, 2018 and December 31, 2017 was approximately $926,483 and $342,693, respectively.

A reconciliation of the U.S. statutory federal income tax rate to the effective tax rate is as follows:

December 31,

2018 2017

U.S. Federal statutory graduated rate


21.00 % 34.00 %

State income tax rate, net of federal benefit

4.12 % 3.06 %

Net rate

25.12 % 37.06 %

Net operating loss used

0.00 % 0.00 %

Net operating loss for which no tax benefit is currently available

-25.12 % -37.06 %

0.00 % 0.00 %

Canada Federal statutory rate


15.00 % 15.00 %

Canada Provincial rate

11.80 % 11.80 %

Net Canada rate

26.80 % 26.80 %

Net operating loss used

0.00 % 0.00 %

Net operating loss for which no tax benefit is currently available (Canada)

-26.80 % -26.80 %

0.00 % 0.00 %

The Company’s income tax filings are subject to audit by various taxation authorities. The Company’s open audit periods are 2015, 2016, and 2017, although, the statute of limitations for the 2015 tax year will expire effective March 15, 2019. In evaluating the Company’s provisions and accruals, future taxable income, and reversal of temporary differences, interpretations and tax planning strategies are considered. The Company believes its estimates are appropriate based on current facts and circumstances.

X

- References
No definition available.
+ Details

Name: SBFM_IncomeTaxesAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R14.htm IDEA: XBRL DOCUMENT v3.19.1

8. Notes Payable
12 Months Ended

Dec. 31, 2018

Notes Payable [Abstract]

Notes Payable
Notes payable consist of the following:

2018 2017

A Note Payable having a Face Value of $24,012 at December 31, 2016 and accruing interest at 12% was due December 31, 2017 (“2016 Note”). On December 31, 2017, the Company renewed the 2016 Note, together with accrued interest of $2,573, for a 12-month period (“2017 Note”). On December 31, 2018 the Company renewed the 2017 Note, together with accrued interest of $2,881, for a 12-month period (“2018 Note”). The 2018 Note has a Face Value of $26,893 and accrues interest at 12%. The 2018 Note is nonconvertible. $ 26,893 $ 24,012

On January 12, 2018 the Company received monies in exchange for a Note Payable having a Face Value of $102,000 with interest accruing at 8% is due October 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $4,080 was converted in 2018 into 3,569,333 shares of Common Stock valued at $166,085 resulting in a loss of $60,005. $ -0- -0-

On February 7, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $150,000 with interest accruing at 8% is due February 7, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note was paid off in 2018

in part by cash of $48,000 and the remainder, together with accrued interest of $5,073, was converted into 5,710,642 shares of Common Stock valued at $183,411 resulting in a loss of $76,338.
$ -0- $ -0-

On February 20, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $85,000 with interest accruing at 8% is due November 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $3,400, was converted in 2018 into 4,376,238 shares of Common Stock valued at $281,663 resulting in a loss of $193,263. $ -0- $ -0-

On May 29, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $26,750 with interest accruing at 8% is due February 29, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued

interest of $1,353, was converted into 4,003,265 shares of Common Stock valued at $192,157 resulting in a loss of $164,054.
$ -0- $ -0-

On June 27, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $53,000 with interest accruing at 8% is due April 15, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.
Interest accrued at December 31, 2018 was $2,137. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.
$ 53,000 $ -0-

On August 17, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $53,000 with interest accruing at 8% is due April 15, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $1,557. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. $ 53,000 $ -0-

On September 10, 2018, the Company received monies in exchange for two Notes Payable having an aggregate Face Value of $36,500 with interest accruing at 8% are due June 20, 2019. Interest accrued at December 31, 2018 was $888. $ 36,500 $ -0-

On October 23, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $90,000 with interest accruing at 8% is due October 23, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $1,361. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. $ 90,000 $ -0-

On December 24, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $87,000 with interest accruing at 8% is due October 23, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $153. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. $ 87,000 $ -0-

On April 1, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $100,000 Canadian ($73,270US) at December 31, 2018 and ($79,710 US) at December 31, 2017 with interest payable quarterly at 9% is due April 1, 2019. The Note is convertible any time after issuance into $0.001 par value Common Stock at a price of $0.015 Canadian (approximately $0.012 US) per share. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. $ 73,270 $ 79,710

On August 3, 2017 the, Company received monies in exchange for a Note Payable having a Face Value of $ 80,000 with interest accruing at 8% is due August 3, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. A principal amount of $40,000 of this note plus accrued interest of $1,712 was converted in 2018 into 327,788 shares of Common Stock valued at $70,507 resulting in a loss of $28,795. The remaining principal amount of $40,000 together with accrued interest of $1,613 was paid in cash reducing the balance to $-0- $ -0- $ 80,000

On August 21, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $ 83,000 with interest accruing at 8% is due May 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, plus accrued interest of $3,419, was paid off in 2018. $ -0- $ 83,000

On September 22, 2017 the Company received monies in exchange for a note having a Face Value of $ 62,000 with interest accruing at 8% is due June 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued interest of $2,480 was converted in 2018 into 790,590 shares of Common Stock valued at $107,056 resulting in a loss of $42,576. $ -0- $ 62,000

On October 26, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $ 115,000 with interest accruing at 8% is due October 26, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued interest of $6,126, was converted in 2018 into 2,921,146 shares of Common Stock valued at $208,661 resulting in a loss of $87,535. $ -0- $ 62,000

On November 14, 2017, the Company received monies in exchange for a Note Payable having a Face Value of $ 113,000 with interest accruing at 8% is due November 14, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $7,018 was converted in 2018 into 4,917,251 shares of Common Stock valued at $351,999 resulting in a loss of $231,981. $ -0- $ 115,000

On December 1, 2017, the Company received monies in exchange for a Note Payable having a Face Value of $50,000 Canadian ($38,568 US) at December 31, 2018 and ($39,855 US) at December 31, 2017 with interest accruing at 8% is due November 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $1,566 was converted in 2018 into 260,000 shares of Common Stock valued at $27,560 resulting in a gain of $12,574.
$ -0- $ 113,000

Total Notes Payable $ 419,663 $ 596,577

Interest expense for the years ended December 31, 2018 and 2017 was $159,420 and $79,674, respectively. The balance of interest payable at December 31, 2018 and 2017 was $9,291 and $9,215, respectively. Loss on conversion of notes payable for the years ended December 31, 2018 and 2017 was $871,973 and $76,929 respectively.

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NotesPayableAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R15.htm IDEA: XBRL DOCUMENT v3.19.1

9. Notes Payable Related Party
12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Notes Payable Related Party
Notes payable to related parties consist of the following:

2018 2017

A Note Payable held by a private individual who became a principal shareholder of the Company having a Face Value of $118,537 at September 30, 2017 and a maturity date of December 31, 2017, accrues interest at 12%. The Note is convertible any time from the date of issuance into $0.001 par value Common Stock at a 35% discount from market price. On December 31, 2017 the Note together with accrued interest was renewed for a 12-month period under the same terms and conditions as before. The new Note has a Face Value of $122,093 and matures on December 31, 2018. On December 31, 2018 the Note, together with accrued interest of $14,651 was renewed for a 12-month period. The new Note has a Face value of $136,744 and matures on December 31, 2019. The new Note is nonconvertible. This individual ceased to be a principal shareholder of the Company in the third quarter of 2018
$ 136,744 $ 122,093

In December 2016, the Company received monies from its CEO in exchange for a note payable having a principal amount of $90,000 Canadian ($67,032 US) with interest at 12% due March 31, 2017. The note was convertible any time after the date of issuance into $0.001 par value Common Stock at a price 35% below market value. This note was collateralized by all of the assets of the Company. In the event of default, the interest rate will increased to 18% per annum and a penalty of $1,000 Canadian ($752 US) per day will accrue. On March 31, 2017, the note, together with accrued interest of $3,021 Canadian ($2,271 US) and an additional principal amount of $3,000 Canadian ($2,247 US) paid to the Company on March 28, 2017, was renewed for a 90-day period under the same terms and conditions as the original note. The new note now having a face value of $96,021 Canadian ($72,198 US) was due on June 30, 2017. On June 30, 2017, the note, together with accrued interest of $2,873 Canadian ($2,005 US), was renewed for a 90-day period under the same terms and conditions as the original note except that the new note is nonconvertible. The new note now having a face value of $98,894 Canadian ($76,072US) is due on September 30, 2017. On September 30, 2017, the note, together with accrued interest of $2,991 Canadian ($2,397 US) was renewed for a 90-day period under the same terms and conditions as the original note except that the new note is nonconvertible. The new note now having a principal balance of $101,885 Canadian ($81,640 US) matures December 31, 2017. On December 31, 2017 the note was renewed for a 12month period under the same terms and conditions as before except that this new note is unsecured and nonconvertible. The new note has a face value of $104,942 Canadian ($83,649 US) and matures on December 31, 2018. On December 31, 2018 the note was renewed for a 12-month period under the same terms and conditions as the previous note. The new note together with interest of $9,227, has a face value of $86,118 US ($117,535 CAD) and matures on December 31, 2019.
86,118 83,649

On January 1, 2018 as part of the acquisition of Atlas Pharma Inc., the Company issued a note payable in the amount of $450,000 Canadian ($358,407 US) and accruing interest at the rate of 3% per annum. The note is due on December 31, 2023. Payments on this note are $10,000 Canadian (approximately $8,000 US) per quarter. The outstanding principal balance at December 31, 2018 was $310,079. The note is nonconvertible and is secured by the Atlas Pharma Inc. shares held by the Company.

The holder of this note is currently a director and officer of Atlas Pharma Inc.
$ 310,079 $ -0-

Total Notes Payable Related Party $ 532,941 $ 205,742

Long-Term Portion $ 289,847 $ 79,710

X

- References
No definition available.
+ Details

Name: SBFM_NotesPayableRelatedPartyDisclosureTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_NotesToFinancialStatementsAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R16.htm IDEA: XBRL DOCUMENT v3.19.1

10. Related Transactions
12 Months Ended

Dec. 31, 2018

Related Party Transactions [Abstract]

Related Party Transactions
In addition to the transactions specified under Note 9 above, during the period ended December 31, 2018, the Company issued 4,050,000 shares of par value $0.001 Common Stock valued at $429,300 or $0.106 per share and 5,700,000 shares of par value $0.001 Common Stock to the Board of Directors valued at $171,000 or $0.03 per share. During the year ended December 31, 2018 the Directors and Officers were paid $154,915 in cash. Of this amount, $85,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

For the period ended December 31, 2017, the Company issued 2,100,000 of par value $0.001 Common Stock to the three Company officers valued at $336,000 or $0.008 per share. During the year ended December 31, 2017 the Directors and officers were paid $184,271 in cash. Of this amount, $147,695 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

During the year ended December 31, 2018, certain Directors of the Company made interest free cash advances to the Company totaling $49,349.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R17.htm IDEA: XBRL DOCUMENT v3.19.1

11. Royalties Payable
12 Months Ended

Dec. 31, 2018

Royalties Payable

Royalties Payable
As part of a subscription agreement entered into in 2016, the Company had an obligation to pay a royalty of 5% of net sales on one of its generic products (Anastrozole) for a period of three (3) years from the date of the first sale of that product. In September 2018, 50,000 shares of the Company’s Common Stock valued at $5,900 were issued in exchange for cancellation of this royalty obligation.

X

- References
No definition available.
+ Details

Name: SBFM_RoyaltiesPayableAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_RoyaltiesPayableDisclosureTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R18.htm IDEA: XBRL DOCUMENT v3.19.1

12. Acquisition of Atlas Pharma Inc.
12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Acquisition of Atlas Pharma Inc.
On January 1, 2018 the Company acquired all of the issued and outstanding shares of Atlas Pharma Inc. (“Atlas”), a Canadian privately held company. The purchase price for the shares was Eight Hundred Forty Eight Thousand Dollars $848,000 Canadian ($676,748 US). The purchase price included a cash payment of $100,500 Canadian ($80,289 US), plus the issuance of 1,000,000 shares of the Company’s Common Stock valued at $238,000 or $0.238 per share, and a promissory note in the principal amount of $450,000 Canadian ($358,407 US), with interest payable at the rate of 3% per annum. Atlas is a certified company dedicated to chemical analysis of pharmaceutical and other industrial samples. Atlas’ operations are authorized by a Drug Establishment License issued by Health Canada. Atlas is also registered with the FDA. The Company has performed analysis of the fair market value of Atlas Pharma Inc. assets and liabilities. The following table summarizes the allocation of the purchase price as of the acquisition date:

Cash $ 4,942

Accounts receivable $ 79,508

Prepaids $ 1,428

Property and equipment $ 62,990

Goodwill $ 665,697

Less: Liabilities assumed ($172,899 Canadian) $ (137,817 )

Total consideration $ 676,748

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2122178

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-URI http://asc.fasb.org/topic&trid=2303972
+ Details

Name: us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R19.htm IDEA: XBRL DOCUMENT v3.19.1

13. Accounts Receivable
12 Months Ended

Dec. 31, 2018

Accounts Receivable

Accounts Receivable
Accounts receivable consist of trade accounts arising in the normal course of business and are classified as current assets and carried at original invoice amounts less an estimate for doubtful receivables based on a review of outstanding balances on a monthly basis. The estimate of allowance for doubtful accounts is based on the Company's bad debt experience, market conditions, and aging of accounts receivable, among other factors. If the financial condition of the Company's customers deteriorates resulting in the customer's inability to pay the Company's receivables as they come due, additional allowances for doubtful accounts will be required.

X

- References
No definition available.
+ Details

Name: SBFM_AccountsReceivableAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_AccountsReceivableDisclosureTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R20.htm IDEA: XBRL DOCUMENT v3.19.1

14. Commitments
12 Months Ended

Dec. 31, 2018

Commitments

Commitments
The Company’s subsidiary, Atlas Pharma Inc., has entered into long-term lease agreements for the rental of buildings which call for minimum aggregate lease payments of $150,347 Canadian (approximately $115,767 US) and additional lease payments based on operating expenses. The lease expires on May 21, 2021. Minimum lease payments for the next three years are $62,213 (approximately $47,904 US) in 2019, $62,213 (approximately $47,904 US) in 2020, and $25,921 (approximately $19,959 US) in 2021.

X

- References
No definition available.
+ Details

Name: SBFM_CommitmentsAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R21.htm IDEA: XBRL DOCUMENT v3.19.1

15. Subsequent Events
12 Months Ended

Dec. 31, 2018

Subsequent Events [Abstract]

Subsequent Events
On January 1, 2019, the Company paid $69,931 to pay off the principal ($53,000) and accrued interest ($16,931) on a note payable dated June 27, 2018.

On January 8, 2019, the Company received net proceeds of $50,500 in exchange for a note payable having a face value of $54,000 and accruing interest at the rate of 8% per annum. The note, due on January 8, 2020, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.

On January 10, 2019, the Company received net proceeds of $38,000 in exchange for a note payable having a face value of $40,660 and accruing interest at the rate of 8% per annum. The note, due on October 10, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.

On February 5, 2019, the Company received net proceeds of $35,000 in exchange for a note payable having a face value of $37,450 and accruing interest at the rate of 8% per annum. The note, due on October 10, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.

On February 11, 2019, the Company received net proceeds of $50,000 in exchange for a note payable having a face value of $52,000 and accruing interest at the rate of 8% per annum. The note, due on November 30, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.

On March 4 and 13, 2019 the holder of a note payable dated August 17, 2018 elected to convert $25,000 in principal into 3,696,581 shares of Common Stock leaving a principal balance of $28,000.

On March 18, 2019, the Company received net proceeds of $38,000 in exchange for a note payable having a face value of $40,660 and accruing interest at the rate of 8% per annum. The note, due on December 18, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.

On March 18, 2019, the Company received another $38,000 of net proceeds in exchange for a note payable having a face value of $40,660 and accruing interest at the rate of 8% per annum. The note, due on December 18, 2019, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.



X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R22.htm IDEA: XBRL DOCUMENT v3.19.1

2. Summary of Significant Accounting Policies (Policies)
12 Months Ended

Dec. 31, 2018

Summary Of Significant Accounting Policies

PRINCIPLES OF CONSOLIDATION
The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

USE OF ESTIMATES
The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

CASH AND CASH EQUIVALENTS
For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $115,216 and $107,532 as of December 31, 2018 and December 31, 2017, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 or the equivalent in Canada.

PROPERTY AND EQUIPMENT
Property and equipment is reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2018 and 2017, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.

Property and equipment are stated at cost. Depreciation is calculated using the straight-line method for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows:

Office Equipment: 5-7 Years

Laboratory Equipment 5 Years

Vehicles 5 Years

INTELLECTUAL PROPERTY RIGHTS - PATENTS
The cost of patents acquired is capitalized and is amortized over the remaining life of the patents.

The Company evaluates recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable. Such circumstances include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of cost significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the assets against the estimated undiscounted future cash flows associated with it.

The Company’s management determined that the expected cash flows would be less than the carrying amount of certain intangible assets; therefore an impairment loss was recognized in 2016. The impairment loss was calculated as the amount by which the carrying amount of the intangible assets exceeded fair value.

EARNINGS PER SHARE
The Company has adopted the Financial Accounting Standards Board (FASB) ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.

INCOME TAXES
In accordance with ASC 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2018 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.

For Canadian and US tax purposes, the Company’s 2015 through 2017 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.

FUNCTIONAL CURRENCY
The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.

The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:

● Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.

● Income statement accounts are translated using the weighted average exchange rate for the period.

The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non U.S. currency transactions.

CONCENTRATION OF CREDIT RISKS
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.

FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company applies the provisions of accounting guidance, FASB Topic ASC 825, Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2018 and 2017, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.

The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.

NOTES PAYABLE
Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method.

ACCOUNTING FOR DERIVATIVES LIABILITIES
The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense.

Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. The Company determined that none of the Company’s financial instruments meet the criteria for derivative accounting as of December 31, 2018 and 2017.

EQUITY INSTRUMENTS ISSUED TO NON-EMPLOYEES FOR AQUIRING GOODS OR SERVICES
Issuances of the Company’s common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.

NONCASH EQUITY TRANSACTIONS
Shares of equity instruments issued for noncash consideration are recorded at the estimated fair market value of the consideration granted based on the estimated market value of the equity instrument, or at the estimated value of the goods or services received whichever is more readily determinable.

RELATED PARTIES
A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.

GENERAL AND ADMINISTRATIVE EXPENSES
General and administrative expenses consisted of professional service fees, rent and utility expenses, meals, travel and entertainment expenses, and other general and administrative overhead costs. Expenses are recognized when incurred.

BASIC AND DILUTED NET GAIN (LOSS) PER SHARE
The Company computes loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.

Basic net income (loss) per share is calculated by dividing net (loss) by the weighted-average common shares outstanding. Diluted net income per share is calculated by dividing net income by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2018 no potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.

Therefore, basic and dilutive net (loss) per share were the same as of December 31, 2018 and 2017.

COMMON STOCK
The Company completed a 20 to 1 reverse stock split of the $.001 par value Common Stock affective February 1, 2019. All shares in this filing have been restated to reflect the 20 to 1 reverse split.

REVENUE RECOGNITION
As of January 1, 2018, the Company adopted ASU No. 201409, “Revenue from Contracts with Customers” (ASU 201409). Under the new guidance, an entity will recognize revenue to depict the transfer of promised goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. A five-step model has been introduced for an entity to apply when recognizing revenue. The new guidance also includes enhanced disclosure requirements. The guidance was effective January 1, 2018 and was applied on a modified retrosspective basis. The adoption did not have an impact on the Company's financial statements. All of the revenues of the Company are generated by Atlas Pharma Inc., the Company's wholly owned Canadian subsidiary, which provides laboratory testing services. Performance obligations for testing services are recognized as revenue at a point in time on the date results are delivered to a customer which is when control is transferred.

Local governmental regulations require that companies recognize revenues upon completion of the work by issuing an invoice and remitting the applicable sales taxes (GST and QST) to the appropriate government agency. Atlas Pharma Inc.'s revenue recognition policy is in compliance with these local regulations.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 will require lessees to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with terms of more than 12 months. Lessor accounting remains substantially similar to current GAAP. In addition, disclosures of leasing activities are to be expanded to include qualitative along with specific quantitative information. ASU 2016-02 will be effective in fiscal years beginning after December 15, 2018 (with early adoption permitted). ASU 2016-02 mandates a modified retrospective transition method. The Company is currently evaluating the potential impact of adopting this guidance on our consolidated financial statements.



DIRECTOR AND OFFICER COMPENSATION
For the period ended December 31, 2018, the Company issued 4,050,000 shares of par value $0.001 Common Stock valued at $429,300 or $0.106 per share and 5,700,000 shares of par value $0.001 Common Stock to the Board of Directors valued at $171,000 or $0.03 per share. During the year ended December 31, 2018 the Directors and officers were paid $154,915 in cash. Of this amount, $85,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

For the period ended December 31, 2017, the Company issued 2,100,000 of par value $0.001 Common Stock to the three Company officers valued at $336,000 or $0.16 per share. During the year ended December 31, 2017 the Directors and officers were paid $184,271 in cash. Of this amount, $147,695 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

LEGAL FEES
During the years ended December 31, 2018 and 2017, the legal fees incurred were related to services provided to the Company to assist with its regulatory requirements with the Securities and Exchange Commission, patenting costs and one ongoing litigation.

DATE OF MANAGEMENT'S REVIEW
Subsequent events have been evaluated through April 12, 2019, which is the date the Financial Statements were available to be issued.

X

- References
No definition available.
+ Details

Name: SBFM_BasicAndDilutedNetGainLossPerShare

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_CommonStockPolicyTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_EquityInstrumentsIssuedToNonemployeesForAquiringGoodsOrServices

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_LegalFeesPolicy

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_NoncashEquityTransactions

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_RelatedParties

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f(1))
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790
+ Details

Name: us-gaap_CompensationRelatedCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_DebtPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for its derivative instruments and hedging activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959
+ Details

Name: us-gaap_DerivativesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13279-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 35
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reporting subsequent events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_SubsequentEventsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R23.htm IDEA: XBRL DOCUMENT v3.19.1

2. Summary of Significant Accounting Policies (Tables)
12 Months Ended

Dec. 31, 2018

Summary Of Significant Accounting Policies Tables Abstract

Estimated useful lives of property plant and equipment

Office Equipment: 5-7 Years

Laboratory Equipment 5 Years

Vehicles 5 Years

X

- References
No definition available.
+ Details

Name: SBFM_SummaryOfSignificantAccountingPoliciesTablesAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R24.htm IDEA: XBRL DOCUMENT v3.19.1

6. Earnings Per Share (Tables)
12 Months Ended

Dec. 31, 2018

Earnings Per Share

Schedule of earnings per share computation

2018 2017

Net (loss) attributable to Common Stock $ (2,156,155 ) $ (1,040,236 )

Basic weighted average outstanding shares of Common Stock 60,936,164 43,634,280

Dilutive effects of common share equivalents -0- -0-

Dilutive weighted average outstanding shares of common stock 60,936,164 43,634,280

Net (loss) attributable to Common Stock $ (0.04 ) $ (0.02 )

X

- References
No definition available.
+ Details

Name: SBFM_EarningsPerShareTablesAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R25.htm IDEA: XBRL DOCUMENT v3.19.1

7. Income Taxes (Tables)
12 Months Ended

Dec. 31, 2018

Income Taxes Tables Abstract

Temporary differences

December 31,
2018 December 31,
2017

Temporary Difference Tax Effect Temporary Difference Tax Effect

Deferred tax assets:

Net operating loss US $ 12,156,020 $ 2,997,675 $ 10,611,921 $ 3,932,778

Net operating loss Canada 298,661 80,041 266,498 71,421

Total 12,454,681 3,077,716 10,878,419 4,004,199

Valuation allowance (12,454,681 ) (3,077,716 ) (10,878,419 ) ( 4,004,199 )

Total deferred tax asset -0- -0- -0- -0-

Net deferred tax asset -0- -0- - -

Income tax reconciliation

December 31,

2018 2017

U.S. Federal statutory graduated rate


21.00 % 34.00 %

State income tax rate, net of federal benefit

4.12 % 3.06 %

Net rate

25.12 % 37.06 %

Net operating loss used

0.00 % 0.00 %

Net operating loss for which no tax benefit is currently available

-25.12 % -37.06 %

0.00 % 0.00 %

Canada Federal statutory rate


15.00 % 15.00 %

Canada Provincial rate

11.80 % 11.80 %

Net Canada rate

26.80 % 26.80 %

Net operating loss used

0.00 % 0.00 %

Net operating loss for which no tax benefit is currently available (Canada)

-26.80 % -26.80 %

0.00 % 0.00 %

X

- References
No definition available.
+ Details

Name: SBFM_IncomeTaxesTablesAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of deferred tax liabilities not recognized because of the exceptions to comprehensive recognition of deferred taxes, including a description of the temporary differences, events that would cause the temporary differences to become taxable, the cumulative amounts of the temporary differences and the amounts not recognized as deferred tax liabilities or a statement that the determination of the deferred tax liabilities is not practicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=115928272&loc=d3e28200-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556
+ Details

Name: us-gaap_SummaryOfDeferredTaxLiabilityNotRecognizedTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R26.htm IDEA: XBRL DOCUMENT v3.19.1

8. Notes Payable (Tables)
12 Months Ended

Dec. 31, 2018

Notes Payable Tables Abstract

Notes payable

2018 2017

A Note Payable having a Face Value of $24,012 at December 31, 2016 and accruing interest at 12% was due December 31, 2017 (“2016 Note”). On December 31, 2017, the Company renewed the 2016 Note, together with accrued interest of $2,573, for a 12-month period (“2017 Note”). On December 31, 2018 the Company renewed the 2017 Note, together with accrued interest of $2,881, for a 12-month period (“2018 Note”). The 2018 Note has a Face Value of $26,893 and accrues interest at 12%. The 2018 Note is nonconvertible. $ 26,893 $ 24,012

On January 12, 2018 the Company received monies in exchange for a Note Payable having a Face Value of $102,000 with interest accruing at 8% is due October 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $4,080 was converted in 2018 into 3,569,333 shares of Common Stock valued at $166,085 resulting in a loss of $60,005. $ -0- -0-

On February 7, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $150,000 with interest accruing at 8% is due February 7, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note was paid off in 2018

in part by cash of $48,000 and the remainder, together with accrued interest of $5,073, was converted into 5,710,642 shares of Common Stock valued at $183,411 resulting in a loss of $76,338.
$ -0- $ -0-

On February 20, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $85,000 with interest accruing at 8% is due November 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $3,400, was converted in 2018 into 4,376,238 shares of Common Stock valued at $281,663 resulting in a loss of $193,263. $ -0- $ -0-

On May 29, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $26,750 with interest accruing at 8% is due February 29, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued

interest of $1,353, was converted into 4,003,265 shares of Common Stock valued at $192,157 resulting in a loss of $164,054.
$ -0- $ -0-

On June 27, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $53,000 with interest accruing at 8% is due April 15, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value.
Interest accrued at December 31, 2018 was $2,137. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.
$ 53,000 $ -0-

On August 17, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $53,000 with interest accruing at 8% is due April 15, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $1,557. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. $ 53,000 $ -0-

On September 10, 2018, the Company received monies in exchange for two Notes Payable having an aggregate Face Value of $36,500 with interest accruing at 8% are due June 20, 2019. Interest accrued at December 31, 2018 was $888. $ 36,500 $ -0-

On October 23, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $90,000 with interest accruing at 8% is due October 23, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $1,361. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. $ 90,000 $ -0-

On December 24, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $87,000 with interest accruing at 8% is due October 23, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. Interest accrued at December 31, 2018 was $153. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. $ 87,000 $ -0-

On April 1, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $100,000 Canadian ($73,270US) at December 31, 2018 and ($79,710 US) at December 31, 2017 with interest payable quarterly at 9% is due April 1, 2019. The Note is convertible any time after issuance into $0.001 par value Common Stock at a price of $0.015 Canadian (approximately $0.012 US) per share. We estimate that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. $ 73,270 $ 79,710

On August 3, 2017 the, Company received monies in exchange for a Note Payable having a Face Value of $ 80,000 with interest accruing at 8% is due August 3, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. A principal amount of $40,000 of this note plus accrued interest of $1,712 was converted in 2018 into 327,788 shares of Common Stock valued at $70,507 resulting in a loss of $28,795. The remaining principal amount of $40,000 together with accrued interest of $1,613 was paid in cash reducing the balance to $-0- $ -0- $ 80,000

On August 21, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $ 83,000 with interest accruing at 8% is due May 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, plus accrued interest of $3,419, was paid off in 2018. $ -0- $ 83,000

On September 22, 2017 the Company received monies in exchange for a note having a Face Value of $ 62,000 with interest accruing at 8% is due June 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued interest of $2,480 was converted in 2018 into 790,590 shares of Common Stock valued at $107,056 resulting in a loss of $42,576. $ -0- $ 62,000

On October 26, 2017 the Company received monies in exchange for a Note Payable having a Face Value of $ 115,000 with interest accruing at 8% is due October 26, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The note, together with accrued interest of $6,126, was converted in 2018 into 2,921,146 shares of Common Stock valued at $208,661 resulting in a loss of $87,535. $ -0- $ 62,000

On November 14, 2017, the Company received monies in exchange for a Note Payable having a Face Value of $ 113,000 with interest accruing at 8% is due November 14, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $7,018 was converted in 2018 into 4,917,251 shares of Common Stock valued at $351,999 resulting in a loss of $231,981. $ -0- $ 115,000

On December 1, 2017, the Company received monies in exchange for a Note Payable having a Face Value of $50,000 Canadian ($38,568 US) at December 31, 2018 and ($39,855 US) at December 31, 2017 with interest accruing at 8% is due November 30, 2018. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. The Note, together with accrued interest of $1,566 was converted in 2018 into 260,000 shares of Common Stock valued at $27,560 resulting in a gain of $12,574.
$ -0- $ 113,000

Total Notes Payable $ 419,663 $ 596,577

X

- References
No definition available.
+ Details

Name: SBFM_NotesPayableTableTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_NotesPayableTablesAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R27.htm IDEA: XBRL DOCUMENT v3.19.1

9. Notes Payable Related Party (Tables)
12 Months Ended

Dec. 31, 2018

Notes Payable Related Party Tables Abstract

Summary of notes payable related party

2018 2017

A Note Payable held by a private individual who became a principal shareholder of the Company having a Face Value of $118,537 at September 30, 2017 and a maturity date of December 31, 2017, accrues interest at 12%. The Note is convertible any time from the date of issuance into $0.001 par value Common Stock at a 35% discount from market price. On December 31, 2017 the Note together with accrued interest was renewed for a 12-month period under the same terms and conditions as before. The new Note has a Face Value of $122,093 and matures on December 31, 2018. On December 31, 2018 the Note, together with accrued interest of $14,651 was renewed for a 12-month period. The new Note has a Face value of $136,744 and matures on December 31, 2019. The new Note is nonconvertible. This individual ceased to be a principal shareholder of the Company in the third quarter of 2018
$ 136,744 $ 122,093

In December 2016, the Company received monies from its CEO in exchange for a note payable having a principal amount of $90,000 Canadian ($67,032 US) with interest at 12% due March 31, 2017. The note was convertible any time after the date of issuance into $0.001 par value Common Stock at a price 35% below market value. This note was collateralized by all of the assets of the Company. In the event of default, the interest rate will increased to 18% per annum and a penalty of $1,000 Canadian ($752 US) per day will accrue. On March 31, 2017, the note, together with accrued interest of $3,021 Canadian ($2,271 US) and an additional principal amount of $3,000 Canadian ($2,247 US) paid to the Company on March 28, 2017, was renewed for a 90-day period under the same terms and conditions as the original note. The new note now having a face value of $96,021 Canadian ($72,198 US) was due on June 30, 2017. On June 30, 2017, the note, together with accrued interest of $2,873 Canadian ($2,005 US), was renewed for a 90-day period under the same terms and conditions as the original note except that the new note is nonconvertible. The new note now having a face value of $98,894 Canadian ($76,072US) is due on September 30, 2017. On September 30, 2017, the note, together with accrued interest of $2,991 Canadian ($2,397 US) was renewed for a 90-day period under the same terms and conditions as the original note except that the new note is nonconvertible. The new note now having a principal balance of $101,885 Canadian ($81,640 US) matures December 31, 2017. On December 31, 2017 the note was renewed for a 12month period under the same terms and conditions as before except that this new note is unsecured and nonconvertible. The new note has a face value of $104,942 Canadian ($83,649 US) and matures on December 31, 2018. On December 31, 2018 the note was renewed for a 12-month period under the same terms and conditions as the previous note. The new note together with interest of $9,227, has a face value of $86,118 US ($117,535 CAD) and matures on December 31, 2019.
86,118 83,649

On January 1, 2018 as part of the acquisition of Atlas Pharma Inc., the Company issued a note payable in the amount of $450,000 Canadian ($358,407 US) and accruing interest at the rate of 3% per annum. The note is due on December 31, 2023. Payments on this note are $10,000 Canadian (approximately $8,000 US) per quarter. The outstanding principal balance at December 31, 2018 was $310,079. The note is nonconvertible and is secured by the Atlas Pharma Inc. shares held by the Company.

The holder of this note is currently a director and officer of Atlas Pharma Inc.
$ 310,079 $ -0-

Total Notes Payable Related Party $ 532,941 $ 205,742

Long-Term Portion $ 289,847 $ 79,710

X

- References
No definition available.
+ Details

Name: SBFM_NotesPayableRelatedPartyTablesAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R28.htm IDEA: XBRL DOCUMENT v3.19.1

12. Acquisition of Atlas Pharma Inc. (Tables)
12 Months Ended

Dec. 31, 2018

Acquisition Of Atlas Pharma Inc.

Acquisition

Cash $ 4,942

Accounts receivable $ 79,508

Prepaids $ 1,428

Property and equipment $ 62,990

Goodwill $ 665,697

Less: Liabilities assumed ($172,899 Canadian) $ (137,817 )

Total consideration $ 676,748

X

- References
No definition available.
+ Details

Name: SBFM_AcquisitionOfAtlasPharmaInc.Abstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R29.htm IDEA: XBRL DOCUMENT v3.19.1

2. Summary of Significant Accounting Policies (Details)
12 Months Ended

Dec. 31, 2018

Office Equipment

Estimated useful lives 5-7 Years

Laboratory Equipment

Estimated useful lives 5 Years

Vehicles

Estimated useful lives 5 Years

X

- Definition
Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 35
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R30.htm IDEA: XBRL DOCUMENT v3.19.1

2. Summary of Significant Accounting Policies (Details Narrative) - USD ($)
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Summary Of Significant Accounting Policies Details Narrative Abstract

Cash $ 115,216 $ 107,532 $ 57,453

Patent impairment $ 556,120

X

- References
No definition available.
+ Details

Name: SBFM_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 46 R31.htm IDEA: XBRL DOCUMENT v3.19.1

6. Earnings Per Share (Details) - USD ($)
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Earnings Per Share Details Abstract

Net (loss) attributable to common stockholders $ (2,156,155) $ (1,040,236)

Basic weighted average outstanding shares of common stock 60,936,164 43,634,280

Dilutive effects of common share equivalents $ 0 $ 0

Dilutive weighted average outstanding shares of common stock 60,936,164 872,685,608

Net loss per share of common stock - basic and diluted $ (0.04) $ (0.02)

X

- References
No definition available.
+ Details

Name: SBFM_EarningsPerShareDetailsAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.
+ References
No definition available.
+ Details

Name: us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The weighted average number of shares or units and dilutive common stock or unit equivalents outstanding in the calculation of proforma diluted earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.
+ References
No definition available.
+ Details

Name: us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 47 R32.htm IDEA: XBRL DOCUMENT v3.19.1

7. Income Taxes (Details) - USD ($)

Dec. 31, 2018

Dec. 31, 2017

Deferred tax assets:

Total $ 3,077,716 $ 4,004,199

Temporary Difference

Deferred tax assets:

Net operating loss US 12,156,020 10,611,921

Net operating loss Canada 298,661 266,498

Total 12,454,681 10,878,419

Valuation allowance (12,454,681) (10,878,419)

Total deferred tax asset 0 0

Net deferred tax asset 0 0

Tax Effect

Deferred tax assets:

Net operating loss US 2,997,675 3,932,778

Net operating loss Canada 80,041 71,421

Total 3,077,716 4,004,199

Valuation allowance (3,077,716) (4,004,199)

Total deferred tax asset 0 0

Net deferred tax asset $ 0 $ 0

X

- References
No definition available.
+ Details

Name: us-gaap_ComponentsOfDeferredTaxAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=SBFM_TemporaryDifferenceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=SBFM_TaxEffectMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R33.htm IDEA: XBRL DOCUMENT v3.19.1

7. Income Taxes (Details 1)
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Income Taxes Details Abstract

U.S. Federal statutory graduated rate 21.00% 34.00%

State income tax rate, net of federal benefit 4.12% 3.06%

Net rate 25.12% 37.06%

Net operating loss used 0.00% 0.00%

Net operating loss for which no tax benefit is currently available (25.12%) (37.06%)

Income tax rate 0.00% 0.00%

Canada Federal statutory rate 15.00% 15.00%

Canada Provincial rate 11.80% 11.80%

Net rate 26.80% 26.80%

Net operating loss used (Canada) 0.00% 0.00%

Net operating loss for which no tax benefit is currently available (Canada) (26.80%) (26.80%)

X

- References
No definition available.
+ Details

Name: SBFM_CanadaNetOperatingLossForWhichNoTaxBenefitIsCurrentlyAvailable

Namespace Prefix: SBFM_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_CanadaNetStatutoryTaxRate

Namespace Prefix: SBFM_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_CanadaProvincialTaxRate

Namespace Prefix: SBFM_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_EffectiveIncomeTaxRate

Namespace Prefix: SBFM_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_IncomeTaxNetOperatingLossUsed

Namespace Prefix: SBFM_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_IncomeTaxesDetailsAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_NetOperatingLossForWhichNoTaxBenefitIsCurrentlyAvailable

Namespace Prefix: SBFM_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 49 R34.htm IDEA: XBRL DOCUMENT v3.19.1

7. Income Taxes (Details Narrative) - USD ($)

Dec. 31, 2018

Dec. 31, 2017

Income Taxes Details Narrative Abstract

Federal net operating loss carryforwards $ 12,454,681 $ 10,611,921

Deferred tax asset net operating loss carryforwards 3,077,716 4,004,199

Change in the valuation allowance $ 926,483 $ 342,693

X

- References
No definition available.
+ Details

Name: SBFM_IncomeTaxesDetailsNarrativeAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 30
-Paragraph 5
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109238119&loc=d3e30536-109315

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_OperatingLossCarryforwardsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 50 R35.htm IDEA: XBRL DOCUMENT v3.19.1

8. Notes Payable (Details) - USD ($)

Dec. 31, 2018

Dec. 31, 2017

Notes payable $ 419,663 $ 596,577

Note 1

Notes payable 26,893 24,012

Note 2

Notes payable 0 0

Note 3

Notes payable 0 0

Note 4

Notes payable 0 0

Note 5

Notes payable 0 0

Note 6

Notes payable 53,000 0

Note 7

Notes payable 53,000 0

Note 8

Notes payable 36,500 0

Note 9

Notes payable 90,000 0

Note 10

Notes payable 87,000 0

Note 11

Notes payable 73,270 79,710

Note 12

Notes payable 0 80,000

Note 13

Notes payable 0 83,000

Note 14

Notes payable 0 62,000

Note 15

Notes payable 0 62,000

Note 16

Notes payable 0 115,000

Note 17

Notes payable $ 0 $ 113,000

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note4Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note5Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note6Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note7Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note8Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note9Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note10Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note11Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note12Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note13Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note14Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note15Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note16Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note17Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R36.htm IDEA: XBRL DOCUMENT v3.19.1

9. Notes Payable Related Party (Details) - USD ($)

Dec. 31, 2018

Dec. 31, 2017

Notes payable related party $ 532,941 $ 205,742

Long-term portion 289,847 79,710

Related Entity Note 1

Notes payable related party 136,744 122,093

Related Entity Note 2

Notes payable related party 86,118 83,649

Related Entity Note 3

Notes payable related party $ 310,079 $ 0

X

- Definition
The amount for notes payable (written promise to pay), due to related parties.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.23)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_RelatedEntityNote1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_RelatedEntityNote2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_RelatedEntityNote3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R37.htm IDEA: XBRL DOCUMENT v3.19.1

12. Acquisition of Atlas Pharma Inc. (Details) - USD ($)

Dec. 31, 2018

Dec. 31, 2017

Acquisition Of Atlas Pharma Inc.Details Abstract

Cash $ 4,942

Accounts receivable 79,508

Prepaids 1,428

Property and equipment 62,990

Goodwill 665,697 $ 0

Less: Liabilities assumed ($172,899 Canadian) (137,817)

Total consideration $ 676,748

X

- References
No definition available.
+ Details

Name: SBFM_AcquisitionOfAtlasPharmaInc.DetailsAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities assumed at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of property, plant, and equipment recognized as of the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 80 196 1 false 32 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://sunshinebiopharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheet Sheet http://sunshinebiopharma.com/role/BalanceSheet Balance Sheet Statements 2 false false R3.htm 00000003 - Statement - Balance Sheet (Parenthetical) Sheet http://sunshinebiopharma.com/role/BalanceSheetParenthetical Balance Sheet (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statement Of Operations and Comprehensive Loss Sheet http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss Statement Of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Statement Of Cash Flows Sheet http://sunshinebiopharma.com/role/StatementOfCashFlows Statement Of Cash Flows Statements 5 false false R6.htm 00000006 - Statement - Statement of Shareholders' Equity Sheet http://sunshinebiopharma.com/role/StatementOfShareholdersEquity Statement of Shareholders' Equity Statements 6 false false R7.htm 00000007 - Disclosure - 1. Description of Business Sheet http://sunshinebiopharma.com/role/DescriptionOfBusiness 1. Description of Business Notes 7 false false R8.htm 00000008 - Disclosure - 2. Summary of Significant Accounting Policies Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies 2. Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - 3. Going Concern Sheet http://sunshinebiopharma.com/role/GoingConcern 3. Going Concern Notes 9 false false R10.htm 00000010 - Disclosure - 4. Patents Sheet http://sunshinebiopharma.com/role/Patents 4. Patents Notes 10 false false R11.htm 00000011 - Disclosure - 5. Capital Stock Sheet http://sunshinebiopharma.com/role/CapitalStock 5. Capital Stock Notes 11 false false R12.htm 00000012 - Disclosure - 6. Earnings Per Share Sheet http://sunshinebiopharma.com/role/EarningsPerShare 6. Earnings Per Share Notes 12 false false R13.htm 00000013 - Disclosure - 7. Income Taxes Sheet http://sunshinebiopharma.com/role/IncomeTaxes 7. Income Taxes Notes 13 false false R14.htm 00000014 - Disclosure - 8. Notes Payable Notes http://sunshinebiopharma.com/role/NotesPayable 8. Notes Payable Notes 14 false false R15.htm 00000015 - Disclosure - 9. Notes Payable Related Party Notes http://sunshinebiopharma.com/role/NotesPayableRelatedParty 9. Notes Payable Related Party Notes 15 false false R16.htm 00000016 - Disclosure - 10. Related Transactions Sheet http://sunshinebiopharma.com/role/RelatedTransactions 10. Related Transactions Notes 16 false false R17.htm 00000017 - Disclosure - 11. Royalties Payable Sheet http://sunshinebiopharma.com/role/RoyaltiesPayable 11. Royalties Payable Notes 17 false false R18.htm 00000018 - Disclosure - 12. Acquisition of Atlas Pharma Inc. Sheet http://sunshinebiopharma.com/role/AcquisitionOfAtlasPharmaInc. 12. Acquisition of Atlas Pharma Inc. Notes 18 false false R19.htm 00000019 - Disclosure - 13. Accounts Receivable Sheet http://sunshinebiopharma.com/role/AccountsReceivable 13. Accounts Receivable Notes 19 false false R20.htm 00000020 - Disclosure - 14. Commitments Sheet http://sunshinebiopharma.com/role/Commitments 14. Commitments Notes 20 false false R21.htm 00000021 - Disclosure - 15. Subsequent Events Sheet http://sunshinebiopharma.com/role/SubsequentEvents 15. Subsequent Events Notes 21 false false R22.htm 00000022 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies 2. Summary of Significant Accounting Policies (Policies) Policies http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - 2. Summary of Significant Accounting Policies (Tables) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables 2. Summary of Significant Accounting Policies (Tables) Tables http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - 6. Earnings Per Share (Tables) Sheet http://sunshinebiopharma.com/role/EarningsPerShareTables 6. Earnings Per Share (Tables) Tables http://sunshinebiopharma.com/role/EarningsPerShare 24 false false R25.htm 00000025 - Disclosure - 7. Income Taxes (Tables) Sheet http://sunshinebiopharma.com/role/IncomeTaxesTables 7. Income Taxes (Tables) Tables http://sunshinebiopharma.com/role/IncomeTaxes 25 false false R26.htm 00000026 - Disclosure - 8. Notes Payable (Tables) Notes http://sunshinebiopharma.com/role/NotesPayableTables 8. Notes Payable (Tables) Tables http://sunshinebiopharma.com/role/NotesPayable 26 false false R27.htm 00000027 - Disclosure - 9. Notes Payable Related Party (Tables) Notes http://sunshinebiopharma.com/role/NotesPayableRelatedPartyTables 9. Notes Payable Related Party (Tables) Tables http://sunshinebiopharma.com/role/NotesPayableRelatedParty 27 false false R28.htm 00000028 - Disclosure - 12. Acquisition of Atlas Pharma Inc. (Tables) Sheet http://sunshinebiopharma.com/role/AcquisitionOfAtlasPharmaInc.Tables 12. Acquisition of Atlas Pharma Inc. (Tables) Tables http://sunshinebiopharma.com/role/AcquisitionOfAtlasPharmaInc. 28 false false R29.htm 00000029 - Disclosure - 2. Summary of Significant Accounting Policies (Details) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails 2. Summary of Significant Accounting Policies (Details) Details http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 00000030 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative 2. Summary of Significant Accounting Policies (Details Narrative) Details http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables 30 false false R31.htm 00000031 - Disclosure - 6. Earnings Per Share (Details) Sheet http://sunshinebiopharma.com/role/EarningsPerShareDetails 6. Earnings Per Share (Details) Details http://sunshinebiopharma.com/role/EarningsPerShareTables 31 false false R32.htm 00000032 - Disclosure - 7. Income Taxes (Details) Sheet http://sunshinebiopharma.com/role/IncomeTaxesDetails 7. Income Taxes (Details) Details http://sunshinebiopharma.com/role/IncomeTaxesTables 32 false false R33.htm 00000033 - Disclosure - 7. Income Taxes (Details 1) Sheet http://sunshinebiopharma.com/role/IncomeTaxesDetails1 7. Income Taxes (Details 1) Details http://sunshinebiopharma.com/role/IncomeTaxesTables 33 false false R34.htm 00000034 - Disclosure - 7. Income Taxes (Details Narrative) Sheet http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative 7. Income Taxes (Details Narrative) Details http://sunshinebiopharma.com/role/IncomeTaxesTables 34 false false R35.htm 00000035 - Disclosure - 8. Notes Payable (Details) Notes http://sunshinebiopharma.com/role/NotesPayableDetails 8. Notes Payable (Details) Details http://sunshinebiopharma.com/role/NotesPayableTables 35 false false R36.htm 00000036 - Disclosure - 9. Notes Payable Related Party (Details) Notes http://sunshinebiopharma.com/role/NotesPayableRelatedPartyDetails 9. Notes Payable Related Party (Details) Details http://sunshinebiopharma.com/role/NotesPayableRelatedPartyTables 36 false false R37.htm 00000037 - Disclosure - 12. Acquisition of Atlas Pharma Inc. (Details) Sheet http://sunshinebiopharma.com/role/AcquisitionOfAtlasPharmaInc.Details 12. Acquisition of Atlas Pharma Inc. (Details) Details http://sunshinebiopharma.com/role/AcquisitionOfAtlasPharmaInc.Tables 37 false false All Reports Book All Reports sbfm-20181231.xml sbfm-20181231.xsd sbfm-20181231_cal.xml sbfm-20181231_def.xml sbfm-20181231_lab.xml sbfm-20181231_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 58 0001654954-19-004354-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-19-004354-xbrl.zip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end

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2018	Apr. 11, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	Sunshine Biopharma, Inc
Entity Central Index Key	0001402328
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Public Float			$ 3,970,144
Entity Common Stock, Shares Outstanding		89,348,981
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

Balance Sheet - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 115,216	$ 107,532
Accounts receivable	94,955	0
Prepaid expenses	1,341	9,667
Total Current Assets	211,512	117,199
Equipment (net of $57,964 and $9,132 depreciation)	269,362	59,996
Patents (net of $58,918 amortization and $556,120 impairment)	0	0
Non-current asset - Goodwill	665,697	0
Non-current asset - Deposits	0	80,290
TOTAL ASSETS	1,146,571	257,485
Current Liabilities:
Current portion of note payable	419,663	516,867
Current portion of notes payable - related party	243,094	205,742
Related party advances	49,349	0
Accounts payable	191,080	19,314
Interest payable	9,291	9,215
Total Curent Liabilities	912,477	751,138
Long-term liabilities - relaed party note payable	289,847	79,710
TOTAL LIABILITIES	1,202,324	830,848
SHAREHOLDERS' EQUITY
Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 85,652,400 and 45,936,825 at December 31, 2018 and 2017, respectively	85,652	45,936
Capital paid in excess of par value	15,586,678	12,948,387
Accumulated other comprehensive income	(3,738)	504
Accumulated (Deficit)	(15,774,345)	(13,618,190)
TOTAL SHAREHOLDERS' DEFICIT	(55,753)	(573,363)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	1,146,571	257,485
Series A Preferred Stock
SHAREHOLDERS' EQUITY
Preferred Stock	0	0
Series B Preferred Stock
SHAREHOLDERS' EQUITY
Preferred Stock	$ 50,000	$ 50,000

Balance Sheet (Parenthetical) - USD ($)	12 Months Ended
Balance Sheet (Parenthetical) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Equipment depreciation	$ 57,964	$ 9,132
Patent amortization	58,918	$ 58,918
Patent impairment	$ 556,120
SHAREHOLDERS' EQUITY
Common stock, par value	$ 0.001	$ 0.001
Common stock shares authorized	3,000,000,000	3,000,000,000
Common stock shares issued	85,652,400	45,936,825
Common stock shares outstanding	85,652,400	45,936,825
Common stock shares reserved for issuance	97,321,836
Series A Preferred Stock
SHAREHOLDERS' EQUITY
Preferred stock, par value	$ 0.10	$ 0.10
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Series B Preferred Stock
SHAREHOLDERS' EQUITY
Preferred stock, par value	$ 0.10	$ 0.10
Preferred stock shares authorized	500,000	500,000
Preferred stock shares issued	500,000	500,000
Preferred stock shares outstanding	500,000	500,000

Statement Of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenue	$ 447,200	$ 0
Cost of Revenues	391,081	0
Gross Profit	56,119	0
General & Administrative Expenses:
Accounting	153,889	81,643
Legal	113,068	75,908
Consulting	36,245	127,013
Office	149,031	45,726
Officer & Director remuneration	755,215	520,271
Research & development	12,800	0
Amortization & Depreciation	2,408	6,629
Total General & Administrative	1,222,656	857,190
Income (Loss) from Operations	(1,166,537)	(857,190)
Other (expense):
Interest expense	(159,420)	(104,829)
Loss on conversion of notes payable	(871,726)	(76,929)
Gain (Loss) from foreign exchange transactions	41,528	(1,288)
Total Other Expenses	(989,618)	(183,046)
Net (loss)	$ (2,156,155)	$ (1,040,236)
Basic (Loss) per common share	$ (0.04)	$ (0.02)
Weighted Average Common Shares Outsanding	60,936,164	43,634,280
Net Income (Loss)	$ (2,156,155)	$ (1,040,236)
Unrealized Comprehensive Gain (Loss) from foreign exchange transactions	(4,242)	110
Comprehensive Income (Loss)	$ (2,160,397)	$ (1,040,126)
Basic (Loss) per common shares	$ (0.04)	$ (0.02)
Weighted Average Common Shares Outstanding	60,936,164	43,634,280

Statement Of Cash Flows - USD ($)	12 Months Ended
Statement Of Cash Flows - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Cash Flows From Operating Activities:
Net (Loss)	$ (2,156,155)	$ (1,040,236)
Amortization & Depreciation	49,361	6,629
Foreign exchange gain	(42,399)	0
Stock issued for services	676,100	427,400
Loss on conversion of notes payable	871,973	76,929
Stock issued for payment of interest	33,977	3,022
Interest forgiven	(247)	0
Increase (decrease) in accounts receivable	(15,447)	0
(Increase) decrease in prepaid expenses	8,326	(8,660)
Increase (decrease) in Accounts Payable	61,629	(8,808)
Increase (decrease) in interest payable	76	204
Net Cash Flows (Used) in Operations	(512,806)	(543,520)
Cash Flows From Investing Activities:
Cash received from purchase of subsidiary	4,942	0
Purchase equipment	(18,850)	(3,718)
Deposits on business acquisition	0	(80,290)
Net Cash Flows (Used) in Investing Activities	(13,908)	(84,008)
Cash Flows From Financing Activities:
Proceed from note payable	609,885	660,565
Notes Payable - Interest expense	26,759	33,977
Payment of notes payable	(194,184)	(115,000)
Note payable - related party	29,930	2,251
Note payable used to pay expenses	36,500	0
Note payable used to pay origination fees & interest	18,750	25,000
Sale of common stock	0	63,912
Net Cash Flows Provided by Financing Activities	527,640	670,705
Net Increase (Decrease) In Cash and cash equivalents	926	43,177
Foreign currency translation adjustment	6,758	6,902
Cash and cash equivalents at beginning of period	107,532	57,453
Cash and cash equivalents at end of period	115,216	107,532
Supplementary Disclosure Of Cash Flow Information:
Cash paid for interest	23,496	21,900
Stock issued for acquisition of Atlas Pharma Inc.	238,000	0
Stock issued for services	676,100	427,400
Stock issued for note and accrued interest conversions	1,589,099	128,451
Stock issued to buy equipment	174,808	56,700
Loan issued for interest	$ 45,509	$ 58,977

Statement of Shareholders' Equity - USD ($)	Common Stock	Capital Paid In Excess Of Par Value	Preferred Shares	Comprehensive Income	Accumulated Deficit	Total
Begining Balance, Shares at Dec. 31, 2016	38,469,993		500,000
Begining Balance, Amount at Dec. 31, 2016	$ 38,470	$ 12,279,390	$ 50,000	$ 394	$ (12,577,954)	$ (209,700)
Stock issued for cash, Shares	1,700,000
Stock issued for cash, Amount	$ 1,700	62,212				63,912
Stock issued for services, Shares	3,090,217
Stock issued for services, Amount	$ 3,090	424,310				427,400
Common stock issued for equipment, Shares	550,208
Common stock issued for equipment, Amount	$ 550	56,150				56,700
Common stock issued for the reduction of notes payable and payment of interest, shares	2,126,406
Common stock issued for the reduction of notes payable and payment of interest, amount	$ 2,126	126,325				128,451
Net Income (Loss)					(1,040,236)	(1,040,126)
Ending balance, Shares at Dec. 31, 2017	45,936,825		500,000
Ending balance, Amount at Dec. 31, 2017	$ 45,936	12,948,387	$ 50,000	504	(13,618,190)	(573,363)
Stock issued for acquisition, Shares	1,000,000
Stock issued for acquisition, Amount	$ 1,000	237,000				238,000
Stock issued for services, Shares	10,382,500
Stock issued for services, Amount	$ 10,383	665,718				676,100
Common stock issued for equipment, Shares	1,456,737
Common stock issued for equipment, Amount	$ 1,457	173,351				174,808
Common stock issued for the reduction of notes payable and payment of interest, shares	26,876,338
Common stock issued for the reduction of notes payable and payment of interest, amount	$ 26,876	1,562,223				1,589,099
Net Income (Loss)				(4,242)	(2,156,155)	(2,160,397)
Ending balance, Shares at Dec. 31, 2018	85,652,400		500,000
Ending balance, Amount at Dec. 31, 2018	$ 85,652	$ 15,586,678	$ 50,000	$ (3,738)	$ (15,774,345)	$ (55,753)

11. Royalties Payable	12 Months Ended
11. Royalties Payable	Dec. 31, 2018
Royalties Payable
Royalties Payable	As part of a subscription agreement entered into in 2016, the Company had an obligation to pay a royalty of 5% of net sales on one of its generic products (Anastrozole) for a period of three (3) years from the date of the first sale of that product. In September 2018, 50,000 shares of the Company’s Common Stock valued at $5,900 were issued in exchange for cancellation of this royalty obligation.

13. Accounts Receivable	12 Months Ended
13. Accounts Receivable	Dec. 31, 2018
Accounts Receivable
Accounts Receivable	Accounts receivable consist of trade accounts arising in the normal course of business and are classified as current assets and carried at original invoice amounts less an estimate for doubtful receivables based on a review of outstanding balances on a monthly basis. The estimate of allowance for doubtful accounts is based on the Company's bad debt experience, market conditions, and aging of accounts receivable, among other factors. If the financial condition of the Company's customers deteriorates resulting in the customer's inability to pay the Company's receivables as they come due, additional allowances for doubtful accounts will be required.

14. Commitments	12 Months Ended
14. Commitments	Dec. 31, 2018
Commitments
Commitments	The Company’s subsidiary, Atlas Pharma Inc., has entered into long-term lease agreements for the rental of buildings which call for minimum aggregate lease payments of $150,347 Canadian (approximately $115,767 US) and additional lease payments based on operating expenses. The lease expires on May 21, 2021. Minimum lease payments for the next three years are $62,213 (approximately $47,904 US) in 2019, $62,213 (approximately $47,904 US) in 2020, and $25,921 (approximately $19,959 US) in 2021.

2. Summary of Significant Accounting Policies (Details)	12 Months Ended
2. Summary of Significant Accounting Policies (Details)	Dec. 31, 2018
Office Equipment
Estimated useful lives	5-7 Years
Laboratory Equipment
Estimated useful lives	5 Years
Vehicles
Estimated useful lives	5 Years

2. Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Summary Of Significant Accounting Policies Details Narrative Abstract
Cash	$ 115,216	$ 107,532	$ 57,453
Patent impairment	$ 556,120

6. Earnings Per Share (Details) - USD ($)	12 Months Ended
6. Earnings Per Share (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share Details Abstract
Net (loss) attributable to common stockholders	$ (2,156,155)	$ (1,040,236)
Basic weighted average outstanding shares of common stock	60,936,164	43,634,280
Dilutive effects of common share equivalents	$ 0	$ 0
Dilutive weighted average outstanding shares of common stock	60,936,164	872,685,608
Net loss per share of common stock - basic and diluted	$ (0.04)	$ (0.02)

7. Income Taxes (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Total	$ 3,077,716	$ 4,004,199
Temporary Difference
Deferred tax assets:
Net operating loss US	12,156,020	10,611,921
Net operating loss Canada	298,661	266,498
Total	12,454,681	10,878,419
Valuation allowance	(12,454,681)	(10,878,419)
Total deferred tax asset	0	0
Net deferred tax asset	0	0
Tax Effect
Deferred tax assets:
Net operating loss US	2,997,675	3,932,778
Net operating loss Canada	80,041	71,421
Total	3,077,716	4,004,199
Valuation allowance	(3,077,716)	(4,004,199)
Total deferred tax asset	0	0
Net deferred tax asset	$ 0	$ 0

7. Income Taxes (Details 1)	12 Months Ended
7. Income Taxes (Details 1)	Dec. 31, 2018	Dec. 31, 2017
Income Taxes Details Abstract
U.S. Federal statutory graduated rate	21.00%	34.00%
State income tax rate, net of federal benefit	4.12%	3.06%
Net rate	25.12%	37.06%
Net operating loss used	0.00%	0.00%
Net operating loss for which no tax benefit is currently available	(25.12%)	(37.06%)
Income tax rate	0.00%	0.00%
Canada Federal statutory rate	15.00%	15.00%
Canada Provincial rate	11.80%	11.80%
Net rate	26.80%	26.80%
Net operating loss used (Canada)	0.00%	0.00%
Net operating loss for which no tax benefit is currently available (Canada)	(26.80%)	(26.80%)

7. Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Taxes Details Narrative Abstract
Federal net operating loss carryforwards	$ 12,454,681	$ 10,611,921
Deferred tax asset net operating loss carryforwards	3,077,716	4,004,199
Change in the valuation allowance	$ 926,483	$ 342,693

8. Notes Payable (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Notes payable	$ 419,663	$ 596,577
Note 1
Notes payable	26,893	24,012
Note 2
Notes payable	0	0
Note 3
Notes payable	0	0
Note 4
Notes payable	0	0
Note 5
Notes payable	0	0
Note 6
Notes payable	53,000	0
Note 7
Notes payable	53,000	0
Note 8
Notes payable	36,500	0
Note 9
Notes payable	90,000	0
Note 10
Notes payable	87,000	0
Note 11
Notes payable	73,270	79,710
Note 12
Notes payable	0	80,000
Note 13
Notes payable	0	83,000
Note 14
Notes payable	0	62,000
Note 15
Notes payable	0	62,000
Note 16
Notes payable	0	115,000
Note 17
Notes payable	$ 0	$ 113,000

9. Notes Payable Related Party (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Notes payable related party	$ 532,941	$ 205,742
Long-term portion	289,847	79,710
Related Entity Note 1
Notes payable related party	136,744	122,093
Related Entity Note 2
Notes payable related party	86,118	83,649
Related Entity Note 3
Notes payable related party	$ 310,079	$ 0

12. Acquisition of Atlas Pharma Inc. (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Acquisition Of Atlas Pharma Inc.Details Abstract
Cash	$ 4,942
Accounts receivable	79,508
Prepaids	1,428
Property and equipment	62,990
Goodwill	665,697	$ 0
Less: Liabilities assumed ($172,899 Canadian)	(137,817)
Total consideration	$ 676,748